1 Apoptosis (Pathway) 440 

1.1 Extrinsic Pathway for Apoptosis (Pathway) 442 

1.1.1 Death Receptor Signalling (Pathway) 444 

1.1.1.1 FasL/ CD95L signaling (Pathway) 445 

1.1.1.2 TNF signaling (Pathway) 454 

1.1.1.3 TRAIL signaling (Pathway) 461 

1.1.2 Caspase-8 activation by cleavage (Pathway) 467 

1.1.2.1 Dimerization of procaspase-8 (Pathway) 468 

1.1.2.3 Regulation by c-FLIP (Pathway) 475 

1.1.3 Regulation by c-FLIP (Pathway) 488 

1.2 Intrinsic Pathway for Apoptosis (Pathway) 490 

1.2.1 Activation, myristolyation of BID and translocation to mitochondria (Pathway) 492 

1.2.2 Activation of BH3-only proteins (Pathway) 498 

1.2.2.1 Activation of BAD and translocation to mitochondria (Pathway) 500 

1.2.2.2 Activation of NOXA and translocation to mitochondria (Pathway) 506 

1.2.2.3 Activation of PUMA and translocation to mitochondria (Pathway) 510 

1.2.2.4 Activation of BIM and translocation to mitochondria (Pathway) 515 

1.2.2.5 Activation of BMF and translocation to mitochondria (Pathway) 518 

1.2.3 BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members 520 (Pathway) 

1.2.4 Activation, translocation and oligomerization of BAX (Pathway) 524 

1.2.5 Activation and oligomerization of BAK protein (Pathway) 527 

1.2.6 Release of apoptotic factors from the mitochondria (Pathway) 530 

1.2.7 Apoptotic factor-mediated response (Pathway) 533 

1.2.7.1 Cytochrome c-mediated apoptotic response (Pathway) 534 

1.2.7.1.1 Formation of apoptosome (Pathway) 536 

1.2.7.1.2 Activation of caspases through apoptosome-mediated cleavage (Pathway) 538 

1.2.7.2 SMAC-mediated apoptotic response (Pathway) 542 

1.2.7.2.1 SMAC binds to IAPs (Pathway) 544 

1.2.7.2.2 SMAC-mediated dissociation of IAP:caspase complexes (Pathway) 548 

1.3 Apoptotic execution phase (Pathway) 552 

1.3.1 Apoptotic cleavage of cellular proteins (Pathway) 555 

1.3.1.1 Caspase-mediated cleavage of cytoskeletal proteins (Pathway) 556 

1.3.1.2 Apoptotic cleavage of cell adhesion proteins (Pathway) 570 

1.3.1.3 Breakdown of the nuclear lamina (Pathway) 585 

1.3.2 Apoptosis induced DNA fragmentation (Pathway) 608 

1.3.2.1 Activation of DNA fragmentation factor (Pathway) 609 

1.3.3 Stimulation of the cell death response by PAK-2p34 (Pathway) 624 

1.4 Regulation of Apoptosis (Pathway) 637 

1.4.1 Regulation of activated PAK-2p34 by proteasome mediated degradation (Pathway) 638 

1.4.2 Regulation of PAK-2p34 activity by PS-GAP/RHG10 (Pathway) 643 

1.4.3 Role of DCC in regulating apoptosis (Pathway) 648 

1.4.3.8 UNC5A binds NRAGE (Reaction) 660 2 Binding and Uptake of Ligands by Scavenger Receptors (Pathway) 663 

2.1 Scavenging of heme from plasma (Pathway) 664 

2.2 Scavenging by Class A Receptors (Pathway) 684 

2.3 Scavenging by Class B Receptors (Pathway) 705 

2.3.4 SCARB1:ligand is endocytosed (BlackBoxEvent) 713 2.4 Scavenging by Class F Receptors (Pathway) 715 

2.5 Scavenging by Class H Receptors (Pathway) 720 

2.5.4 STAB2:ligand is endocytosed (BlackBoxEvent) 726 3 Cell Cycle (Pathway) 728 

3.1 Cell Cycle Checkpoints (Pathway) 729 

3.1.1 G1/S DNA Damage Checkpoints (Pathway) 730 

3.1.1.1 p53-Dependent G1/S DNA damage checkpoint (Pathway) 731 

3.1.1.1.1 p53-Dependent G1 DNA Damage Response (Pathway) 732 

3.1.1.1.1.1 Stabilization of p53 (Pathway) 733 

3.1.1.1.1.1.3 Autodegradation of the E3 ubiquitin ligase COP1 (Pathway) 737 

3.1.1.1.1.2 Transcriptional activation of p53 responsive genes (Pathway) 744 

3.1.1.1.1.2.1 Transcriptional activation of cell cycle inhibitor p21 (Pathway) 745 

3.1.1.2 p53-Independent G1/S DNA damage checkpoint (Pathway) 750 

3.1.1.2.1 p53-Independent DNA Damage Response (Pathway) 750 

3.1.1.2.1.2 Ubiquitin Mediated Degradation of Phosphorylated Cdc25A (Pathway) 753 

3.1.2 G2/M Checkpoints (Pathway) 757 

3.1.2.1 G2/M DNA damage checkpoint (Pathway) 757 

3.1.2.1.3 Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex (Pathway) 762 

3.1.2.2 G2/M DNA replication checkpoint (Pathway) 768 

3.1.2.3 Activation of ATR in response to replication stress (Pathway) 770 

3.1.3 Mitotic Spindle Checkpoint (Pathway) 786 

3.1.3.1 Amplification of signal from the kinetochores (Pathway) 787 

3.1.3.1.1 Amplification of signal from unattached kinetochores via a MAD2 inhibitory 788 signal (Pathway) 

3.1.3.2 Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by792 mitotic spindle checkpoint components (Pathway) 

3.1.3.2.2 Inactivation of APC/C via direct inhibition of the APC/C complex (Pathway) 795 

3.2 Cell Cycle, Mitotic (Pathway) 798 

3.2.1 Mitotic G1-G1/S phases (Pathway) 799 

3.2.1.1 G0 and Early G1 (Pathway) 800 

3.2.1.2 G1 Phase (Pathway) 812 

3.2.1.2.1 Cyclin D associated events in G1 (Pathway) 813 

3.2.1.3 G1/S Transition (Pathway) 828 

3.2.1.3.1 Cyclin E associated events during G1/S transition (Pathway) 829 

3.2.1.3.1.6 SCF(Skp2)-mediated degradation of p27/p21 (Pathway) 834 

3.2.1.3.1.14 Phosphorylation of proteins involved in G1/S transition by active Cyclin 853 E:Cdk2 complexes (Pathway) 

3.2.1.3.2 G1/S-Specific Transcription (Pathway) 855 

3.2.1.3.3 Activation of the pre-replicative complex (Pathway) 858 

3.2.1.3.4 E2F mediated regulation of DNA replication (Pathway) 868 

3.2.1.3.4.1 Inhibition of replication initiation of damaged DNA by RB1/E2F1 (Pathway) 869 

3.2.1.3.4.2 E2F-enabled inhibition of pre-replication complex formation (Pathway) 872 

3.2.2 S Phase (Pathway) 874 

3.2.2.1 Cyclin A:Cdk2-associated events at S phase entry (Pathway) 875 

3.2.2.1.5 SCF(Skp2)-mediated degradation of p27/p21 (Pathway) 879 

3.2.2.2 Synthesis of DNA (Pathway) 889 

3.2.2.2.1 DNA replication initiation (Pathway) 889 

3.2.2.2.2 Switching of origins to a post-replicative state (Pathway) 892 

3.2.2.2.2.1 Orc1 removal from chromatin (Pathway) 892 

3.2.2.2.2.2 CDK-mediated phosphorylation and removal of Cdc6 (Pathway) 896 

3.2.2.2.3 DNA strand elongation (Pathway) 902 

3.2.2.2.3.1 Unwinding of DNA (Pathway) 903 

3.2.2.2.3.2 Leading Strand Synthesis (Pathway) 909 

3.2.2.2.3.2.1 Polymerase switching (Pathway) 910 

3.2.2.2.3.3 Lagging Strand Synthesis (Pathway) 916 

3.2.2.2.3.3.1 Polymerase switching (Pathway) 916 

3.2.2.2.3.3.2 Processive synthesis on the lagging strand (Pathway) 917 

3.2.2.2.3.3.2.3 Removal of the Flap Intermediate (Pathway) 920 

3.2.2.3 Ubiquitin-dependent degradation of Cyclin D (Pathway) 925 

3.2.2.3.1 Ubiquitin-dependent degradation of Cyclin D1 (Pathway) 926 

3.2.2.4 Establishment of Sister Chromatid Cohesion (Pathway) 930 

3.2.3 Regulation of DNA replication (Pathway) 938 

3.2.3.1 Association of licensing factors with the pre-replicative complex (Pathway) 939 

3.2.3.2 Removal of licensing factors from origins (Pathway) 941 

3.2.3.2.1 Orc1 removal from chromatin (Pathway) 942 

3.2.3.2.4 CDK-mediated phosphorylation and removal of Cdc6 (Pathway) 944 

3.2.4 Mitotic G2-G2/M phases (Pathway) 946 

3.2.4.1 G2 Phase (Pathway) 946 

3.2.4.2 G2/M Transition (Pathway) 949 

3.2.4.2.1 Cyclin A/B1 associated events during G2/M transition (Pathway) 950 

3.2.4.2.1.8 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2961 complexes (Pathway) 

3.2.4.2.2 Cyclin B2 mediated events (Pathway) 978 

3.2.4.2.3 Regulation of PLK1 Activity at G2/M Transition (Pathway) 983 

3.2.4.2.4 Polo-like kinase mediated events (Pathway) 999 

3.2.4.2.5 Centrosome maturation (Pathway) 1023 

3.2.4.2.5.1 Recruitment of mitotic centrosome proteins and complexes (Pathway) 1024 

3.2.4.2.5.1.3 Recruitment of NuMA to mitotic centrosomes (Pathway) 1029 

3.2.4.2.5.2 Loss of proteins required for interphase microtubule organizationÂ from the 1037 centrosome (Pathway) 

3.2.4.2.5.2.2 Loss of Nlp from mitotic centrosomes (Pathway) 1039 

3.2.5 M Phase (Pathway) 1042 

3.2.5.1 Mitotic Prophase (Pathway) 1043 

3.2.5.1.1 Golgi Cisternae Pericentriolar Stack Reorganization (Pathway) 1043 

3.2.5.1.2 Condensation of Prophase Chromosomes (Pathway) 1059 

3.2.5.1.3 MASTL Facilitates Mitotic Progression (Pathway) 1075 

3.2.5.1.4 Nuclear Envelope Breakdown (Pathway) 1083 

3.2.5.1.4.1 Activation of NIMA Kinases NEK9, NEK6, NEK7 (Pathway) 1084 

3.2.5.1.4.2 Nuclear Pore Complex (NPC) Disassembly (Pathway) 1091 

3.2.5.1.4.3 Clearance of Nuclear Envelope Membranes from Chromatin (Pathway) 1095 

3.2.5.1.4.4 Depolymerisation of the Nuclear Lamina (Pathway) 1100 

3.2.5.2 Mitotic Prometaphase (Pathway) 1112 

3.2.5.2.2 Resolution of Sister Chromatid Cohesion (Pathway) 1114 

3.2.5.2.3 Condensation of Prometaphase Chromosomes (Pathway) 1129 

3.2.5.3 Mitotic Metaphase and Anaphase (Pathway) 1139 

3.2.5.3.1 Mitotic Metaphase/Anaphase Transition (Pathway) 1139 

3.2.5.3.2 Mitotic Anaphase (Pathway) 1142 

3.2.5.3.2.1 Separation of Sister Chromatids (Pathway) 1142 

3.2.5.3.2.2 Nuclear Envelope Reassembly (Pathway) 1154 

3.2.5.3.2.2.1 Initiation of Nuclear Envelope Reformation (Pathway) 1155 

3.2.5.4 Mitotic Telophase/Cytokinesis (Pathway) 1161 

3.2.5.4.4 Cohesin Loading onto Chromatin (Pathway) 1163 

3.2.6 M/G1 Transition (Pathway) 1168 

3.2.6.1 DNA Replication Pre-Initiation (Pathway) 1168 

3.2.6.1.1 Assembly of the pre-replicative complex (Pathway) 1169 

3.2.6.1.1.1 Assembly of the ORC complex at the origin of replication (Pathway) 1171 

3.2.6.1.1.3 CDC6 association with the ORC:origin complex (Pathway) 1177 

3.2.6.1.1.4 CDT1 association with the CDC6:ORC:origin complex (Pathway) 1180 

3.2.6.1.2 Activation of the pre-replicative complex (Pathway) 1186 

3.2.7 Regulation of mitotic cell cycle (Pathway) 1188 

3.2.7.1 APC/C-mediated degradation of cell cycle proteins (Pathway) 1188 

3.2.7.1.1 Regulation of APC/C activators between G1/S and early anaphase (Pathway)1192 

3.2.7.1.1.6 Phosphorylation of Emi1 (Pathway) 1200 

3.2.7.1.1.7 SCF-beta-TrCP mediated degradation of Emi1 (Pathway) 1204 

3.2.7.1.1.9 Inhibition of the proteolytic activity of APC/C required for the onset of 1209 anaphase by mitotic spindle checkpoint components (Pathway) 

3.2.7.1.1.9.2 Inactivation of APC/C via direct inhibition of the APC/C complex 1210 (Pathway) 

3.2.7.1.2 Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins (Pathway) 

3.2.7.1.2.1 Phosphorylation of the APC/C (Pathway) 1212 

3.2.7.1.2.2 APC/C:Cdc20 mediated degradation of mitotic proteins (Pathway) 1215 

3.2.7.1.2.2.2 APC/C:Cdc20 mediated degradation of Cyclin B (Pathway) 1218 

3.2.7.1.2.2.3 APC/C:Cdc20 mediated degradation of Securin (Pathway) 1222 

3.2.7.1.3 Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase (Pathway) 1225 

3.2.7.1.4 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted1229 proteins in late mitosis/early G1 (Pathway) 

3.2.7.1.5 Autodegradation of Cdh1 by Cdh1:APC/C (Pathway) 1238 

3.3 Chromosome Maintenance (Pathway) 1241 

3.3.1 Nucleosome assembly (Pathway) 1242 

3.3.1.1 Deposition of new CENPA-containing nucleosomes at the centromere (Pathway)1243 

3.3.2 Telomere Maintenance (Pathway) 1250 

3.3.2.1 Extension of Telomeres (Pathway) 1254 

3.3.2.1.1 Telomere Extension By Telomerase (Pathway) 1254 

3.3.2.1.2 Telomere C-strand (Lagging Strand) Synthesis (Pathway) 1273 

3.3.2.1.2.1 Telomere C-strand synthesis initiation (Pathway) 1274 

3.3.2.1.2.2 Polymerase switching on the C-strand of the telomere (Pathway) 1278 

3.3.2.1.2.3 Processive synthesis on the C-strand of the telomere (Pathway) 1285 

3.3.2.1.2.3.3 Removal of the Flap Intermediate from the C-strand (Pathway) 1290 

3.3.2.2 Packaging Of Telomere Ends (Pathway) 1298 

3.4 Meiosis (Pathway) 1306 

3.4.1 Meiotic recombination (Pathway) 1307 

3.4.2 Meiotic synapsis (Pathway) 1332 

3.4.2.6 ATR phosphorylates Histone H2A.X at unsynapsed regions (Reaction) 1346 4 Cell-Cell communication (Pathway) 1348 

4.1 Cell junction organization (Pathway) 1349 

4.1.1 Cell-cell junction organization (Pathway) 1349 

4.1.1.1 Adherens junctions interactions (Pathway) 1351 

4.1.1.1.8 Nectin/Necl trans heterodimerization (Pathway) 1362 

4.1.1.2 Tight junction interactions (Pathway) 1373 

4.1.2 Cell-extracellular matrix interactions (Pathway) 1383 

4.1.2.2 Localization of the PINCH-ILK-PARVIN complex to focal adhesions (Pathway) 1386 

4.1.2.3 Regulation of cytoskeletal remodeling and cell spreading by IPP complex 1389 components (Pathway) 

4.1.3 Type I hemidesmosome assembly (Pathway) 1400 

4.2 Signal regulatory protein (SIRP) family interactions (Pathway) 1408 

4.3 DSCAM interactions (Pathway) 1426 

4.4 Nephrin interactions (Pathway) 1436 

4.4.12 Interaction of nephrin with adherens junction-associated proteins (Reaction) 1455 5 Cellular responses to stress (Pathway) 1458 

5.1 Cellular response to hypoxia (Pathway) 1459 

5.1.1 Regulation of Hypoxia-inducible Factor (HIF) by oxygen (Pathway) 1460 

5.1.1.1 Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha 1461 (Pathway) 

5.1.1.2 Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 1465 (Pathway) 

5.1.1.3 Regulation of gene expression by Hypoxia-inducible Factor (Pathway) 1492 5.1.1.3.1 HIF-alpha translocates from cytosol to nucleus (BlackBoxEvent) 1494 

5.2 Detoxification of Reactive Oxygen Species (Pathway) 1504 

5.3 Cellular response to heat stress (Pathway) 1551 

5.3.1 HSF1 activation (Pathway) 1555 5.3.1.1 Dissociation of cytosolic HSF1:HSP90 complex (Reaction) 1557 

5.3.2 HSF1-dependent transactivation (Pathway) 1573 

5.3.2.4 Attenuation phase (Pathway) 1581 

5.3.3 Regulation of HSF1-mediated heat shock response (Pathway) 1589 

5.4 Cellular Senescence (Pathway) 1604 

5.4.1 Oncogene Induced Senescence (Pathway) 1607 

5.4.2 Oxidative Stress Induced Senescence (Pathway) 1633 

5.4.3 DNA Damage/Telomere Stress Induced Senescence (Pathway) 1686 

5.4.3.12 Formation of Senescence-Associated Heterochromatin Foci (SAHF) (Pathway)1700 

5.4.4 Senescence-Associated Secretory Phenotype (SASP) (Pathway) 1706 

5.4.4.22 AP-1 stimulates IL1A transcription (BlackBoxEvent) 1743 6 Chromatin organization (Pathway) 1746 

6.1 Chromatin modifying enzymes (Pathway) 1747 

6.1.1 HATs acetylate histones (Pathway) 1749 

6.1.2 HDACs deacetylate histones (Pathway) 1785 

6.1.3 HDMs demethylate histones (Pathway) 1800 

6.1.4 RMTs methylate histone arginines (Pathway) 1817 

6.1.4.19 PRMT6 methylates histone H2A arginine-30 (H2AR29) (Reaction) 1847 7 Circadian Clock (Pathway) 1849 

7.6 BMAL1:CLOCK,NPAS2 activates circadian gene expression (Pathway) 1861 

7.8 REV-ERBA represses gene expression (Pathway) 1894 

7.21 RORA activates circadian gene expression (Pathway) 1924 

7.21.5 Expression of CPT1A (BlackBoxEvent) 1928 8 Developmental Biology (Pathway) 1930 

8.1 Axon guidance (Pathway) 1930 

8.1.1 Semaphorin interactions (Pathway) 1931 

8.1.1.1 Sema4D in semaphorin signaling (Pathway) 1933 

8.1.1.1.1 Sema4D mediated inhibition of cell attachment and migration (Pathway) 1934 

8.1.1.1.2 Sema4D induced cell migration and growth-cone collapse (Pathway) 1944 

8.1.1.2 SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion (Pathway) 1956 

8.1.1.3 Sema3A PAK dependent Axon repulsion (Pathway) 1971 

8.1.1.4 CRMPs in Sema3A signaling (Pathway) 1982 

8.1.1.5 Other semaphorin interactions (Pathway) 1990 

8.1.2 NCAM signaling for neurite out-growth (Pathway) 2003 

8.1.2.12 RAF/MAP kinase cascade (Pathway) 2026 

8.1.2.12.1 RAF activation (Pathway) 2028 

8.1.2.12.2 MEK activation (Pathway) 2037 

8.1.2.12.2.2 RAF phosphorylates MEK (Pathway) 2039 

8.1.2.12.3 ERK activation (Pathway) 2045 

8.1.2.12.3.1 ERK1 activation (Pathway) 2045 

8.1.2.12.3.2 ERK2 activation (Pathway) 2055 

8.1.2.15 NCAM1 interactions (Pathway) 2066 

8.1.3 Netrin-1 signaling (Pathway) 2083 

8.1.3.1 DCC mediated attractive signaling (Pathway) 2084 

8.1.3.2 Netrin mediated repulsion signals (Pathway) 2103 

8.1.3.14 Role of second messengers in netrin-1 signaling (Pathway) 2127 

8.1.4 Signaling by Robo receptor (Pathway) 2136 

8.1.4.1 Regulation of Commissural axon pathfinding by Slit and Robo (Pathway) 2138 

8.1.4.6 Inactivation of Cdc42 and Rac (Pathway) 2149 

8.1.4.7 Activation of Rac (Pathway) 2158 

8.1.4.8 Role of Abl in Robo-Slit signaling (Pathway) 2165 

8.1.5 L1CAM interactions (Pathway) 2172 

8.1.5.1 Recycling pathway of L1 (Pathway) 2174 

8.1.5.2 Interaction between L1 and Ankyrins (Pathway) 2196 

8.1.5.3 Signal transduction by L1 (Pathway) 2204 

8.1.5.12 CHL1 interactions (Pathway) 2232 

8.1.5.13 Neurofascin interactions (Pathway) 2242 

8.1.5.14 NrCAM interactions (Pathway) 2254 

8.1.6 EPH-Ephrin signaling (Pathway) 2262 

8.1.6.7 EPHA-mediated growth cone collapse (Pathway) 2274 

8.1.6.8 EPHB-mediated forward signaling (Pathway) 2286 

8.1.6.9 Ephrin signaling (Pathway) 2328 

8.1.6.10 EPH-ephrin mediated repulsion of cells (Pathway) 2345 

8.2 Myogenesis (Pathway) 2359 

8.2.1 CDO in myogenesis (Pathway) 2360 

8.3 Regulation of beta-cell development (Pathway) 2383 

8.3.1 Regulation of gene expression in early pancreatic precursor cells (Pathway) 2385 

8.3.2 Regulation of gene expression in late stage (branching morphogenesis) pancreatic 2398 bud precursor cells (Pathway) 

2407 (Pathway) 

8.3.4 Regulation of gene expression in beta cells (Pathway) 2414 

8.3.4.1 AKT-mediated inactivation of FOXO1A (Pathway) 2415 

8.4 Signaling by NODAL (Pathway) 2442 

8.4.10 Regulation of signaling by NODAL (Pathway) 2461 

8.5 Transcriptional regulation of white adipocyte differentiation (Pathway) 2467 

8.6 Transcriptional regulation of pluripotent stem cells (Pathway) 2511 

8.6.13 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation (Pathway)2543 

8.6.14 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation (Pathway)

8.6.14.7 POU5F1 (OCT4), SOX2, NANOG bind the TSC22D1 promoter (Reaction) 2580 9 Disease (Pathway) 2582 

9.1 HIV Infection (Pathway) 2583 

9.1.1 HIV Life Cycle (Pathway) 2584 

9.1.1.1 Early Phase of HIV Life Cycle (Pathway) 2586 

9.1.1.1.1 Binding and entry of HIV virion (Pathway) 2587 

9.1.1.1.2 Uncoating of the HIV Virion (Pathway) 2604 

9.1.1.1.5 Reverse Transcription of HIV RNA (Pathway) 2612 

9.1.1.1.5.1 Minus-strand DNA synthesis (Pathway) 2614 

9.1.1.1.5.2 Plus-strand DNA synthesis (Pathway) 2633 

9.1.1.1.7 Integration of provirus (Pathway) 2645 

9.1.1.1.7.5 Integration of viral DNA into host genomic DNA (Pathway) 2657 

9.1.1.1.7.7 2-LTR circle formation (Pathway) 2668 

9.1.1.1.7.8 Autointegration results in viral DNA circles (Pathway) 2673 

9.1.1.2 Late Phase of HIV Life Cycle (Pathway) 2677 

9.1.1.2.1 Transcription of the HIV genome (Pathway) 2678 

9.1.1.2.1.3 HIV Transcription Initiation (Pathway) 2684 

9.1.1.2.1.4 RNA Polymerase II HIV Promoter Escape (Pathway) 2691 

9.1.1.2.1.5 RNA Pol II CTD phosphorylation and interaction with CE (Pathway) 2703 

9.1.1.2.1.6 HIV Transcription Elongation (Pathway) 2710 

9.1.1.2.1.6.1 Formation of the HIV-1 Early Elongation Complex (Pathway) 2712 

9.1.1.2.1.6.2 Tat-mediated elongation of the HIV-1 transcript (Pathway) 2722 

9.1.1.2.1.6.2.1 Formation of HIV-1 elongation complex containing HIV-1 Tat 2724 (Pathway) 

9.1.1.2.1.6.3 Abortive elongation of HIV-1 transcript in the absence of Tat (Pathway)2738 

9.1.1.2.1.7 HIV elongation arrest and recovery (Pathway) 2742 

9.1.1.2.1.8 Formation of HIV elongation complex in the absence of HIV Tat (Pathway)2747 

9.1.1.2.1.9 Pausing and recovery of HIV elongation (Pathway) 2752 

9.1.1.2.1.10 Tat-mediated HIV elongation arrest and recovery (Pathway) 2755 

9.1.1.2.1.11 Pausing and recovery of Tat-mediated HIV elongation (Pathway) 2760 

9.1.1.2.1.12 HIV Transcription Termination (Pathway) 2763 

9.1.1.2.2 Rev-mediated nuclear export of HIV RNA (Pathway) 2764 

9.1.1.2.4 Assembly Of The HIV Virion (Pathway) 2779 

9.1.1.2.4.1 Synthesis And Processing Of GAG, GAGPOL Polyproteins (Pathway) 2780 

9.1.1.2.4.1.2 Membrane binding and targetting of GAG proteins (Pathway) 2782 

9.1.1.2.4.2 Synthesis and processing of ENV and VPU (Pathway) 2788 

9.1.1.2.5 Budding and maturation of HIV virion (Pathway) 2802 

9.2 Influenza Infection (Pathway) 2807 

9.2.1 Influenza Life Cycle (Pathway) 2809 

9.2.1.2 Entry of Influenza Virion into Host Cell via Endocytosis (Pathway) 2813 

9.2.1.3 Fusion and Uncoating of the Influenza Virion (Pathway) 2815 

9.2.1.3.1 Fusion of the Influenza Virion to the Host Cell Endosome (Pathway) 2816 

9.2.1.3.2 Uncoating of the Influenza Virion (Pathway) 2819 

9.2.1.3.2.2 Ribonucleoprotein release from M1 proteins (Reaction) 2821 9.2.1.4 Transport of Ribonucleoproteins into the Host Nucleus (Pathway) 2822 

9.2.1.5 Influenza Viral RNA Transcription and Replication (Pathway) 2828 

9.2.1.5.1 vRNP Assembly (Pathway) 2830 

9.2.1.5.2 Viral Messenger RNA Synthesis (Pathway) 2835 

9.2.1.5.3 cRNA Synthesis (Pathway) 2849 

9.2.1.5.4 vRNA Synthesis (Pathway) 2853 

9.2.1.5.5 Viral mRNA Translation (Pathway) 2856 

9.2.1.6 Export of Viral Ribonucleoproteins from Nucleus (Pathway) 2861 

9.2.1.6.1 Viral RNP Complexes in the Host Cell Nucleus (Pathway) 2863 

9.2.1.6.2 NEP/NS2 Interacts with the Cellular Export Machinery (Pathway) 2868 

9.2.1.7 Virus Assembly and Release (Pathway) 2872 

9.2.1.7.1 Assembly of Viral Components at the Budding Site (Pathway) 2874 

9.2.1.7.1.9 Transport of HA trimer, NA tetramer and M2 tetramer from the endoplasmic2884 reticulum to the Golgi Apparatus (Pathway) 

9.2.1.7.2 Packaging of Eight RNA Segments (Pathway) 2896 

9.2.1.7.3 Budding (Pathway) 2901 

9.2.1.7.4 Release (Pathway) 2903 

9.2.2 Host Interactions with Influenza Factors (Pathway) 2906 

9.2.2.1 NS1 Mediated Effects on Host Pathways (Pathway) 2906 

9.2.2.1.1 Inhibition of Host mRNA Processing and RNA Silencing (Pathway) 2907 

9.2.2.1.2 Inhibition of Interferon Synthesis (Pathway) 2909 

9.2.2.1.2.1 Inhibition of IFN-beta (Pathway) 2910 

9.2.2.1.3 Inhibition of PKR (Pathway) 2911 

9.2.2.2 Influenza Virus Induced Apoptosis (Pathway) 2912 

9.3 Latent infection of Homo sapiens with Mycobacterium tuberculosis (Pathway) 2915 

9.3.1 Phagosomal maturation (early endosomal stage) (Pathway) 2916 

9.3.2 Response of Mtb to phagocytosis (Pathway) 2937 

9.3.2.1 Tolerance by Mtb to nitric oxide produced by macrophages (Pathway) 2939 

9.3.2.2 Tolerance of reactive oxygen produced by macrophages (Pathway) 2951 

9.3.2.3 Cell redox homeostasis (Pathway) 2961 

9.3.2.4 Mtb iron assimilation by chelation (Pathway) 2971 

9.4 Uptake and actions of bacterial toxins (Pathway) 2982 

9.4.1 Neurotoxicity of clostridium toxins (Pathway) 2983 

9.4.1.1 Toxicity of botulinum toxin type A (BoNT/A) (Pathway) 2985 

9.4.1.2 Toxicity of botulinum toxin type B (BoNT/B) (Pathway) 2994 

9.4.1.3 Toxicity of botulinum toxin type E (BoNT/E) (Pathway) 3002 

9.4.1.4 Toxicity of botulinum toxin type C (BoNT/C) (Pathway) 3012 

9.4.1.5 Toxicity of botulinum toxin type D (BoNT/D) (Pathway) 3020 

9.4.1.6 Toxicity of botulinum toxin type F (BoNT/F) (Pathway) 	3028 

9.4.1.7 Toxicity of botulinum toxin type G (BoNT/G) (Pathway) 	3036 

9.4.2 Uptake and function of anthrax toxins (Pathway) 	3044 

9.5 Signaling by EGFR in Cancer (Pathway) 	30233071 9.5.1 Signaling by constitutively active EGFR (Pathway) 3072 

9.6 Amyloids (Pathway) 3124 

9.7 Signaling by FGFR in disease (Pathway) 3137 

9.7.1 Signaling by FGFR mutants (Pathway) 3138 

9.7.1.1 Signaling by FGFR1 mutants (Pathway) 3142 

9.7.1.1.1 Signaling by FGFR1 amplification mutants (Pathway) 3145 

9.7.1.1.2 Signaling by FGFR1 fusion mutants (Pathway) 3153 

9.7.1.1.3 Signaling by activated point mutants of FGFR1 (Pathway) 3183 

9.7.1.2 Signaling by FGFR2 mutants (Pathway) 3193 

9.7.1.2.1 Activated point mutants of FGFR2 (Pathway) 3195 

9.7.1.2.2 Signaling by FGFR2 amplification mutants (Pathway) 3217 

9.7.1.3 Signaling by FGFR3 mutants (Pathway) 3225 

9.7.1.3.1 Signaling by activated point mutants of FGFR3 (Pathway) 3229 

9.7.1.3.2 t(4;14) translocations of FGFR3 (Pathway) 3241 

9.7.1.4 Signaling by FGFR4 mutants (Pathway) 3249 

9.8 Abnormal metabolism in phenylketonuria (Pathway) 3281 

9.9 Mucopolysaccharidoses (Pathway) 3291 

9.9.1 MPS I - Hurler syndrome (Pathway) 3292 

9.9.1.2 Glycosaminoglycan metabolism (Pathway) 3297 

9.9.1.2.1 Hyaluronan metabolism (Pathway) 3298 

9.9.1.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3299 

9.9.1.2.1.2 Hyaluronan uptake and degradation (Pathway) 3303 

9.9.1.2.2 Transport and synthesis of PAPS (Pathway) 3317 

9.9.1.2.3 Keratan sulfate/keratin metabolism (Pathway) 3324 

9.9.1.2.3.1 Keratan sulfate biosynthesis (Pathway) 3326 

9.9.1.2.3.2 Keratan sulfate degradation (Pathway) 3341 

9.9.1.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3351 

9.9.1.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3352 

9.9.1.2.4.2 HS-GAG biosynthesis (Pathway) 3359 

9.9.1.2.4.3 HS-GAG degradation (Pathway) 3380 

9.9.1.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3400 

9.9.1.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3402 

9.9.1.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3403 

9.9.1.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3414 

9.9.1.2.5.4 CS/DS degradation (Pathway) 3420 

9.9.2 MPS II - Hunter syndrome (Pathway) 3434 

9.9.2.2 Glycosaminoglycan metabolism (Pathway) 3438 

9.9.2.2.1 Hyaluronan metabolism (Pathway) 3438 

9.9.2.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3438 

9.9.2.2.1.2 Hyaluronan uptake and degradation (Pathway) 3439 

9.9.2.2.2 Transport and synthesis of PAPS (Pathway) 3442 

9.9.2.2.3 Keratan sulfate/keratin metabolism (Pathway) 3443 

9.9.2.2.3.1 Keratan sulfate biosynthesis (Pathway) 3443 

9.9.2.2.3.2 Keratan sulfate degradation (Pathway) 3446 

9.9.2.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3448 

9.9.2.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3449 

9.9.2.2.4.2 HS-GAG biosynthesis (Pathway) 3450 

9.9.2.2.4.3 HS-GAG degradation (Pathway) 3454 

9.9.2.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3459 

9.9.2.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3459 

9.9.2.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3460 

9.9.2.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3462 

9.9.2.2.5.4 CS/DS degradation (Pathway) 3463 

9.9.3 MPS IIIA - Sanfilippo syndrome A (Pathway) 3466 

9.9.3.2 Glycosaminoglycan metabolism (Pathway) 3470 

9.9.3.2.1 Hyaluronan metabolism (Pathway) 3470 

9.9.3.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3471 

9.9.3.2.1.2 Hyaluronan uptake and degradation (Pathway) 3471 

9.9.3.2.2 Transport and synthesis of PAPS (Pathway) 3474 

9.9.3.2.3 Keratan sulfate/keratin metabolism (Pathway) 3476 

9.9.3.2.3.1 Keratan sulfate biosynthesis (Pathway) 3476 

9.9.3.2.3.2 Keratan sulfate degradation (Pathway) 3478 

9.9.3.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3481 

9.9.3.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3481 

9.9.3.2.4.1.4 B3GATs transfer GlcA to tetrasaccharide linker (Reaction) 3482 9.9.3.2.4.2 HS-GAG biosynthesis (Pathway) 3482 

9.9.3.2.4.3 HS-GAG degradation (Pathway) 3486 

9.9.3.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3491 

9.9.3.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3491 

9.9.3.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3492 

9.9.3.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3494 

9.9.3.2.5.4 CS/DS degradation (Pathway) 3496 

9.9.4 MPS IIIB - Sanfilippo syndrome B (Pathway) 3499 

9.9.4.2 Glycosaminoglycan metabolism (Pathway) 3502 

9.9.4.2.1 Hyaluronan metabolism (Pathway) 3502 9.9.4.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3503 

9.9.4.2.1.2 Hyaluronan uptake and degradation (Pathway) 3503 

9.9.4.2.2 Transport and synthesis of PAPS (Pathway) 3506 

9.9.4.2.3 Keratan sulfate/keratin metabolism (Pathway) 3508 

9.9.4.2.3.1 Keratan sulfate biosynthesis (Pathway) 3508 

9.9.4.2.3.2 Keratan sulfate degradation (Pathway) 3510 

9.9.4.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3513 

9.9.4.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3513 

9.9.4.2.4.2 HS-GAG biosynthesis (Pathway) 3514 

9.9.4.2.4.3 HS-GAG degradation (Pathway) 3518 

9.9.4.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3523 

9.9.4.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3523 

9.9.4.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3524 

9.9.4.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3526 

9.9.4.2.5.4 CS/DS degradation (Pathway) 3528 

9.9.5 MPS IIIC - Sanfilippo syndrome C (Pathway) 3531 

9.9.5.2 Glycosaminoglycan metabolism (Pathway) 3535 

9.9.5.2.1 Hyaluronan metabolism (Pathway) 3535 

9.9.5.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3535 

9.9.5.2.1.2 Hyaluronan uptake and degradation (Pathway) 3536 

9.9.5.2.2 Transport and synthesis of PAPS (Pathway) 3539 

9.9.5.2.3 Keratan sulfate/keratin metabolism (Pathway) 3540 

9.9.5.2.3.1 Keratan sulfate biosynthesis (Pathway) 3540 

9.9.5.2.3.2 Keratan sulfate degradation (Pathway) 3543 

9.9.5.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3545 

9.9.5.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3545 

9.9.5.2.4.2 HS-GAG biosynthesis (Pathway) 3546 

9.9.5.2.4.3 HS-GAG degradation (Pathway) 3550 

9.9.5.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3555 

9.9.5.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3555 

9.9.5.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3556 

9.9.5.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3558 

9.9.5.2.5.4 CS/DS degradation (Pathway) 3560 

9.9.6 MPS IIID - Sanfilippo syndrome D (Pathway) 3563 

9.9.6.2 Glycosaminoglycan metabolism (Pathway) 3566 

9.9.6.2.1 Hyaluronan metabolism (Pathway) 3567 

9.9.6.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3567 

9.9.6.2.1.2 Hyaluronan uptake and degradation (Pathway) 3568 

9.9.6.2.2 Transport and synthesis of PAPS (Pathway) 3571 

9.9.6.2.3 Keratan sulfate/keratin metabolism (Pathway) 3572 

9.9.6.2.3.1 Keratan sulfate biosynthesis (Pathway) 3572 

9.9.6.2.3.2 Keratan sulfate degradation (Pathway) 3575 

9.9.6.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3577 

9.9.6.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3577 

9.9.6.2.4.2 HS-GAG biosynthesis (Pathway) 3578 

9.9.6.2.4.3 HS-GAG degradation (Pathway) 3582 

9.9.6.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3587 

9.9.6.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3587 

9.9.6.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3588 

9.9.6.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3590 

9.9.6.2.5.4 CS/DS degradation (Pathway) 3592 

9.9.7 MPS IV - Morquio syndrome A (Pathway) 3595 

9.9.7.2 Glycosaminoglycan metabolism (Pathway) 3598 

9.9.7.2.1 Hyaluronan metabolism (Pathway) 3598 

9.9.7.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3598 

9.9.7.2.1.2 Hyaluronan uptake and degradation (Pathway) 3599 

9.9.7.2.2 Transport and synthesis of PAPS (Pathway) 3602 

9.9.7.2.3 Keratan sulfate/keratin metabolism (Pathway) 3604 

9.9.7.2.3.1 Keratan sulfate biosynthesis (Pathway) 3604 

9.9.7.2.3.2 Keratan sulfate degradation (Pathway) 3606 

9.9.7.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3609 

9.9.7.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3609 

9.9.7.2.4.2 HS-GAG biosynthesis (Pathway) 3610 

9.9.7.2.4.3 HS-GAG degradation (Pathway) 3614 

9.9.7.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3619 

9.9.7.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3619 

9.9.7.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3620 

9.9.7.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3622 

9.9.7.2.5.4 CS/DS degradation (Pathway) 3624 

9.9.8 MPS IV - Morquio syndrome B (Pathway) 3627 

9.9.8.2 Glycosaminoglycan metabolism (Pathway) 3631 

9.9.8.2.1 Hyaluronan metabolism (Pathway) 3631 

9.9.8.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3631 

9.9.8.2.1.2 Hyaluronan uptake and degradation (Pathway) 3632 

9.9.8.2.2 Transport and synthesis of PAPS (Pathway) 3635 

9.9.8.2.3 Keratan sulfate/keratin metabolism (Pathway) 3636 

9.9.8.2.3.1 Keratan sulfate biosynthesis (Pathway) 3636 

9.9.8.2.3.2 Keratan sulfate degradation (Pathway) 3639 

9.9.8.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3641 

9.9.8.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3641 

9.9.8.2.4.2 HS-GAG biosynthesis (Pathway) 3642 

9.9.8.2.4.3 HS-GAG degradation (Pathway) 3646 

9.9.8.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3651 

9.9.8.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3651 

9.9.8.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3652 

9.9.8.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3654 

9.9.8.2.5.4 CS/DS degradation (Pathway) 3656 

9.9.9 MPS VI - Maroteaux-Lamy syndrome (Pathway) 3659 

9.9.9.2 Glycosaminoglycan metabolism (Pathway) 3663 

9.9.9.2.1 Hyaluronan metabolism (Pathway) 3663 

9.9.9.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3663 

9.9.9.2.1.2 Hyaluronan uptake and degradation (Pathway) 3664 

9.9.9.2.2 Transport and synthesis of PAPS (Pathway) 3667 

9.9.9.2.3 Keratan sulfate/keratin metabolism (Pathway) 3668 

9.9.9.2.3.1 Keratan sulfate biosynthesis (Pathway) 3668 

9.9.9.2.3.2 Keratan sulfate degradation (Pathway) 3671 

9.9.9.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3673 

9.9.9.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3673 

9.9.9.2.4.2 HS-GAG biosynthesis (Pathway) 3674 

9.9.9.2.4.3 HS-GAG degradation (Pathway) 3678 

9.9.9.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 	3683 

9.9.9.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)3683 

9.9.9.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 	3684 

9.9.9.2.5.3 Dermatan sulfate biosynthesis (Pathway) 	3686 

9.9.9.2.5.4 CS/DS degradation (Pathway) 	3688 

9.9.10 MPS VII - Sly syndrome (Pathway) 	36823691 9.9.10.1 Defective GUSB does not hydrolyse glucuronate (BlackBoxEvent) 3692 

9.9.10.2 Glycosaminoglycan metabolism (Pathway) 3695 

9.9.10.2.1 Hyaluronan metabolism (Pathway) 3695 

9.9.10.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3695 

9.9.10.2.1.2 Hyaluronan uptake and degradation (Pathway) 3696 

9.9.10.2.2 Transport and synthesis of PAPS (Pathway) 3699 

9.9.10.2.3 Keratan sulfate/keratin metabolism (Pathway) 3700 

9.9.10.2.3.1 Keratan sulfate biosynthesis (Pathway) 3700 

9.9.10.2.3.2 Keratan sulfate degradation (Pathway) 3703 

9.9.10.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3705 

9.9.10.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)

9.9.10.2.4.2 HS-GAG biosynthesis (Pathway) 3706 

9.9.10.2.4.3 HS-GAG degradation (Pathway) 3711 

9.9.10.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3715 

9.9.10.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)

9.9.10.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3717 

9.9.10.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3719 

9.9.10.2.5.4 CS/DS degradation (Pathway) 3720 

9.9.11 MPS IX - Natowicz syndrome (Pathway) 3723 

9.9.11.2 Glycosaminoglycan metabolism (Pathway) 3726 

9.9.11.2.1 Hyaluronan metabolism (Pathway) 3726 

9.9.11.2.1.1 Hyaluronan biosynthesis and export (Pathway) 3726 

9.9.11.2.1.2 Hyaluronan uptake and degradation (Pathway) 3727 

9.9.11.2.2 Transport and synthesis of PAPS (Pathway) 3730 

9.9.11.2.3 Keratan sulfate/keratin metabolism (Pathway) 3732 

9.9.11.2.3.1 Keratan sulfate biosynthesis (Pathway) 3732 

9.9.11.2.3.2 Keratan sulfate degradation (Pathway) 3734 

9.9.11.2.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 3737 

9.9.11.2.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)

9.9.11.2.4.2 HS-GAG biosynthesis (Pathway) 3738 

9.9.11.2.4.3 HS-GAG degradation (Pathway) 3742 

9.9.11.2.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 3747 

9.9.11.2.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway)

9.9.11.2.5.2 Chondroitin sulfate biosynthesis (Pathway) 3748 

9.9.11.2.5.3 Dermatan sulfate biosynthesis (Pathway) 3750 

9.9.11.2.5.4 CS/DS degradation (Pathway) 3752 

9.10 Diseases associated with visual transduction (Pathway) 3755 

9.10.1 Retinoid cycle disease events (Pathway) 3756 

9.10.1.13 Biosynthesis of A2E, implicated in retinal degradation (Pathway) 3785 

9.11 PI3K/AKT Signaling in Cancer (Pathway) 3794 

9.11.1 Constitutive PI3K/AKT Signaling in Cancer (Pathway) 3795 

9.12 Signaling by NOTCH1 in Cancer (Pathway) 3863 

9.12.1 Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant 3866 (Pathway) 

3867 Mutant (Pathway) 

9.12.2 Signaling by NOTCH1 HD Domain Mutants in Cancer (Pathway) 3877 

9.12.2.1 Constitutive Signaling by NOTCH1 HD Domain Mutants (Pathway) 3878 

ligand binding (Reaction) 9.12.3 Signaling by NOTCH1 PEST Domain Mutants in Cancer (Pathway) 3889 

9.12.3.1 Constitutive Signaling by NOTCH1 PEST Domain Mutants (Pathway) 3890 

9.12.4 Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer (Pathway) 3926 

9.12.4.1 Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants (Pathway) 3927 

9.12.5 FBXW7 Mutants and NOTCH1 in Cancer (Pathway) 3943 

9.12.5.1 Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling (Pathway) 3944 

9.13 Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate (Pathway) 3948 

9.14 Glycogen storage diseases (Pathway) 3951 

9.14.1 Myoclonic epilepsy of Lafora (Pathway) 3952 

9.14.1.3 Metabolism of carbohydrates (Pathway) 3959 

9.14.1.3.1 Digestion of dietary carbohydrate (Pathway) 3960 

9.14.1.3.2 Hexose transport (Pathway) 3977 

9.14.1.3.2.4 Glucose transport (Pathway) 3983 

9.14.1.3.2.4.6 Regulation of Glucokinase by Glucokinase Regulatory Protein (Pathway)3992 

9.14.1.3.3 Glucose metabolism (Pathway) 4004 

9.14.1.3.3.1 Glycolysis (Pathway) 4006 

9.14.1.3.3.2 Gluconeogenesis (Pathway) 4021 

9.14.1.3.3.3 Glycogen synthesis (Pathway) 4048 

9.14.1.3.3.4 Glycogen breakdown (glycogenolysis) (Pathway) 4073 

9.14.1.3.4 Fructose catabolism (Pathway) 4092 

9.14.1.3.5 Galactose catabolism (Pathway) 4097 

9.14.1.3.6 Pentose phosphate pathway (hexose monophosphate shunt) (Pathway) 4101 

9.14.1.3.7 5-Phosphoribose 1-diphosphate biosynthesis (Pathway) 4113 

9.14.1.3.8 Glycosaminoglycan metabolism (Pathway) 4116 

9.14.1.3.8.1 Hyaluronan metabolism (Pathway) 4117 

9.14.1.3.8.1.1 Hyaluronan biosynthesis and export (Pathway) 4117 

9.14.1.3.8.1.2 Hyaluronan uptake and degradation (Pathway) 4118 

9.14.1.3.8.2 Transport and synthesis of PAPS (Pathway) 4121 

9.14.1.3.8.3 Keratan sulfate/keratin metabolism (Pathway) 4122 

9.14.1.3.8.3.1 Keratan sulfate biosynthesis (Pathway) 4122 

9.14.1.3.8.3.2 Keratan sulfate degradation (Pathway) 4125 

9.14.1.3.8.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 4127 

9.14.1.3.8.4.1 A tetrasaccharide linker sequence is required for GAG synthesis 4127 (Pathway) 

9.14.1.3.8.4.2 HS-GAG biosynthesis (Pathway) 4129 

9.14.1.3.8.4.3 HS-GAG degradation (Pathway) 4133 

9.14.1.3.8.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 4138 

9.14.1.3.8.5.1 A tetrasaccharide linker sequence is required for GAG synthesis 4138 (Pathway) 

9.14.1.3.8.5.2 Chondroitin sulfate biosynthesis (Pathway) 4139 

9.14.1.3.8.5.3 Dermatan sulfate biosynthesis (Pathway) 4141 

9.14.1.3.8.5.4 CS/DS degradation (Pathway) 4142 

9.15 Defects in vitamin and cofactor metabolism (Pathway) 4145 

9.15.1 Defects in cobalamin (B12) metabolism (Pathway) 4146 

9.15.1.1 Defective AMN causes hereditary megaloblastic anemia 1 (Pathway) 4148 

9.15.1.1.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4151 

9.15.1.1.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4152 

9.15.1.1.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4158 

9.15.1.1.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4164 

9.15.1.1.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4169 

9.15.1.1.2.4.2 Coenzyme A biosynthesis (Pathway) 4171 

9.15.1.1.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4180 

9.15.1.1.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4189 

9.15.1.1.2.7 Biotin transport and metabolism (Pathway) 4231 

9.15.1.1.2.8 Nicotinate metabolism (Pathway) 4251 

9.15.1.1.2.8.8 Nicotinamide salvaging (Pathway) 4257 

9.15.1.1.2.9 Metabolism of folate and pterines (Pathway) 4263 

9.15.1.1.2.10 Molybdenum cofactor biosynthesis (Pathway) 4280 

9.15.1.2 Defective CUBN causes hereditary megaloblastic anemia 1 (Pathway) 4289 

9.15.1.2.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4292 

9.15.1.2.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4292 

9.15.1.2.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4294 

9.15.1.2.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4295 

9.15.1.2.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4297 

9.15.1.2.2.4.2 Coenzyme A biosynthesis (Pathway) 4297 

9.15.1.2.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4299 

9.15.1.2.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4301 

9.15.1.2.2.7 Biotin transport and metabolism (Pathway) 4308 

9.15.1.2.2.8 Nicotinate metabolism (Pathway) 4312 

9.15.1.2.2.8.8 Nicotinamide salvaging (Pathway) 4314 

9.15.1.2.2.9 Metabolism of folate and pterines (Pathway) 4316 

9.15.1.2.2.10 Molybdenum cofactor biosynthesis (Pathway) 4321 

9.15.1.3 Defective TCN2 causes hereditary megaloblastic anemia (Pathway) 4323 

9.15.1.3.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4326 

9.15.1.3.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4326 

9.15.1.3.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4328 

9.15.1.3.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4329 

9.15.1.3.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4330 

9.15.1.3.2.4.2 Coenzyme A biosynthesis (Pathway) 4331 

9.15.1.3.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4333 

9.15.1.3.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4335 

9.15.1.3.2.7 Biotin transport and metabolism (Pathway) 4342 

9.15.1.3.2.8 Nicotinate metabolism (Pathway) 4346 

9.15.1.3.2.8.8 Nicotinamide salvaging (Pathway) 4348 

9.15.1.3.2.9 Metabolism of folate and pterines (Pathway) 4350 

9.15.1.3.2.10 Molybdenum cofactor biosynthesis (Pathway) 4355 

4357 (Pathway) 

9.15.1.4.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4360 

9.15.1.4.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4361 

9.15.1.4.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4362 

9.15.1.4.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4363 

9.15.1.4.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4365 

9.15.1.4.2.4.2 Coenzyme A biosynthesis (Pathway) 4365 

9.15.1.4.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4368 

9.15.1.4.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4370 

9.15.1.4.2.7 Biotin transport and metabolism (Pathway) 4377 

9.15.1.4.2.8 Nicotinate metabolism (Pathway) 4381 

9.15.1.4.2.8.8 Nicotinamide salvaging (Pathway) 4383 

9.15.1.4.2.9 Metabolism of folate and pterines (Pathway) 4384 

9.15.1.4.2.10 Molybdenum cofactor biosynthesis (Pathway) 4390 

9.15.1.5 Defective GIF causes intrinsic factor deficiency (Pathway) 4392 

9.15.1.5.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4394 

9.15.1.5.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4395 

9.15.1.5.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4396 

9.15.1.5.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4397 

9.15.1.5.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4399 

9.15.1.5.2.4.2 Coenzyme A biosynthesis (Pathway) 4399 

9.15.1.5.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4402 

9.15.1.5.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4404 

9.15.1.5.2.7 Biotin transport and metabolism (Pathway) 4411 

9.15.1.5.2.8 Nicotinate metabolism (Pathway) 4415 

9.15.1.5.2.8.8 Nicotinamide salvaging (Pathway) 4417 

9.15.1.5.2.9 Metabolism of folate and pterines (Pathway) 4418 

9.15.1.5.2.10 Molybdenum cofactor biosynthesis (Pathway) 4424 

4426 (Pathway) 

9.15.1.6.3 Metabolism of water-soluble vitamins and cofactors (Pathway) 4432 

9.15.1.6.3.1 Vitamin C (ascorbate) metabolism (Pathway) 4432 

9.15.1.6.3.2 Vitamin B1 (thiamin) metabolism (Pathway) 4434 

9.15.1.6.3.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4435 

9.15.1.6.3.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4436 

9.15.1.6.3.4.2 Coenzyme A biosynthesis (Pathway) 4437 

9.15.1.6.3.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4423

9.15.1.6.3.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4441 

9.15.1.6.3.7 Biotin transport and metabolism (Pathway) 4448 

9.15.1.6.3.8 Nicotinate metabolism (Pathway) 4452 

9.15.1.6.3.8.8 Nicotinamide salvaging (Pathway) 4454 

9.15.1.6.3.9 Metabolism of folate and pterines (Pathway) 4456 

9.15.1.6.3.10 Molybdenum cofactor biosynthesis (Pathway) 4461 

4463 (Pathway) 

9.15.1.7.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4466 

9.15.1.7.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4467 

9.15.1.7.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4468 

9.15.1.7.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4469 

9.15.1.7.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4471 

9.15.1.7.2.4.2 Coenzyme A biosynthesis (Pathway) 4471 

9.15.1.7.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4474 

9.15.1.7.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4476 

9.15.1.7.2.7 Biotin transport and metabolism (Pathway) 4483 

9.15.1.7.2.8 Nicotinate metabolism (Pathway) 4487 

9.15.1.7.2.8.8 Nicotinamide salvaging (Pathway) 4489 

9.15.1.7.2.9 Metabolism of folate and pterines (Pathway) 4490 

9.15.1.7.2.10 Molybdenum cofactor biosynthesis (Pathway) 4496 

9.15.1.8 Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE 4498 (Pathway) 

9.15.1.8.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4503 

9.15.1.8.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4503 

9.15.1.8.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4504 

9.15.1.8.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4506 

9.15.1.8.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4507 

9.15.1.8.2.4.2 Coenzyme A biosynthesis (Pathway) 4508 

9.15.1.8.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4510 

9.15.1.8.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4512 

9.15.1.8.2.7 Biotin transport and metabolism (Pathway) 4519 

9.15.1.8.2.8 Nicotinate metabolism (Pathway) 4523 

9.15.1.8.2.8.8 Nicotinamide salvaging (Pathway) 4525 

9.15.1.8.2.9 Metabolism of folate and pterines (Pathway) 4526 

9.15.1.8.2.10 Molybdenum cofactor biosynthesis (Pathway) 4532 

9.15.1.9 Defective MTR causes methylmalonic aciduria and homocystinuria type cblG 4534 (Pathway) 

9.15.1.9.3 Metabolism of water-soluble vitamins and cofactors (Pathway) 4539 

9.15.1.9.3.1 Vitamin C (ascorbate) metabolism (Pathway) 4539 

9.15.1.9.3.2 Vitamin B1 (thiamin) metabolism (Pathway) 4540 

9.15.1.9.3.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4542 

9.15.1.9.3.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4543 

9.15.1.9.3.4.2 Coenzyme A biosynthesis (Pathway) 4544 

9.15.1.9.3.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4546 

9.15.1.9.3.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4548 

9.15.1.9.3.7 Biotin transport and metabolism (Pathway) 4555 

9.15.1.9.3.8 Nicotinate metabolism (Pathway) 4559 

9.15.1.9.3.8.7 NAD+ is phosphorylated to NADP+ (Reaction) 4560 9.15.1.9.3.8.8 Nicotinamide salvaging (Pathway) 4561 

9.15.1.9.3.9 Metabolism of folate and pterines (Pathway) 4562 

9.15.1.9.3.10 Molybdenum cofactor biosynthesis (Pathway) 4568 

9.15.1.10 Defective MMAB causes methylmalonic aciduria type cblB (Pathway) 4570 

9.15.1.10.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4573 

9.15.1.10.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4573 

9.15.1.10.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4574 

9.15.1.10.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4576 

9.15.1.10.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4577 

9.15.1.10.2.4.2 Coenzyme A biosynthesis (Pathway) 4578 

9.15.1.10.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4580 

9.15.1.10.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4582 

9.15.1.10.2.7 Biotin transport and metabolism (Pathway) 4589 

9.15.1.10.2.8 Nicotinate metabolism (Pathway) 4593 

9.15.1.10.2.8.8 Nicotinamide salvaging (Pathway) 4595 

9.15.1.10.2.9 Metabolism of folate and pterines (Pathway) 4596 

9.15.1.10.2.10 Molybdenum cofactor biosynthesis (Pathway) 4602 

9.15.1.11 Defective MMAA causes methylmalonic aciduria type cblA (Pathway) 4604 

9.15.1.11.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4607 

9.15.1.11.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4607 

9.15.1.11.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4609 

9.15.1.11.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4610 

9.15.1.11.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4612 

9.15.1.11.2.4.2 Coenzyme A biosynthesis (Pathway) 4612 

9.15.1.11.2.4.3 Phosphopantetheine conjugation of the ACP domain of FAS (Reaction)9.15.1.11.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4614 

9.15.1.11.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4616 

9.15.1.11.2.7 Biotin transport and metabolism (Pathway) 4623 

9.15.1.11.2.8 Nicotinate metabolism (Pathway) 4627 

9.15.1.11.2.8.8 Nicotinamide salvaging (Pathway) 4629 

9.15.1.11.2.9 Metabolism of folate and pterines (Pathway) 4631 

9.15.1.11.2.10 Molybdenum cofactor biosynthesis (Pathway) 4636 

9.15.1.12 Defective MUT causes methylmalonic aciduria mut type (Pathway) 4638 

9.15.1.12.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4642 

9.15.1.12.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4642 

9.15.1.12.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4644 

9.15.1.12.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4645 

9.15.1.12.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4646 

9.15.1.12.2.4.2 Coenzyme A biosynthesis (Pathway) 4647 

9.15.1.12.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4649 

9.15.1.12.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4651 

9.15.1.12.2.7 Biotin transport and metabolism (Pathway) 4658 

9.15.1.12.2.8 Nicotinate metabolism (Pathway) 4662 

9.15.1.12.2.8.8 Nicotinamide salvaging (Pathway) 4664 

9.15.1.12.2.9 Metabolism of folate and pterines (Pathway) 4666 

9.15.1.12.2.10 Molybdenum cofactor biosynthesis (Pathway) 4671 

9.15.1.13 Defective CD320 causes methylmalonic aciduria (Pathway) 4673 

9.15.1.13.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4676 

9.15.1.13.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4676 

9.15.1.13.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4678 

9.15.1.13.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4679 

9.15.1.13.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4680 

9.15.1.13.2.4.2 Coenzyme A biosynthesis (Pathway) 4681 

9.15.1.13.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4683 

9.15.1.13.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4685 

9.15.1.13.2.7 Biotin transport and metabolism (Pathway) 4692 

9.15.1.13.2.8 Nicotinate metabolism (Pathway) 4696 

9.15.1.13.2.8.8 Nicotinamide salvaging (Pathway) 4698 

9.15.1.13.2.9 Metabolism of folate and pterines (Pathway) 4700 

9.15.1.13.2.10 Molybdenum cofactor biosynthesis (Pathway) 4705 

9.15.2 Defects in biotin (Btn) metabolism (Pathway) 4707 

9.15.2.1 Defective HLCS causes multiple carboxylase deficiency (Pathway) 4708 

9.15.2.1.2 Metabolism of water-soluble vitamins and cofactors (Pathway) 4715 

9.15.2.1.2.1 Vitamin C (ascorbate) metabolism (Pathway) 4715 

9.15.2.1.2.2 Vitamin B1 (thiamin) metabolism (Pathway) 4716 

9.15.2.1.2.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4718 

9.15.2.1.2.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4719 

9.15.2.1.2.4.2 Coenzyme A biosynthesis (Pathway) 4720 

9.15.2.1.2.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4722 

9.15.2.1.2.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4724 

9.15.2.1.2.7 Biotin transport and metabolism (Pathway) 4731 

9.15.2.1.2.8 Nicotinate metabolism (Pathway) 4735 

9.15.2.1.2.8.8 Nicotinamide salvaging (Pathway) 4737 

9.15.2.1.2.9 Metabolism of folate and pterines (Pathway) 4738 

9.15.2.1.2.10 Molybdenum cofactor biosynthesis (Pathway) 4744 

9.15.2.2 Defective BTD causes biotidinase deficiency (Pathway) 4746 

9.15.2.2.3 Metabolism of water-soluble vitamins and cofactors (Pathway) 4751 

9.15.2.2.3.1 Vitamin C (ascorbate) metabolism (Pathway) 4752 

9.15.2.2.3.2 Vitamin B1 (thiamin) metabolism (Pathway) 4753 

9.15.2.2.3.3 Vitamin B2 (riboflavin) metabolism (Pathway) 4754 

9.15.2.2.3.4 Vitamin B5 (pantothenate) metabolism (Pathway) 4756 

9.15.2.2.3.4.2 Coenzyme A biosynthesis (Pathway) 4756 

9.15.2.2.3.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 4759 

9.15.2.2.3.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 4761 

9.15.2.2.3.7 Biotin transport and metabolism (Pathway) 4768 

9.15.2.2.3.8 Nicotinate metabolism (Pathway) 4772 

9.15.2.2.3.8.8 Nicotinamide salvaging (Pathway) 4774 

9.15.2.2.3.9 Metabolism of folate and pterines (Pathway) 4775 

9.15.2.2.3.10 Molybdenum cofactor biosynthesis (Pathway) 4781 

9.16 Signaling by TGF-beta Receptor Complex in Cancer (Pathway) 4783 

9.16.1 Loss of Function of SMAD4 in Cancer (Pathway) 4786 

9.16.1.1 SMAD4 MH2 Domain Mutants in Cancer (Pathway) 4788 

9.16.1.1.2 Signaling by TGF-beta Receptor Complex (Pathway) 4791 

9.16.1.1.2.1 TGF-beta receptor signaling activates SMADs (Pathway) 4795 

9.16.1.1.2.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 4810 

9.16.1.1.2.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)4862 (Pathway) 

9.16.1.1.2.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)4872 

9.16.1.1.2.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)4874 

9.16.1.1.2.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)4896 

9.16.2 Loss of Function of SMAD2/3 in Cancer (Pathway) 4929 

9.16.2.1 SMAD2/3 Phosphorylation Motif Mutants in Cancer (Pathway) 4930 

9.16.2.1.3 Signaling by TGF-beta Receptor Complex (Pathway) 4935 

9.16.2.1.3.1 TGF-beta receptor signaling activates SMADs (Pathway) 4936 

9.16.2.1.3.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 4938 

9.16.2.1.3.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)4947 (Pathway) 

9.16.2.1.3.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)4948 

9.16.2.1.3.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)4949 

9.16.2.1.3.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)4954 

9.16.2.2 SMAD2/3 MH2 Domain Mutants in Cancer (Pathway) 4959 

9.16.2.2.5 Signaling by TGF-beta Receptor Complex (Pathway) 4968 

9.16.2.2.5.1 TGF-beta receptor signaling activates SMADs (Pathway) 4968 

9.16.2.2.5.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 4971 

9.16.2.2.5.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)4980 (Pathway) 

9.16.2.2.5.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)4981 

9.16.2.2.5.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)4982 

9.16.2.2.5.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)4987 

9.16.3 Loss of Function of TGFBR2 in Cancer (Pathway) 4992 

9.16.3.1 TGFBR2 MSI Frameshift Mutants in Cancer (Pathway) 4994 

9.16.3.1.2 Signaling by TGF-beta Receptor Complex (Pathway) 4998 

9.16.3.1.2.1 TGF-beta receptor signaling activates SMADs (Pathway) 4998 

9.16.3.1.2.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 5001 

9.16.3.1.2.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)5010 (Pathway) 

9.16.3.1.2.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)5011 

9.16.3.1.2.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)5012 

9.16.3.1.2.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)5017 

9.16.3.2 TGFBR2 Kinase Domain Mutants in Cancer (Pathway) 5022 

9.16.3.2.3 TGFBR2 KD mutants do not phosphorylate TGFBR1 (BlackBoxEvent) 5028 9.16.3.2.4 Signaling by TGF-beta Receptor Complex (Pathway) 5030 

9.16.3.2.4.1 TGF-beta receptor signaling activates SMADs (Pathway) 5030 

9.16.3.2.4.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 5033 

9.16.3.2.4.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)5041 (Pathway) 

9.16.3.2.4.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)5043 

9.16.3.2.4.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)5043 

9.16.3.2.4.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)5048 

9.16.4 Loss of Function of TGFBR1 in Cancer (Pathway) 5053 

9.16.4.1 TGFBR1 LBD Mutants in Cancer (Pathway) 5055 

9.16.4.1.2 Signaling by TGF-beta Receptor Complex (Pathway) 5059 

9.16.4.1.2.1 TGF-beta receptor signaling activates SMADs (Pathway) 5059 

9.16.4.1.2.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 5062 

9.16.4.1.2.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)5070 (Pathway) 

9.16.4.1.2.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)5072 

9.16.4.1.2.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)5072 

9.16.4.1.2.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)5077 

9.16.4.2 TGFBR1 KD Mutants in Cancer (Pathway) 5082 

9.16.4.2.4 Signaling by TGF-beta Receptor Complex (Pathway) 5090 

9.16.4.2.4.1 TGF-beta receptor signaling activates SMADs (Pathway) 5090 

9.16.4.2.4.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 5093 

9.16.4.2.4.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)5101 (Pathway) 

9.16.4.2.4.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway)5103 

9.16.4.2.4.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway)5103 

9.16.4.2.4.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway)5108 

9.17 Signaling by WNT in cancer (Pathway) 5113 

9.17.1 truncated APC mutants destabilize the destruction complex (Pathway) 5116 

9.17.1.1 APC truncation mutants are not K63 polyubiquitinated (Pathway) 5118 

9.17.1.1.2 Degradation of beta-catenin by the destruction complex (Pathway) 5121 

9.17.1.1.2.7 Beta-catenin phosphorylation cascade (Pathway) 5131 

9.17.1.1.2.13 repression of WNT target genes (Pathway) 5144 

9.17.1.2 APC truncation mutants have impaired AXIN binding (Pathway) 5157 

9.17.1.2.2 Degradation of beta-catenin by the destruction complex (Pathway) 5161 

9.17.1.2.2.7 Beta-catenin phosphorylation cascade (Pathway) 5162 

9.17.1.2.2.13 repression of WNT target genes (Pathway) 5166 

9.17.1.3 Degradation of beta-catenin by the destruction complex (Pathway) 5167 

9.17.1.3.7 Beta-catenin phosphorylation cascade (Pathway) 5169 

9.17.1.3.13 repression of WNT target genes (Pathway) 5172 

9.17.2 AXIN mutants destabilize the destruction complex, activating WNT signaling 5174 (Pathway) 

9.17.2.1 deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT5175 signaling (Pathway) 

9.17.2.1.2 Degradation of beta-catenin by the destruction complex (Pathway) 5178 

9.17.2.1.2.7 Beta-catenin phosphorylation cascade (Pathway) 5180 

9.17.2.1.2.13 repression of WNT target genes (Pathway) 5183 

9.17.2.2 AXIN missense mutants destabilize the destruction complex (Pathway) 5185 

9.17.2.2.2 Degradation of beta-catenin by the destruction complex (Pathway) 5188 

9.17.2.2.2.7 Beta-catenin phosphorylation cascade (Pathway) 5190 

9.17.2.2.2.13 repression of WNT target genes (Pathway) 5193 

9.17.2.3 Degradation of beta-catenin by the destruction complex (Pathway) 5195 

9.17.2.3.7 Beta-catenin phosphorylation cascade (Pathway) 5197 

9.17.2.3.13 repression of WNT target genes (Pathway) 5200 

9.17.3 AMER1 mutants destabilize the destruction complex (Pathway) 5201 

9.17.3.1 deletions in the AMER1 gene destabilize the destruction complex (Pathway) 5203 

9.17.3.1.2 Degradation of beta-catenin by the destruction complex (Pathway) 5206 

9.17.3.1.2.7 Beta-catenin phosphorylation cascade (Pathway) 5208 

9.17.3.1.2.13 repression of WNT target genes (Pathway) 5211 

9.17.3.2 truncations of AMER1 destabilize the destruction complex (Pathway) 5213 

9.17.3.2.2 Degradation of beta-catenin by the destruction complex (Pathway) 5216 

9.17.3.2.2.7 Beta-catenin phosphorylation cascade (Pathway) 5218 

9.17.3.2.2.13 repression of WNT target genes (Pathway) 5221 

9.17.3.3 Degradation of beta-catenin by the destruction complex (Pathway) 5223 

9.17.3.3.7 Beta-catenin phosphorylation cascade (Pathway) 5225 

9.17.3.3.13 repression of WNT target genes (Pathway) 5228 

9.17.4 phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the5229 destruction complex (Pathway) 

9.17.4.1 S45 mutants of beta-catenin aren't phosphorylated (Pathway) 5231 

9.17.4.1.2 Degradation of beta-catenin by the destruction complex (Pathway) 5234 

9.17.4.1.2.7 Beta-catenin phosphorylation cascade (Pathway) 5236 

9.17.4.1.2.13 repression of WNT target genes (Pathway) 5239 

9.17.4.2 T41 mutants of beta-catenin aren't phosphorylated (Pathway) 5241 

9.17.4.2.2 Degradation of beta-catenin by the destruction complex (Pathway) 5244 

9.17.4.2.2.7 Beta-catenin phosphorylation cascade (Pathway) 5246 

9.17.4.2.2.13 repression of WNT target genes (Pathway) 5249 

9.17.4.3 S37 mutants of beta-catenin aren't phosphorylated (Pathway) 5251 

9.17.4.3.2 Degradation of beta-catenin by the destruction complex (Pathway) 5253 

9.17.4.3.2.7 Beta-catenin phosphorylation cascade (Pathway) 5255 

9.17.4.3.2.13 repression of WNT target genes (Pathway) 5258 

9.17.4.4 S33 mutants of beta-catenin aren't phosphorylated (Pathway) 5260 

9.17.4.4.2 Degradation of beta-catenin by the destruction complex (Pathway) 5263 

9.17.4.4.2.7 Beta-catenin phosphorylation cascade (Pathway) 5265 

9.17.4.4.2.13 repression of WNT target genes (Pathway) 5256

9.17.4.5 Degradation of beta-catenin by the destruction complex (Pathway) 5270 

9.17.4.5.7 Beta-catenin phosphorylation cascade (Pathway) 5271 

9.17.4.5.13 repression of WNT target genes (Pathway) 5275 

9.17.5 misspliced GSK3beta mutants stabilize beta-catenin (Pathway) 5276 

9.17.5.2 Degradation of beta-catenin by the destruction complex (Pathway) 5279 

9.17.5.2.6 Association of beta-catenin with the destruction complex (Reaction) 5281 9.17.5.2.7 Beta-catenin phosphorylation cascade (Pathway) 5281 

9.17.5.2.13 repression of WNT target genes (Pathway) 5284 

9.17.6 TCF7L2 mutants don't bind CTBP (Pathway) 5286 

9.17.6.2 Degradation of beta-catenin by the destruction complex (Pathway) 5289 

9.17.6.2.7 Beta-catenin phosphorylation cascade (Pathway) 5291 

9.17.6.2.13 repression of WNT target genes (Pathway) 5294 

9.17.7 misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling 5296 (Pathway) 

9.17.7.2 TCF dependent signaling in response to WNT (Pathway) 5299 

9.17.7.2.2 WNT mediated activation of DVL (Pathway) 5303 

9.17.7.2.4 disassembly of the destruction complex and recruitment of AXIN to the 5314 membrane (Pathway) 

9.17.7.2.6 formation of the beta-catenin:TCF transactivating complex (Pathway) 5333 

9.17.7.2.6.1 binding of TCF/LEF:CTNNB1 to target gene promoters (Pathway) 5335 

9.17.7.2.7 deactivation of the beta-catenin transactivating complex (Pathway) 5360 

9.17.7.2.8 degradation of DVL (Pathway) 5379 

9.17.7.2.9 degradation of AXIN (Pathway) 5389 

9.17.7.2.11 regulation of FZD by ubiquitination (Pathway) 5403 

9.17.7.2.12 negative regulation of TCF-dependent signaling by WNT ligand antagonists5414 (Pathway) 

9.17.7.2.13 negative regulation of TCF-dependent signaling by DVL-interacting proteins5426 (Pathway) 

9.17.8 RNF mutants show enhanced WNT signaling and proliferation (Pathway) 5434 

9.17.8.2 TCF dependent signaling in response to WNT (Pathway) 5438 

9.17.8.2.2 WNT mediated activation of DVL (Pathway) 5438 

9.17.8.2.4 disassembly of the destruction complex and recruitment of AXIN to the 5440 membrane (Pathway) 

9.17.8.2.6 formation of the beta-catenin:TCF transactivating complex (Pathway) 5442 

9.17.8.2.6.1 binding of TCF/LEF:CTNNB1 to target gene promoters (Pathway) 5443 

9.17.8.2.7 deactivation of the beta-catenin transactivating complex (Pathway) 5446 

9.17.8.2.8 degradation of DVL (Pathway) 5449 

9.17.8.2.9 degradation of AXIN (Pathway) 5452 

9.17.8.2.11 regulation of FZD by ubiquitination (Pathway) 5454 

9.17.8.2.12 negative regulation of TCF-dependent signaling by WNT ligand antagonists5456 (Pathway) 

9.17.8.2.13 negative regulation of TCF-dependent signaling by DVL-interacting proteins5457 (Pathway) 

9.17.9 XAV939 inhibits tankyrase, stabilizing AXIN (Pathway) 5458 

9.17.9.2 TCF dependent signaling in response to WNT (Pathway) 5461 

9.17.9.2.2 WNT mediated activation of DVL (Pathway) 5461 

9.17.9.2.4 disassembly of the destruction complex and recruitment of AXIN to the 5463 membrane (Pathway) 

9.17.9.2.6 formation of the beta-catenin:TCF transactivating complex (Pathway) 5466 

9.17.9.2.6.1 binding of TCF/LEF:CTNNB1 to target gene promoters (Pathway) 5466 

9.17.9.2.7 deactivation of the beta-catenin transactivating complex (Pathway) 5470 

9.17.9.2.8 degradation of DVL (Pathway) 5473 

9.17.9.2.9 degradation of AXIN (Pathway) 5475 

9.17.9.2.11 regulation of FZD by ubiquitination (Pathway) 5477 

9.17.9.2.12 negative regulation of TCF-dependent signaling by WNT ligand antagonists5479 (Pathway) 

9.17.9.2.13 negative regulation of TCF-dependent signaling by DVL-interacting proteins5481 (Pathway) 

9.17.10 WNT ligand secretion is abrogated by the PORCN inhibitor LGK974 (Pathway) 5482 

9.17.10.2 WNT ligand biogenesis and trafficking (Pathway) 5486 

9.18 Processing-defective Hh variants abrogate ligand secretion (Pathway) 5506 

9.18.1 Hh ligand biogenesis disease (Pathway) 5508 

9.18.1.7 G287V HHAT variants doesn't palmitoylate Hh-Np (FailedReaction) 5520 10 DNA Repair (Pathway) 5523 

10.1 Base Excision Repair (Pathway) 5524 

10.1.1 Base-Excision Repair, AP Site Formation (Pathway) 5525 

10.1.1.1 Depurination (Pathway) 5525 

10.1.1.1.1 Recognition and association of DNA glycosylase with site containing an 5526 affected purine (Pathway) 

10.1.1.1.2 Cleavage of the damaged purine (Pathway) 5530 

10.1.1.2 Depyrimidination (Pathway) 5534 

10.1.1.2.1 Recognition and association of DNA glycosylase with site containing an 5535 affected pyrimidine (Pathway) 

10.1.1.2.2 Cleavage of the damaged pyrimidine (Pathway) 5541 

10.1.2 Resolution of Abasic Sites (AP sites) (Pathway) 5548 

10.1.2.1 Resolution of AP sites via the single-nucleotide replacement pathway (Pathway)5548 

10.1.2.1.1 Base-free sugar-phosphate removal via the single-nucleotide replacement 5551 pathway (Pathway) 

10.1.2.1.1.1 Displacement of DNA glycosylase by APE1 (Pathway) 5551 

10.1.2.2 Resolution of AP sites via the multiple-nucleotide patch replacement pathway 5561 (Pathway) 

10.1.2.2.1 Removal of DNA patch containing abasic residue (Pathway) 5563 

10.1.2.2.1.1 Displacement of DNA glycosylase by APE1 (Pathway) 5563 

10.2 DNA Damage Bypass (Pathway) 5573 

10.2.1 Translesion synthesis by DNA polymerases bypassing lesion on DNA template 5574 (Pathway) 

10.2.1.1 Translesion synthesis by HREV1 (Pathway) 5575 

10.2.1.2 Translesion synthesis by Pol eta (Pathway) 5577 

10.2.1.3 Translesion synthesis by Pol zeta (Pathway) 5579 

10.3 DNA Damage Reversal (Pathway) 5581 

10.3.2 Reversal of Alkylation Damage By DNA Dioxygenases (Pathway) 5583 

10.3.2.1 ABH2 mediated Reversal of Alkylation Damage (Pathway) 5584 

10.3.2.2 ABH3 mediated Reversal of Alkylation Damage (Pathway) 5587 

10.4 Double-Strand Break Repair (Pathway) 5591 

10.4.1 Homologous Recombination Repair (Pathway) 5593 

10.4.1.1 Homologous recombination repair of replication-independent double-strand 5595 breaks (Pathway) 

10.4.1.1.1 ATM mediated response to DNA double-strand break (Pathway) 5596 

10.4.1.1.1.3 ATM mediated phosphorylation of repair proteins (Pathway) 5598 

10.4.1.1.2 Recruitment of repair and signaling proteins to double-strand breaks (Pathway)

10.4.1.1.2.4 MRN complex relocalizes to nuclear foci (Pathway) 5608 

10.4.1.1.2.4.2 Assembly of the RAD50-MRE11-NBS1 complex at DNA double-strand5610 breaks (Pathway) 

10.4.1.1.3 Processing of DNA double-strand break ends (Pathway) 5613 

10.4.1.1.4 Homologous DNA pairing and strand exchange (Pathway) 5617 

10.4.1.1.4.1 Presynaptic phase of homologous DNA pairing and strand exchange 5618 (Pathway) 

10.4.1.1.4.1.5 Assembly of the RAD51-ssDNA nucleoprotein complex (Pathway) 5622 

10.4.1.1.6 Resolution of D-loop structures (Pathway) 5631 

10.4.1.1.6.1 Resolution of D-loop structures through Holliday junction intermediates 5633 (Pathway) 

10.4.1.1.6.2 Resolution of D-loop structures through synthesis-dependent 5639 strand-annealing (Pathway) 

10.4.2 Nonhomologous End-joining (NHEJ) (Pathway) 5645 

10.4.2.5 Processing of DNA ends prior to end rejoining (Pathway) 5651 

10.5 Nucleotide Excision Repair (Pathway) 5657 

10.5.1 Global Genomic NER (GG-NER) (Pathway) 5659 

10.5.1.1 DNA Damage Recognition in GG-NER (Pathway) 5660 10.5.1.1.1 XPC binds to HR23B forming a heterodimeric complex (Reaction) 5661 

10.5.1.2 Formation of incision complex in GG-NER (Pathway) 5662 

10.5.1.3 Dual incision reaction in GG-NER (Pathway) 5666 

10.5.1.4 Gap-filling DNA repair synthesis and ligation in GG-NER (Pathway) 5669 

10.5.1.4.1 Repair synthesis of patch ~27-30 bases long by DNA polymerase (Pathway)5670 

10.5.2 Transcription-coupled NER (TC-NER) (Pathway) 5673 

10.5.2.1 Formation of transcription-coupled NER (TC-NER) repair complex (Pathway) 5674 

10.5.2.2 Dual incision reaction in TC-NER (Pathway) 5677 

10.5.2.3 Gap-filling DNA repair synthesis and ligation in TC-NER (Pathway) 5680 

10.5.2.3.1 Repair synthesis for gap-filling by DNA polymerase in TC-NER (Pathway) 5680 

10.6 Fanconi Anemia pathway (Pathway) 5684 

10.6.5 Regulation of the Fanconi anemia pathway (Pathway) 5691 

10.7 Mismatch Repair (Pathway) 5697 

10.7.1 Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) (Pathway) 5699 

10.7.2 Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) (Pathway) 5714 

10.7.2.8 DNA ligase I ligates single stranded nick in double stranded DNA (Reaction) 5731 11 DNA Replication (Pathway) 5732 

11.1 M/G1 Transition (Pathway) 5733 

11.1.1 DNA Replication Pre-Initiation (Pathway) 5733 

11.1.1.1 Assembly of the pre-replicative complex (Pathway) 5734 

11.1.1.1.1 Assembly of the ORC complex at the origin of replication (Pathway) 5734 

11.1.1.1.3 CDC6 association with the ORC:origin complex (Pathway) 5736 

11.1.1.1.4 CDT1 association with the CDC6:ORC:origin complex (Pathway) 5737 

11.1.1.2 Activation of the pre-replicative complex (Pathway) 5739 

11.2 Synthesis of DNA (Pathway) 5742 

11.2.1 DNA replication initiation (Pathway) 5742 

11.2.2 Switching of origins to a post-replicative state (Pathway) 5743 

11.2.2.1 Orc1 removal from chromatin (Pathway) 5743 

11.2.2.2 CDK-mediated phosphorylation and removal of Cdc6 (Pathway) 5745 

11.2.3 DNA strand elongation (Pathway) 5748 

11.2.3.1 Unwinding of DNA (Pathway) 5748 

11.2.3.2 Leading Strand Synthesis (Pathway) 5750 

11.2.3.2.1 Polymerase switching (Pathway) 5750 

11.2.3.3 Lagging Strand Synthesis (Pathway) 5752 

11.2.3.3.1 Polymerase switching (Pathway) 5752 

11.2.3.3.2 Processive synthesis on the lagging strand (Pathway) 5753 

11.2.3.3.2.3 Removal of the Flap Intermediate (Pathway) 5754 

11.3 Regulation of DNA replication (Pathway) 5756 

11.3.1 Association of licensing factors with the pre-replicative complex (Pathway) 5756 

11.3.2 Removal of licensing factors from origins (Pathway) 5758 

11.3.2.1 Orc1 removal from chromatin (Pathway) 5758 

11.3.2.4 CDK-mediated phosphorylation and removal of Cdc6 (Pathway) 5760 

11.3.2.5 Mcm4,6,7 trimer forms and associates with the replication fork (Reaction) 5761 12 Extracellular matrix organization (Pathway) 5762 

12.1 Collagen formation (Pathway) 5765 

12.1.1 Collagen biosynthesis and modifying enzymes (Pathway) 5769 12.1.1.1 PDI is a chaperone for collagen peptides (Reaction) 5773 

12.1.2 Assembly of collagen fibrils and other multimeric structures (Pathway) 5805 

12.1.2.3 Anchoring fibril formation (Pathway) 5817 

12.1.2.4 Crosslinking of collagen fibrils (Pathway) 5824 

12.2 Fibronectin matrix formation (Pathway) 5856 

12.4 Elastic fibre formation (Pathway) 5866 

12.4.8 Molecules associated with elastic fibres (Pathway) 5885 

12.5 Laminin interactions (Pathway) 5905 

12.6 Non-integrin membrane-ECM interactions (Pathway) 5945 

12.6.8 Syndecan interactions (Pathway) 5961 

12.7 ECM proteoglycans (Pathway) 6004 

12.8 Degradation of the extracellular matrix (Pathway) 6057 

12.8.1 Activation of Matrix Metalloproteinases (Pathway) 6059 

12.8.2 Collagen degradation (Pathway) 6106 

12.9 Integrin cell surface interactions (Pathway) 6275 

12.9.55 Endorepellin binds alpha2beta1 integrin (Reaction) 6361 13 Gene Expression (Pathway) 6363 

13.1 Generic Transcription Pathway (Pathway) 6364 

13.1.4 Notch-HLH transcription pathway (Pathway) 6377 

13.1.5 Nuclear Receptor transcription pathway (Pathway) 6381 

13.1.7 YAP1- and WWTR1 (TAZ)-stimulated gene expression (Pathway) 6389 

13.1.8 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway) 6399 

13.1.8.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway) 6399 

13.1.8.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway) 6406 

13.2 RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription (Pathway) 6413 

13.2.1 RNA Polymerase I Transcription (Pathway) 6414 

13.2.1.1 RNA Polymerase I Promoter Clearance (Pathway) 6415 

13.2.1.1.1 RNA Polymerase I Promoter Opening (Pathway) 6416 

13.2.1.1.2 RNA Polymerase I Transcription Initiation (Pathway) 6419 

13.2.1.1.3 RNA Polymerase I Promoter Escape (Pathway) 6430 

13.2.1.2 RNA Polymerase I Chain Elongation (Pathway) 6431 

13.2.1.3 RNA Polymerase I Transcription Termination (Pathway) 6432 

13.2.2 RNA Polymerase III Transcription (Pathway) 6439 

13.2.2.1 RNA Polymerase III Abortive And Retractive Initiation (Pathway) 6440 

13.2.2.2 RNA Polymerase III Transcription Initiation (Pathway) 6464 

13.2.2.2.1 RNA Polymerase III Transcription Initiation From Type 1 Promoter (Pathway)6466 

13.2.2.2.2 RNA Polymerase III Transcription Initiation From Type 2 Promoter (Pathway)6476 

13.2.2.2.3 RNA Polymerase III Transcription Initiation From Type 3 Promoter (Pathway)6481 

13.2.2.3 RNA Polymerase III Chain Elongation (Pathway) 6487 

13.2.2.4 RNA Polymerase III Transcription Termination (Pathway) 6492 

13.2.3 Transcription from mitochondrial promoters (Pathway) 6493 

13.2.3.1 Mitochondrial transcription initiation (Pathway) 6495 

13.2.3.2 Mitochondrial transcription termination (Pathway) 6499 

13.3 RNA Polymerase II Transcription (Pathway) 6502 

13.3.1 RNA Polymerase II Pre-transcription Events (Pathway) 6502 

13.3.2 RNA Polymerase II Transcription Pre-Initiation And Promoter Opening (Pathway) 6515 

13.3.3 RNA Polymerase II Transcription Initiation And Promoter Clearance (Pathway) 6521 

13.3.3.2 RNA Polymerase II Transcription Initiation (Pathway) 6523 

13.3.3.3 RNA Polymerase II Promoter Escape (Pathway) 6526 

13.3.4 RNA Pol II CTD phosphorylation and interaction with CE (Pathway) 6533 

13.3.5 RNA Polymerase II Transcription Elongation (Pathway) 6536 

13.3.5.1 Formation of the Early Elongation Complex (Pathway) 6538 

13.3.5.2 Formation of RNA Pol II elongation complex (Pathway) 6542 

13.3.6 RNA Polymerase II Transcription Termination (Pathway) 6547 

13.3.6.1 Cleavage of Growing Transcript in the Termination Region (Pathway) 6548 

13.4 mRNA Capping (Pathway) 6553 

13.5 Processing of Capped Intron-Containing Pre-mRNA (Pathway) 6564 

13.5.3 mRNA Splicing (Pathway) 6567 

13.5.3.1 mRNA Splicing - Major Pathway (Pathway) 6567 

13.5.3.2 mRNA Splicing - Minor Pathway (Pathway) 6579 

13.5.4 mRNA 3'-end processing (Pathway) 6591 

13.5.5 Transport of Mature Transcript to Cytoplasm (Pathway) 6593 

13.5.5.1 Transport of Mature mRNA derived from an Intron-Containing Transcript 6594 (Pathway) 

13.5.5.2 Transport of Mature mRNAs Derived from Intronless Transcripts (Pathway) 6597 

13.5.5.2.1 Transport of the SLBP Dependant Mature mRNA (Pathway) 6598 

13.5.5.2.2 Transport of the SLBP independent Mature mRNA (Pathway) 6602 

13.5.5.2.3 Transport of Mature mRNA Derived from an Intronless Transcript (Pathway)6605 

13.6 Processing of Capped Intronless Pre-mRNA (Pathway) 6608 

13.6.1 SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 6609 (Pathway) 

13.6.2 SLBP independent Processing of Histone Pre-mRNAs (Pathway) 6614 

13.6.3 Processing of Intronless Pre-mRNAs (Pathway) 6616 

13.7 mRNA Editing (Pathway) 6621 

13.7.1 mRNA Editing: C to U Conversion (Pathway) 6623 

13.7.1.1 Formation of the Editosome (Pathway) 6624 

13.7.2 mRNA Editing: A to I Conversion (Pathway) 6627 

13.7.2.2 Formation of editosomes by ADAR proteins (Pathway) 6629 

13.7.2.3 C6 deamination of adenosine (Pathway) 6632 

13.8 tRNA Aminoacylation (Pathway) 6633 

13.8.1 Cytosolic tRNA aminoacylation (Pathway) 6635 

13.8.2 Mitochondrial tRNA aminoacylation (Pathway) 6666 

13.9 Deadenylation-dependent mRNA decay (Pathway) 6702 

13.9.1 Deadenylation of mRNA (Pathway) 6704 

13.9.2 mRNA decay by 3' to 5' exoribonuclease (Pathway) 6711 

13.9.3 mRNA decay by 5' to 3' exoribonuclease (Pathway) 6716 

13.10 Nonsense-Mediated Decay (NMD) (Pathway) 6724 

6726 (Pathway) 

13.10.2 Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex 6740 (EJC) (Pathway) 

13.11 Regulatory RNA pathways (Pathway) 6744 

13.11.1 MicroRNA (miRNA) biogenesis (Pathway) 6745 

13.11.2 Small interfering RNA (siRNA) biogenesis (Pathway) 6761 

13.11.3 Post-transcriptional silencing by small RNAs (Pathway) 6769 

13.12 Regulation of mRNA stability by proteins that bind AU-rich elements (Pathway) 6777 

13.12.1 AUF1 (hnRNP D0) destabilizes mRNA (Pathway) 6778 

13.12.2 Butyrate Response Factor 1 (BRF1) destabilizes mRNA (Pathway) 6786 

13.12.3 Tristetraprolin (TTP) destabilizes mRNA (Pathway) 6796 

13.12.4 KSRP destabilizes mRNA (Pathway) 6803 

13.12.5 HuR stabilizes mRNA (Pathway) 6811 

13.13 Translation (Pathway) 6822 

13.13.1 Eukaryotic Translation Initiation (Pathway) 6823 

13.13.1.1 Cap-dependent Translation Initiation (Pathway) 6824 

13.13.1.1.1 Formation of a pool of free 40S subunits (Pathway) 6765

13.13.1.1.2 Formation of the ternary complex, and subsequently, the 43S complex 6828 (Pathway) 

13.13.1.1.3 Activation of the mRNA upon binding of the cap-binding complex and eIFs,6831 and subsequent binding to 43S (Pathway) 

13.13.1.1.3.5 Translation initiation complex formation (Pathway) 6834 

13.13.1.1.4 Ribosomal scanning and start codon recognition (Pathway) 6838 

13.13.1.1.5 GTP hydrolysis and joining of the 60S ribosomal subunit (Pathway) 6840 

13.13.1.1.6 Recycling of eIF2:GDP (Pathway) 6844 

13.13.1.2 L13a-mediated translational silencing of Ceruloplasmin expression (Pathway) 6846 

13.13.2 SRP-dependent cotranslational protein targeting to membrane (Pathway) 6852 

13.13.3 Eukaryotic Translation Elongation (Pathway) 6861 

13.13.3.3 Peptide chain elongation (Pathway) 6866 

13.13.4 Eukaryotic Translation Termination (Pathway) 6877 

13.14 Metabolism of non-coding RNA (Pathway) 6884 

13.14.1 snRNP Assembly (Pathway) 6885 

13.15 Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind 6900 RNA (Pathway) 

13.16 Epigenetic regulation of gene expression (Pathway) 6907 

13.16.1 PRC2 methylates histones and DNA (Pathway) 6909 

13.16.2 TET1,2,3 and TDG demethylate DNA (Pathway) 6917 

13.16.3 Negative epigenetic regulation of rRNA expression (Pathway) 6932 

13.16.3.1 SIRT1 negatively regulates rRNA Expression (Pathway) 6933 

13.16.3.2 NoRC negatively regulates rRNA expression (Pathway) 6941 

13.16.3.2.7 MBD2 binds methylcytosine in chromatin (Reaction) 6955 14 Hemostasis (Pathway) 6957 

14.1 Platelet homeostasis (Pathway) 6959 

14.1.1 Prostacyclin signalling through prostacyclin receptor (Pathway) 6960 

14.1.2 Nitric oxide stimulates guanylate cyclase (Pathway) 6967 

14.1.2.4 cGMP effects (Pathway) 6973 

14.1.4 Platelet calcium homeostasis (Pathway) 6982 

14.1.4.1 Elevation of cytosolic Ca2+ levels (Pathway) 6983 

14.1.4.2 Reduction of cytosolic Ca++ levels (Pathway) 6992 

14.1.5 Platelet sensitization by LDL (Pathway) 6998 

14.2 Platelet Adhesion to exposed collagen (Pathway) 7010 

14.3 Platelet activation, signaling and aggregation (Pathway) 7018 

14.3.1 GP1b-IX-V activation signalling (Pathway) 7020 

14.3.2 Signal amplification (Pathway) 7032 

14.3.2.1 ADP signalling through P2Y purinoceptor 12 (Pathway) 7034 

14.3.2.2 ADP signalling through P2Y purinoceptor 1 (Pathway) 7040 

14.3.2.3 Thromboxane signalling through TP receptor (Pathway) 7050 

14.3.3 Thrombin signalling through proteinase activated receptors (PARs) (Pathway) 7059 

14.3.4 GPVI-mediated activation cascade (Pathway) 7079 

14.3.5 Platelet Aggregation (Plug Formation) (Pathway) 7112 

14.3.5.1 Integrin alphaIIb beta3 signaling (Pathway) 7113 

14.3.5.1.14 GRB2:SOS provides linkage to MAPK signaling for Integrins (Pathway) 7134 

14.3.5.1.15 p130Cas linkage to MAPK signaling for integrins (Pathway) 7138 

14.3.5.2 Adrenaline signalling through Alpha-2 adrenergic receptor (Pathway) 7153 

14.3.6 Effects of PIP2 hydrolysis (Pathway) 7159 

14.3.6.6 Arachidonate production from DAG (Pathway) 7167 

14.3.7 Response to elevated platelet cytosolic Ca2+ (Pathway) 7173 

14.3.7.2 Disinhibition of SNARE formation (Pathway) 7176 

14.3.7.3 Platelet degranulation (Pathway) 7178 

14.4 Formation of Fibrin Clot (Clotting Cascade) (Pathway) 7194 

14.4.1 Extrinsic Pathway (Pathway) 7195 

14.4.2 Intrinsic Pathway (Pathway) 7203 

14.4.3 Common Pathway (Pathway) 7228 

14.5 Dissolution of Fibrin Clot (Pathway) 7244 

14.6 Cell surface interactions at the vascular wall (Pathway) 7269 

14.6.23 Tie2 Signaling (Pathway) 7291 

14.6.24 PECAM1 interactions (Pathway) 7311 

14.6.25 Basigin interactions (Pathway) 7317 

14.7 Factors involved in megakaryocyte development and platelet production (Pathway) 7330 

14.7.29 Kinesins (Pathway) 7378 

14.7.29.14 Kinesins move along microtubules consuming ATP (BlackBoxEvent) 7402 15 Immune System (Pathway) 7404 

15.1 Adaptive Immune System (Pathway) 7404 

15.1.1 TCR signaling (Pathway) 7406 

15.1.1.1 Phosphorylation of CD3 and TCR zeta chains (Pathway) 7408 

15.1.1.2 Translocation of ZAP-70 to Immunological synapse (Pathway) 7416 

15.1.1.3 Generation of second messenger molecules (Pathway) 7421 

15.1.1.4 Downstream TCR signaling (Pathway) 7443 

15.1.1.4.21 Activation of NF-kB complex (Reaction) 7469 15.1.2 Costimulation by the CD28 family (Pathway) 7470 

15.1.2.1 CD28 co-stimulation (Pathway) 7473 

15.1.2.1.5 CD28 dependent PI3K/Akt signaling (Pathway) 7480 

15.1.2.1.6 CD28 dependent Vav1 pathway (Pathway) 7495 

15.1.2.2 CTLA4 inhibitory signaling (Pathway) 7505 

15.1.2.5 PD-1 signaling (Pathway) 7515 

15.1.3 Signaling by the B Cell Receptor (BCR) (Pathway) 7525 

15.1.3.1 Antigen activates B Cell Receptor (BCR) leading to generation of second 7529 messengers (Pathway) 

15.1.3.2 Downstream signaling events of B Cell Receptor (BCR) (Pathway) 7564 

15.1.3.2.1 Activation of NF-kappaB in B cells (Pathway) 7565 

15.1.3.2.2 Activation of RAS in B cells (Pathway) 7586 

15.1.3.2.3 PIP3 activates AKT signaling (Pathway) 7591 

15.1.3.2.3.6 PDPK1 phosphorylates AKT at T308 (Reaction) 7597 15.1.3.2.3.7 AKT phosphorylates targets in the cytosol (Pathway) 7597 

15.1.3.2.3.9 AKT phosphorylates targets in the nucleus (Pathway) 7609 

15.1.3.2.3.10 Negative regulation of the PI3K/AKT network (Pathway) 7614 

15.1.4 Class I MHC mediated antigen processing & presentation (Pathway) 7622 

15.1.4.1 Antigen processing: Ubiquitination & Proteasome degradation (Pathway) 7624 

15.1.4.2 Antigen Presentation: Folding, assembly and peptide loading of class I MHC 7637 (Pathway) 

15.1.4.3 Antigen processing-Cross presentation (Pathway) 7659 

15.1.4.3.1 Cross-presentation of particulate exogenous antigens (phagosomes) 7660 (Pathway) 

15.1.4.3.2 ER-Phagosome pathway (Pathway) 7670 

15.1.4.3.3 Endosomal/Vacuolar pathway (Pathway) 7683 

15.1.4.3.4 Cross-presentation of soluble exogenous antigens (endosomes) (Pathway) 7691 

15.1.5 MHC class II antigen presentation (Pathway) 7702 

15.1.6 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 7744 (Pathway) 

15.1.7 Rap1 signalling (Pathway) 7776 

15.2 Innate Immune System (Pathway) 7784 

15.2.1 Toll-Like Receptors Cascades (Pathway) 7785 

15.2.1.1 Trafficking and processing of endosomal TLR (Pathway) 7787 

15.2.1.2 Toll Like Receptor 10 (TLR10) Cascade (Pathway) 7801 

15.2.1.2.2 MyD88 cascade initiated on plasma membrane (Pathway) 7804 

15.2.1.2.2.12 IRAK1 recruits IKK complex (Pathway) 7820 

15.2.1.2.2.13 IRAK2 mediated activation of TAK1 complex (Pathway) 7829 

15.2.1.2.2.15 TAK1 activates NFkB by phosphorylation and activation of IKKs complex7840 (Pathway) 

15.2.1.2.2.16 MAP kinase activation in TLR cascade (Pathway) 7846 

15.2.1.2.2.16.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 7848 activated human TAK1 (Pathway) 

15.2.1.2.2.16.2 activated TAK1 mediates p38 MAPK activation (Pathway) 7852 

15.2.1.2.2.16.3 ERK activation (Pathway) 7858 

15.2.1.2.2.16.3.1 ERK1 activation (Pathway) 7858 

15.2.1.2.2.16.3.2 ERK2 activation (Pathway) 7860 

15.2.1.2.2.16.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway) 7862 

15.2.1.2.2.16.4.1 ERK/MAPK targets (Pathway) 7864 

15.2.1.2.2.16.4.1.7 ERKs are inactivated (Pathway) 7871 

15.2.1.2.2.16.4.2 CREB phosphorylation (Pathway) 7873 

15.2.1.2.2.16.4.3 Activation of the AP-1 family of transcription factors (Pathway) 7878 

15.2.1.3 Toll Like Receptor 3 (TLR3) Cascade (Pathway) 7883 

15.2.1.3.2 MyD88-independent cascade (Pathway) 7886 

15.2.1.3.2.4 TRIF-mediated TLR3/TLR4 signaling (Pathway) 7892 

15.2.1.3.2.4.1 Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon (Pathway) 7893 

15.2.1.3.2.4.2 IKK complex recruitment mediated by RIP1 (Pathway) 7910 

15.2.1.3.2.4.3 TRIF-mediated programmed cell death (Pathway) 7916 

15.2.1.3.2.4.4 TRAF6 mediated induction of TAK1 complex (Pathway) 7923 

7933 (Pathway) 

15.2.1.3.2.4.6 MAP kinase activation in TLR cascade (Pathway) 7934 

15.2.1.3.2.4.6.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 7934 activated human TAK1 (Pathway) 

15.2.1.3.2.4.6.2 activated TAK1 mediates p38 MAPK activation (Pathway) 7935 

15.2.1.3.2.4.6.3 ERK activation (Pathway) 7937 

15.2.1.3.2.4.6.3.1 ERK1 activation (Pathway) 7937 

15.2.1.3.2.4.6.3.2 ERK2 activation (Pathway) 7939 

15.2.1.3.2.4.6.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)7941 

15.2.1.3.2.4.6.4.1 ERK/MAPK targets (Pathway) 7941 

15.2.1.3.2.4.6.4.1.7 ERKs are inactivated (Pathway) 7943 

15.2.1.3.2.4.6.4.2 CREB phosphorylation (Pathway) 7943 

15.2.1.3.2.4.6.4.3 Activation of the AP-1 family of transcription factors (Pathway) 7945 

15.2.1.4 Toll Like Receptor 5 (TLR5) Cascade (Pathway) 7946 

15.2.1.4.2 MyD88 cascade initiated on plasma membrane (Pathway) 7949 

15.2.1.4.2.12 IRAK1 recruits IKK complex (Pathway) 7952 

15.2.1.4.2.13 IRAK2 mediated activation of TAK1 complex (Pathway) 7953 

15.2.1.4.2.15 TAK1 activates NFkB by phosphorylation and activation of IKKs complex7955 (Pathway) 

15.2.1.4.2.16 MAP kinase activation in TLR cascade (Pathway) 7957 

15.2.1.4.2.16.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 7957 activated human TAK1 (Pathway) 

15.2.1.4.2.16.2 activated TAK1 mediates p38 MAPK activation (Pathway) 7958 

15.2.1.4.2.16.3 ERK activation (Pathway) 7960 

15.2.1.4.2.16.3.1 ERK1 activation (Pathway) 7960 

15.2.1.4.2.16.3.2 ERK2 activation (Pathway) 7962 

15.2.1.4.2.16.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway) 7963 

15.2.1.4.2.16.4.1 ERK/MAPK targets (Pathway) 7963 

15.2.1.4.2.16.4.1.7 ERKs are inactivated (Pathway) 7965 

15.2.1.4.2.16.4.2 CREB phosphorylation (Pathway) 7966 

15.2.1.4.2.16.4.3 Activation of the AP-1 family of transcription factors (Pathway)  7967  

15.2.1.5 Toll Like Receptor 7/8 (TLR7/8) Cascade (Pathway) 7969 

15.2.1.5.2 MyD88 dependent cascade initiated on endosome (Pathway) 7971 

15.2.1.5.2.11 TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 7988 activation (Pathway) 

15.2.1.5.2.11.2 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation (Pathway)7991 

15.2.1.5.2.11.3 IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 8000 stimulation (Pathway) 

15.2.1.5.2.11.4 TAK1 activates NFkB by phosphorylation and activation of IKKs 8008 complex (Pathway) 

15.2.1.5.2.11.6 MAP kinase activation in TLR cascade (Pathway) 8010 

15.2.1.5.2.11.6.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 8010 activated human TAK1 (Pathway) 

15.2.1.5.2.11.6.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8011 

15.2.1.5.2.11.6.3 ERK activation (Pathway) 8013 

15.2.1.5.2.11.6.3.1 ERK1 activation (Pathway) 8013 

15.2.1.5.2.11.6.3.2 ERK2 activation (Pathway) 8015 

15.2.1.5.2.11.6.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)

15.2.1.5.2.11.6.4.1 ERK/MAPK targets (Pathway) 8017 

15.2.1.5.2.11.6.4.1.7 ERKs are inactivated (Pathway) 8018 

15.2.1.5.2.11.6.4.2 CREB phosphorylation (Pathway) 8019 

15.2.1.5.2.11.6.4.3 Activation of the AP-1 family of transcription factors (Pathway)8020 

15.2.1.5.2.12 TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling (Pathway) 8022 

15.2.1.6 Toll Like Receptor 9 (TLR9) Cascade (Pathway) 8030 

15.2.1.6.5 MyD88 dependent cascade initiated on endosome (Pathway) 8037 

15.2.1.6.5.11 TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 8040 activation (Pathway) 

15.2.1.6.5.11.2 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation (Pathway)8041 

15.2.1.6.5.11.3 IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 8042 stimulation (Pathway) 

15.2.1.6.5.11.4 TAK1 activates NFkB by phosphorylation and activation of IKKs 8044 complex (Pathway) 

15.2.1.6.5.11.6 MAP kinase activation in TLR cascade (Pathway) 8046 

15.2.1.6.5.11.6.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 8046 activated human TAK1 (Pathway) 

15.2.1.6.5.11.6.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8047 

15.2.1.6.5.11.6.3 ERK activation (Pathway) 8049 

15.2.1.6.5.11.6.3.1 ERK1 activation (Pathway) 8049 

15.2.1.6.5.11.6.3.2 ERK2 activation (Pathway) 8051 

15.2.1.6.5.11.6.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)

15.2.1.6.5.11.6.4.1 ERK/MAPK targets (Pathway) 8053 

15.2.1.6.5.11.6.4.1.7 ERKs are inactivated (Pathway) 8054 

15.2.1.6.5.11.6.4.2 CREB phosphorylation (Pathway) 8055 

15.2.1.6.5.11.6.4.3 Activation of the AP-1 family of transcription factors (Pathway)8056 

15.2.1.6.5.12 TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling (Pathway) 8058 

15.2.1.7 Toll Like Receptor 4 (TLR4) Cascade (Pathway) 8060 

15.2.1.7.2 Transfer of LPS from LBP carrier to CD14 (Pathway) 8063 

15.2.1.7.9 Activated TLR4 signalling (Pathway) 8076 

15.2.1.7.9.1 MyD88:Mal cascade initiated on plasma membrane (Pathway) 8078 

15.2.1.7.9.1.17 IRAK2 mediated activation of TAK1 complex (Pathway) 8104 

15.2.1.7.9.1.18 IRAK1 recruits IKK complex (Pathway) 8105 

15.2.1.7.9.1.20 TAK1 activates NFkB by phosphorylation and activation of IKKs 8107 complex (Pathway) 

15.2.1.7.9.1.21 MAP kinase activation in TLR cascade (Pathway) 8108 

15.2.1.7.9.1.21.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 8108 activated human TAK1 (Pathway) 

15.2.1.7.9.1.21.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8109 

15.2.1.7.9.1.21.3 ERK activation (Pathway) 8111 

15.2.1.7.9.1.21.3.1 ERK1 activation (Pathway) 8111 

15.2.1.7.9.1.21.3.2 ERK2 activation (Pathway) 8113 

15.2.1.7.9.1.21.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)8114 

15.2.1.7.9.1.21.4.1 ERK/MAPK targets (Pathway) 8115 

15.2.1.7.9.1.21.4.1.7 ERKs are inactivated (Pathway) 8116 

15.2.1.7.9.1.21.4.2 CREB phosphorylation (Pathway) 8117 

15.2.1.7.9.1.21.4.3 Activation of the AP-1 family of transcription factors (Pathway)8118 

15.2.1.7.9.2 MyD88-independent cascade (Pathway) 8120 

15.2.1.7.9.2.4 TRIF-mediated TLR3/TLR4 signaling (Pathway) 8121 

15.2.1.7.9.2.4.1 Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon (Pathway) 8121 

15.2.1.7.9.2.4.2 IKK complex recruitment mediated by RIP1 (Pathway) 8124 

15.2.1.7.9.2.4.3 TRIF-mediated programmed cell death (Pathway) 8125 

15.2.1.7.9.2.4.4 TRAF6 mediated induction of TAK1 complex (Pathway) 8126 

15.2.1.7.9.2.4.5 TAK1 activates NFkB by phosphorylation and activation of IKKs 8128 complex (Pathway) 

15.2.1.7.9.2.4.6 MAP kinase activation in TLR cascade (Pathway) 8130 

15.2.1.7.9.2.4.6.1 JNK (c-Jun kinases) phosphorylation and activation mediated by8130 activated human TAK1 (Pathway) 

15.2.1.7.9.2.4.6.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8131 

15.2.1.7.9.2.4.6.3 ERK activation (Pathway) 8133 

15.2.1.7.9.2.4.6.3.1 ERK1 activation (Pathway) 8133 

15.2.1.7.9.2.4.6.3.2 ERK2 activation (Pathway) 8135 

15.2.1.7.9.2.4.6.4 MAPK targets/ Nuclear events mediated by MAP kinases 8136 (Pathway) 

15.2.1.7.9.2.4.6.4.1 ERK/MAPK targets (Pathway) 8136 

15.2.1.7.9.2.4.6.4.1.7 ERKs are inactivated (Pathway) 8138 

15.2.1.7.9.2.4.6.4.2 CREB phosphorylation (Pathway) 8139 

15.2.1.7.9.2.4.6.4.3 Activation of the AP-1 family of transcription factors (Pathway)8140 

15.2.1.8 Toll Like Receptor 2 (TLR2) Cascade (Pathway) 8142 

15.2.1.8.1 Toll Like Receptor TLR1:TLR2 Cascade (Pathway) 8143 

15.2.1.8.1.3 MyD88:Mal cascade initiated on plasma membrane (Pathway) 8147 

15.2.1.8.1.3.17 IRAK2 mediated activation of TAK1 complex (Pathway) 8152 

15.2.1.8.1.3.18 IRAK1 recruits IKK complex (Pathway) 8153 

15.2.1.8.1.3.20 TAK1 activates NFkB by phosphorylation and activation of IKKs 8155 complex (Pathway) 

15.2.1.8.1.3.21 MAP kinase activation in TLR cascade (Pathway) 8156 

15.2.1.8.1.3.21.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 8156 activated human TAK1 (Pathway) 

15.2.1.8.1.3.21.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8157 

15.2.1.8.1.3.21.3 ERK activation (Pathway) 8159 

15.2.1.8.1.3.21.3.1 ERK1 activation (Pathway) 8159 15.2.1.8.1.3.21.3.1.1 Inactivation of MEK1 by p34cdc2 (Reaction) 8159 

15.2.1.8.1.3.21.3.2 ERK2 activation (Pathway) 8161 

15.2.1.8.1.3.21.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)

15.2.1.8.1.3.21.4.1 ERK/MAPK targets (Pathway) 8163 

15.2.1.8.1.3.21.4.1.7 ERKs are inactivated (Pathway) 8164 

15.2.1.8.1.3.21.4.2 CREB phosphorylation (Pathway) 8165 

15.2.1.8.1.3.21.4.3 Activation of the AP-1 family of transcription factors (Pathway)8166 

15.2.1.8.2 Toll Like Receptor TLR6:TLR2 Cascade (Pathway) 8168 

15.2.1.8.2.3 MyD88:Mal cascade initiated on plasma membrane (Pathway) 8172 

15.2.1.8.2.3.17 IRAK2 mediated activation of TAK1 complex (Pathway) 8177 

15.2.1.8.2.3.18 IRAK1 recruits IKK complex (Pathway) 8178 

15.2.1.8.2.3.20 TAK1 activates NFkB by phosphorylation and activation of IKKs 8180 complex (Pathway) 

15.2.1.8.2.3.21 MAP kinase activation in TLR cascade (Pathway) 8181 15.2.1.8.2.3.21.1 JNK (c-Jun kinases) phosphorylation and activation mediated by 8181 activated human TAK1 (Pathway) 

15.2.1.8.2.3.21.2 activated TAK1 mediates p38 MAPK activation (Pathway) 8182 

15.2.1.8.2.3.21.3 ERK activation (Pathway) 8184 

15.2.1.8.2.3.21.3.1 ERK1 activation (Pathway) 8184 

15.2.1.8.2.3.21.3.2 ERK2 activation (Pathway) 8186 

15.2.1.8.2.3.21.4 MAPK targets/ Nuclear events mediated by MAP kinases (Pathway)8187 

15.2.1.8.2.3.21.4.1 ERK/MAPK targets (Pathway) 8188 

15.2.1.8.2.3.21.4.1.7 ERKs are inactivated (Pathway) 8189 

15.2.1.8.2.3.21.4.2 CREB phosphorylation (Pathway) 8190 

15.2.1.8.2.3.21.4.3 Activation of the AP-1 family of transcription factors (Pathway)8191 

15.2.2 Complement cascade (Pathway) 8193 

15.2.2.1 Initial triggering of complement (Pathway) 8201 

15.2.2.1.1 Creation of C4 and C2 activators (Pathway) 8202 

15.2.2.1.1.1 Lectin pathway of complement activation (Pathway) 8203 

15.2.2.1.1.1.1 Ficolins bind to repetitive carbohydrate structures on the target cell 8206 surface (Pathway) 

15.2.2.1.1.2 Classical antibody-mediated complement activation (Pathway) 8216 

15.2.2.1.6 Alternative complement activation (Pathway) 8226 

15.2.2.2 Activation of C3 and C5 (Pathway) 8239 

15.2.2.3 Terminal pathway of complement (Pathway) 8246 

15.2.2.4 Regulation of Complement cascade (Pathway) 8251 

15.2.3 Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling8292 pathways (Pathway) 

15.2.3.1 NOD1/2 Signaling Pathway (Pathway) 8294 

15.2.3.2 Inflammasomes (Pathway) 8320 

15.2.3.2.1 The NLRP3 inflammasome (Pathway) 8322 

15.2.3.2.2 The NLRP1 inflammasome (Pathway) 8350 

15.2.3.2.3 The IPAF inflammasome (Pathway) 8357 

15.2.3.2.4 The AIM2 inflammasome (Pathway) 8363 

15.2.4 Advanced glycosylation endproduct receptor signaling (Pathway) 8370 

15.2.5 RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways (Pathway) 8380 

15.2.5.5 TRAF3-dependent IRF activation pathway (Pathway) 8389 

15.2.5.6 NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -108402 (Pathway) 

15.2.5.7 TRAF6 mediated IRF7 activation (Pathway) 8410 

15.2.5.8 TRAF6 mediated NF-kB activation (Pathway) 8422 

15.2.5.9 Negative regulators of RIG-I/MDA5 signaling (Pathway) 8427 

15.2.6 Defensins (Pathway) 8447 

15.2.6.2 Alpha-defensins (Pathway) 8451 

15.2.6.3 Beta defensins (Pathway) 8470 

15.2.7 Cytosolic sensors of pathogen-associated DNA (Pathway) 8482 

15.2.7.1 ZBP1(DAI) mediated induction of type I IFNs (Pathway) 8484 

15.2.7.1.2 IRF3 mediated activation of type 1 IFN (Pathway) 8487 

15.2.7.1.3 RIP-mediated NFkB activation via ZBP1 (Pathway) 8495 

15.2.7.2 STING mediated induction of host immune responses (Pathway) 8501 

15.2.7.2.8 IRF3-mediated induction of type I IFN (Pathway) 8516 

15.2.7.2.9 STAT6-mediated induction of chemokines (Pathway) 8524 

15.2.7.4 LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production 8535 (Pathway) 

15.2.7.5 DEx/H-box helicases activate type I IFN and inflammatory cytokines production8543 (Pathway) 

15.2.7.7 MRE11 binds cytosolic DNA (Reaction) 8551 15.2.7.8 Regulation of innate immune responses to cytosolic DNA (Pathway) 8552 

15.2.7.8.6 Regulation by TREX1 (Pathway) 8560 

15.2.8 Fcgamma receptor (FCGR) dependent phagocytosis (Pathway) 8566 

15.2.8.1 FCGR activation (Pathway) 8568 

15.2.8.2 Regulation of actin dynamics for phagocytic cup formation (Pathway) 8582 

15.2.8.3 Role of phospholipids in phagocytosis (Pathway) 8620 

15.2.9 DAP12 interactions (Pathway) 8637 

15.2.9.17 DAP12 signaling (Pathway) 8663 

15.2.9.17.6 PIP3 activates AKT signaling (Pathway) 8673 

15.2.9.17.6.7 AKT phosphorylates targets in the cytosol (Pathway) 8674 

15.2.9.17.6.9 AKT phosphorylates targets in the nucleus (Pathway) 8677 

15.2.9.17.6.10 Negative regulation of the PI3K/AKT network (Pathway) 8678 

15.2.9.17.12 RAF/MAP kinase cascade (Pathway) 8689 

15.2.9.17.12.1 RAF activation (Pathway) 8689 

15.2.9.17.12.2 MEK activation (Pathway) 8692 

15.2.9.17.12.2.2 RAF phosphorylates MEK (Pathway) 8692 

15.2.9.17.12.3 ERK activation (Pathway) 8693 

15.2.9.17.12.3.1 ERK1 activation (Pathway) 8693 

15.2.9.17.12.3.2 ERK2 activation (Pathway) 8695 

15.2.9.17.18 DAG and IP3 signaling (Pathway) 8704 

15.2.9.17.18.5 CaM pathway (Pathway) 8705 

15.2.9.17.18.5.2 Calmodulin induced events (Pathway) 8707 

15.2.9.17.18.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 8708 

15.2.9.17.18.5.2.1.1 PKA activation (Pathway) 8709 

15.2.9.17.18.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 8717 

15.2.9.17.18.5.2.3 Cam-PDE 1 activation (Pathway) 8724 

15.2.10 Fc epsilon receptor (FCERI) signaling (Pathway) 8733 

15.2.10.7 FCERI mediated MAPK activation (Pathway) 8745 

15.2.10.7.5 RAF/MAP kinase cascade (Pathway) 8750 

15.2.10.7.5.1 RAF activation (Pathway) 8750 

15.2.10.7.5.2 MEK activation (Pathway) 8751 

15.2.10.7.5.2.2 RAF phosphorylates MEK (Pathway) 8752 

15.2.10.7.5.3 ERK activation (Pathway) 8753 

15.2.10.7.5.3.1 ERK1 activation (Pathway) 8753 

15.2.10.7.5.3.2 ERK2 activation (Pathway) 8755 

15.2.10.8 FCERI mediated Ca+2 mobilization (Pathway) 8772 

15.2.10.9 FCERI mediated NF-kB activation (Pathway) 8788 

15.2.10.10 Role of LAT2/NTAL/LAB on calcium mobilization (Pathway) 8813 

15.2.10.10.8 PIP3 activates AKT signaling (Pathway) 8825 

15.2.10.10.8.7 AKT phosphorylates targets in the cytosol (Pathway) 8826 

15.2.10.10.8.9 AKT phosphorylates targets in the nucleus (Pathway) 8829 

15.2.10.10.8.10 Negative regulation of the PI3K/AKT network (Pathway) 8830 

15.3 Cytokine Signaling in Immune system (Pathway) 8832 

15.3.1 Interferon Signaling (Pathway) 8833 

15.3.1.1 Interferon alpha/beta signaling (Pathway) 8835 

15.3.1.1.15 Regulation of IFNA signaling (Pathway) 8859 

15.3.1.2 Interferon gamma signaling (Pathway) 8867 

15.3.1.2.12 Regulation of IFNG signaling (Pathway) 8886 

15.3.1.3 Antiviral mechanism by IFN-stimulated genes (Pathway) 8892 

15.3.1.3.1 ISG15 antiviral mechanism (Pathway) 8893 

15.3.2 Signaling by Interleukins (Pathway) 8917 

15.3.2.1 Interleukin-1 processing (Pathway) 8918 

15.3.2.2 Interleukin-1 signaling (Pathway) 8927 

15.3.2.3 Interleukin-2 signaling (Pathway) 8970 

15.3.2.3.11 Interleukin receptor SHC signaling (Pathway) 8988 

15.3.2.3.12 RAF/MAP kinase cascade (Pathway) 9002 

15.3.2.3.12.1 RAF activation (Pathway) 9002 

15.3.2.3.12.2 MEK activation (Pathway) 9003 

15.3.2.3.12.2.2 RAF phosphorylates MEK (Pathway) 9004 

15.3.2.3.12.3 ERK activation (Pathway) 9005 

15.3.2.3.12.3.1 ERK1 activation (Pathway) 9005 

15.3.2.3.12.3.2 ERK2 activation (Pathway) 9007 

15.3.2.4 Interleukin-3, 5 and GM-CSF signaling (Pathway) 9020 

15.3.2.4.19 Interleukin receptor SHC signaling (Pathway) 9052 

15.3.2.4.20 Regulation of signaling by CBL (Pathway) 9054 

15.3.2.5 Interleukin-6 signaling (Pathway) 9080 

15.3.2.6 Interleukin-7 signaling (Pathway) 9112 

15.3.3 Growth hormone receptor signaling (Pathway) 9134 

15.3.4 Prolactin receptor signaling (Pathway) 9184 

15.3.4.14 Prolactin receptor is internalized (BlackBoxEvent) 9211 16 Membrane Trafficking (Pathway) 9213 

16.1 ER to Golgi Transport (Pathway) 9214 

16.1.1 COPII (Coat Protein 2) Mediated Vesicle Transport (Pathway) 9215 

16.2 Golgi to ER Retrograde Transport (Pathway) 9224 

16.2.1 COPI Mediated Transport (Pathway) 9225 

16.3 trans-Golgi Network Vesicle Budding (Pathway) 9235 

16.3.1 Clathrin derived vesicle budding (Pathway) 9236 

16.3.1.2 Golgi Associated Vesicle Biogenesis (Pathway) 9239 

16.3.1.3 Lysosome Vesicle Biogenesis (Pathway) 9248 

16.3.1.6 Vamp8 associated secretory vesicle to plasma membrane transport (Reaction) 9256 16.4 Gap junction trafficking and regulation (Pathway) 9257 

16.4.1 Gap junction trafficking (Pathway) 9259 

16.4.1.1 Gap junction assembly (Pathway) 9261 

16.4.1.1.5 Transport of connexins along the secretory pathway (Pathway) 9268 

16.4.1.1.6 Oligomerization of connexins into connexons (Pathway) 9272 

16.4.1.1.7 Transport of connexons to the plasma membrane (Pathway) 9278 

16.4.1.1.7.2 Microtubule-dependent trafficking of connexons from Golgi to the plasma9281 membrane (Pathway) 

16.4.1.2 Gap junction degradation (Pathway) 9294 

16.4.1.2.1 Formation of annular gap junctions (Pathway) 9295 

16.4.2 Regulation of gap junction activity (Pathway) 9301 

16.4.2.1 c-src mediated regulation of Cx43 function and closure of gap junctions (Pathway)

16.5 Endosomal Sorting Complex Required For Transport (ESCRT) (Pathway) 9307 

16.6 Translocation of GLUT4 to the plasma membrane (Pathway) 9314 

16.6.14 GLUT4 vesicle fuses with the plasma membrane (BlackBoxEvent) 9339 17 Metabolism (Pathway) 9342 

17.1 Metabolism of carbohydrates (Pathway) 9342 

17.1.1 Digestion of dietary carbohydrate (Pathway) 9343 

17.1.2 Hexose transport (Pathway) 9348 

17.1.2.4 Glucose transport (Pathway) 9350 

17.1.2.4.6 Regulation of Glucokinase by Glucokinase Regulatory Protein (Pathway) 9352 

17.1.3 Glucose metabolism (Pathway) 9357 

17.1.3.1 Glycolysis (Pathway) 9357 

17.1.3.2 Gluconeogenesis (Pathway) 9363 

17.1.3.3 Glycogen synthesis (Pathway) 9373 

17.1.3.4 Glycogen breakdown (glycogenolysis) (Pathway) 9382 

17.1.4 Fructose catabolism (Pathway) 9389 

17.1.5 Galactose catabolism (Pathway) 9390 

17.1.6 Pentose phosphate pathway (hexose monophosphate shunt) (Pathway) 9392 

17.1.7 5-Phosphoribose 1-diphosphate biosynthesis (Pathway) 9398 

17.1.8 Glycosaminoglycan metabolism (Pathway) 9399 

17.1.8.1 Hyaluronan metabolism (Pathway) 9399 

17.1.8.1.1 Hyaluronan biosynthesis and export (Pathway) 9400 

17.1.8.1.2 Hyaluronan uptake and degradation (Pathway) 9401 

17.1.8.2 Transport and synthesis of PAPS (Pathway) 9405 

17.1.8.3 Keratan sulfate/keratin metabolism (Pathway) 9408 

17.1.8.3.1 Keratan sulfate biosynthesis (Pathway) 9408 

17.1.8.3.2 Keratan sulfate degradation (Pathway) 9413 

17.1.8.4 Heparan sulfate/heparin (HS-GAG) metabolism (Pathway) 9416 

17.1.8.4.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway) 9416 

17.1.8.4.2 HS-GAG biosynthesis (Pathway) 9418 

17.1.8.4.3 HS-GAG degradation (Pathway) 9425 

17.1.8.5 Chondroitin sulfate/dermatan sulfate metabolism (Pathway) 9433 

17.1.8.5.1 A tetrasaccharide linker sequence is required for GAG synthesis (Pathway) 9433 

17.1.8.5.2 Chondroitin sulfate biosynthesis (Pathway) 9434 

17.1.8.5.3 Dermatan sulfate biosynthesis (Pathway) 9438 

17.1.8.5.4 CS/DS degradation (Pathway) 9440 

17.2 Inositol phosphate metabolism (Pathway) 9444 

17.2.1 Synthesis of IP3 and IP4 in the cytosol (Pathway) 9446 

17.2.2 IP3 and IP4 transport between cytosol and nucleus (Pathway) 9463 

17.2.3 Synthesis of IPs in the nucleus (Pathway) 9467 

17.2.4 IPs transport between nucleus and cytosol (Pathway) 9483 

17.2.5 Synthesis of pyrophosphates in the cytosol (Pathway) 9489 

17.2.6 IP6 and IP7 transport between cytosol and nucleus (Pathway) 9515 

17.2.7 IPs transport between cytosol and ER lumen (Pathway) 9518 

17.2.8 Synthesis of IPs in the ER lumen (Pathway) 9523 

17.2.9 IPs transport between ER lumen and cytosol (Pathway) 9529 

17.2.10 IPs transport between ER lumen and nucleus (Pathway) 9533 

17.2.11 IPs transport between nucleus and ER lumen (Pathway) 9537 

17.2.12 Synthesis of IP2, IP, and Ins in the cytosol (Pathway) 9539 

17.3 Metabolism of lipids and lipoproteins (Pathway) 9554 

17.3.1 Lipid digestion, mobilization, and transport (Pathway) 9555 

17.3.1.1 Digestion of dietary lipid (Pathway) 9556 

17.3.1.2 Trafficking of dietary sterols (Pathway) 9566 

17.3.1.3 Lipoprotein metabolism (Pathway) 9575 

17.3.1.3.1 Chylomicron-mediated lipid transport (Pathway) 9575 

17.3.1.3.2 HDL-mediated lipid transport (Pathway) 9594 

17.3.1.3.3 LDL-mediated lipid transport (Pathway) 9625 

17.3.1.4 Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis (Pathway) 9637 

17.3.2 Fatty acid, triacylglycerol, and ketone body metabolism (Pathway) 9664 

17.3.2.1 Triglyceride Biosynthesis (Pathway) 9665 

17.3.2.1.1 Fatty Acyl-CoA Biosynthesis (Pathway) 9665 

17.3.2.1.1.6 Synthesis of very long-chain fatty acyl-CoAs (Pathway) 9671 

17.3.2.2 Import of palmitoyl-CoA into the mitochondrial matrix (Pathway) 9701 

17.3.2.3 Mitochondrial Fatty Acid Beta-Oxidation (Pathway) 9709 

17.3.2.3.1 mitochondrial fatty acid beta-oxidation of saturated fatty acids (Pathway) 9710 

17.3.2.3.1.1 Beta oxidation of palmitoyl-CoA to myristoyl-CoA (Pathway) 9711 

17.3.2.3.1.2 Beta oxidation of myristoyl-CoA to lauroyl-CoA (Pathway) 9716 

17.3.2.3.1.3 Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA (Pathway) 9720 

17.3.2.3.1.4 Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA (Pathway) 9724 

17.3.2.3.1.5 Beta oxidation of octanoyl-CoA to hexanoyl-CoA (Pathway) 9728 

17.3.2.3.1.6 Beta oxidation of hexanoyl-CoA to butanoyl-CoA (Pathway) 9732 

17.3.2.3.1.7 Beta oxidation of butanoyl-CoA to acetyl-CoA (Pathway) 9736 

17.3.2.3.2 mitochondrial fatty acid beta-oxidation of unsaturated fatty acids (Pathway) 9739 

17.3.2.3.3 Propionyl-CoA catabolism (Pathway) 9753 

17.3.2.4 Ketone body metabolism (Pathway) 9756 

17.3.2.4.1 Synthesis of Ketone Bodies (Pathway) 9757 

17.3.2.4.2 Utilization of Ketone Bodies (Pathway) 9761 

(PPARalpha) (Pathway) 

17.3.2.6.4 PPARA activates gene expression (Pathway) 9773 

17.3.3 Peroxisomal lipid metabolism (Pathway) 9831 

17.3.3.1 Alpha-oxidation of phytanate (Pathway) 9832 

17.3.3.2 Beta-oxidation of pristanoyl-CoA (Pathway) 9842 

17.3.3.3 Beta-oxidation of very long chain fatty acids (Pathway) 9858 

17.3.3.4 Plasmalogen biosynthesis (Pathway) 9868 

17.3.3.5 NADPH regeneration (Pathway) 9877 

17.3.4 Cholesterol biosynthesis (Pathway) 9883 

17.3.5 Regulation of cholesterol biosynthesis by SREBP (SREBF) (Pathway) 9916 

17.3.5.11 Activation of gene expression by SREBF (SREBP) (Pathway) 9934 

17.3.6 Bile acid and bile salt metabolism (Pathway) 9990 

17.3.6.1 Synthesis of bile acids and bile salts (Pathway) 9992 

17.3.6.1.1 Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol (Pathway)

17.3.6.1.2 Synthesis of bile acids and bile salts via 24-hydroxycholesterol (Pathway) 10051 

17.3.6.1.3 Synthesis of bile acids and bile salts via 27-hydroxycholesterol (Pathway) 10091 

17.3.6.2 Recycling of bile acids and salts (Pathway) 10112 

17.3.7 Metabolism of steroid hormones and vitamin D (Pathway) 10126 

17.3.7.1 Pregnenolone biosynthesis (Pathway) 10128 

17.3.7.2 Glucocorticoid biosynthesis (Pathway) 10138 

17.3.7.2.8 Oxidation of cortisol to yield cortisone (Reaction) 10149 17.3.7.3 Mineralocorticoid biosynthesis (Pathway) 10150 

17.3.7.4 Androgen biosynthesis (Pathway) 10162 

17.3.7.5 Estrogen biosynthesis (Pathway) 10173 

17.3.7.6 Vitamin D (calciferol) metabolism (Pathway) 10178 

17.3.8 Phospholipid metabolism (Pathway) 10194 

17.3.8.1 Glycerophospholipid biosynthesis (Pathway) 10196 

17.3.8.1.1 Synthesis of PA (Pathway) 10198 

17.3.8.1.2 Acyl chain remodeling of DAG and TAG (Pathway) 10209 

17.3.8.1.3 Synthesis of PE (Pathway) 10218 

17.3.8.1.4 Acyl chain remodelling of PE (Pathway) 10229 

17.3.8.1.5 Hydrolysis of LPE (Pathway) 10242 

17.3.8.1.6 Synthesis of PC (Pathway) 10247 

17.3.8.1.7 PI and PC transport between ER and Golgi membranes (Pathway) 10260 

17.3.8.1.8 Acyl chain remodelling of PC (Pathway) 10267 

17.3.8.1.9 Hydrolysis of LPC (Pathway) 10281 

17.3.8.1.10 Synthesis of PS (Pathway) 10290 

17.3.8.1.11 Acyl chain remodelling of PS (Pathway) 10293 

17.3.8.1.12 Synthesis of PI (Pathway) 10302 

17.3.8.1.13 Acyl chain remodelling of PI (Pathway) 10305 

17.3.8.1.14 Synthesis of PG (Pathway) 10314 

17.3.8.1.15 Acyl chain remodelling of PG (Pathway) 10324 

17.3.8.1.16 Synthesis of CL (Pathway) 10337 

17.3.8.1.17 Acyl chain remodeling of CL (Pathway) 10339 

17.3.8.1.18 Synthesis of BMP (Pathway) 10356 

17.3.8.2 PI Metabolism (Pathway) 10361 

17.3.8.2.1 Synthesis of PIPs at the ER membrane (Pathway) 10363 

17.3.8.2.2 PI and PC transport between ER and Golgi membranes (Pathway) 10368 

17.3.8.2.3 Synthesis of PIPs at the Golgi membrane (Pathway) 10369 

17.3.8.2.4 PIPs transport between Golgi and plasma membranes (Pathway) 10388 

17.3.8.2.5 Synthesis of PIPs at the plasma membrane (Pathway) 10391 

17.3.8.2.6 PIPs transport between plasma and early endosome membranes (Pathway)10423 

17.3.8.2.7 Synthesis of PIPs at the early endosome membrane (Pathway) 10426 

17.3.8.2.8 PIPs transport between early endosome and Golgi membranes (Pathway) 10439 

17.3.8.2.9 PIPs transport between early and late endosome membranes (Pathway) 10442 

17.3.8.2.10 Synthesis of PIPs at the late endosome membrane (Pathway) 10444 

17.3.8.2.11 PIPs transport between late endosome and Golgi membranes (Pathway) 10456 

17.3.9 alpha-linolenic (omega3) and linoleic (omega6) acid metabolism (Pathway) 10458 

17.3.9.1 alpha-linolenic acid (ALA) metabolism (Pathway) 10459 

17.3.9.2 Linoleic acid (LA) metabolism (Pathway) 1043810479 17.3.9.2.1 Activation of linoleic acid to linoleoyl-CoA (Reaction) 10481 

17.3.10 Arachidonic acid metabolism (Pathway) 10494 

17.3.10.3 Synthesis of Prostaglandins (PG) and Thromboxanes (TX) (Pathway) 10498 

17.3.10.4 Synthesis of Leukotrienes (LT) and Eoxins (EX) (Pathway) 10539 

17.3.10.5 Synthesis of 5-eicosatetraenoic acids (Pathway) 10567 

17.3.10.6 Synthesis of 15-eicosatetraenoic acid derivatives (Pathway) 10572 

17.3.10.7 Synthesis of 12-eicosatetraenoic acid derivatives (Pathway) 10578 

17.3.10.8 Synthesis of Lipoxins (LX) (Pathway) 10586 

17.3.10.9 Synthesis of Hepoxilins (HX) and Trioxilins (TrX) (Pathway) 10595 

17.3.10.10 Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) (Pathway) 10599 

17.3.10.11 Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) (Pathway)

17.3.11 Sphingolipid metabolism (Pathway) 10610 

17.3.11.1 Sphingolipid de novo biosynthesis (Pathway) 10612 

17.3.11.2 Glycosphingolipid metabolism (Pathway) 10648 

17.3.12 Ubiquinol biosynthesis (Pathway) 10685 

17.4 Integration of energy metabolism (Pathway) 10702 

17.4.1 Regulation of insulin secretion (Pathway) 10705 

17.4.1.1 Adrenaline,noradrenaline inhibits insulin secretion (Pathway) 10708 

17.4.1.2 Acetylcholine regulates insulin secretion (Pathway) 10723 

17.4.1.3 Free fatty acids regulate insulin secretion (Pathway) 10736 

17.4.1.3.1 Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion (Pathway)10737 

17.4.1.4 Glucagon-like Peptide-1 (GLP1) regulates insulin secretion (Pathway) 10743 

17.4.2 Glucagon signaling in metabolic regulation (Pathway) 10783 

17.4.2.5 PKA activation in glucagon signalling (Pathway) 10789 

17.4.3 PKA-mediated phosphorylation of key metabolic factors (Pathway) 10791 

17.4.3.5 Phosphorylation of PF2K-Pase by PKA catalytic subunit (Reaction) 10795 17.4.4 Insulin effects increased synthesis of Xylulose-5-Phosphate (Pathway) 10795 

17.4.6 AMPK inhibits chREBP transcriptional activation activity (Pathway) 10800 

17.4.7 PP2A-mediated dephosphorylation of key metabolic factors (Pathway) 10805 

17.4.8 ChREBP activates metabolic gene expression (Pathway) 10809 

17.5 Metabolism of nitric oxide (Pathway) 10815 

17.5.1 eNOS activation and regulation (Pathway) 10817 

17.5.1.1 eNOS activation (Pathway) 10818 

17.5.1.2 NOSIP mediated eNOS trafficking (Pathway) 10837 

17.5.1.3 NOSTRIN mediated eNOS trafficking (Pathway) 10839 

17.5.1.4 Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation (Pathway)

17.6 The citric acid (TCA) cycle and respiratory electron transport (Pathway) 10865 

17.6.1 Pyruvate metabolism and Citric Acid (TCA) cycle (Pathway) 10865 

17.6.1.1 Pyruvate metabolism (Pathway) 10867 

17.6.1.1.7 Regulation of pyruvate dehydrogenase (PDH) complex (Pathway) 10876 

17.6.1.2 Citric acid cycle (TCA cycle) (Pathway) 

17.6.1.3 Interconversion of 2-oxoglutarate and 2-hydroxyglutarate (Pathway) 10898 

17.6.2 Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat10906 production by uncoupling proteins. (Pathway) 

17.6.2.1 Respiratory electron transport (Pathway) 10907 

17.6.2.2 Formation of ATP by chemiosmotic coupling (Pathway) 10918 

17.6.2.3 Mitochondrial Uncoupling Proteins (Pathway) 10922 

17.6.2.3.1 The fatty acid cycling model (Pathway) 10924 

17.6.2.3.2 The proton buffering model (Pathway) 10929 

17.7 Metabolism of nucleotides (Pathway) 10931 

17.7.1 Purine metabolism (Pathway) 10933 

17.7.1.1 Purine ribonucleoside monophosphate biosynthesis (Pathway) 10934 

17.7.1.2 Purine salvage (Pathway) 10957 

17.7.1.3 Purine catabolism (Pathway) 10970 

17.7.2 Pyrimidine metabolism (Pathway) 10982 

17.7.2.1 Pyrimidine biosynthesis (Pathway) 10983 

17.7.2.2 Pyrimidine salvage reactions (Pathway) 10995 

17.7.2.3 Pyrimidine catabolism (Pathway) 11004 

17.7.3 Synthesis and interconversion of nucleotide di- and triphosphates (Pathway) 11024 

17.7.11 Phosphate bond hydrolysis by NUDT proteins (Pathway) 11059 

17.8 Metabolism of vitamins and cofactors (Pathway) 11080 

17.8.1 Metabolism of water-soluble vitamins and cofactors (Pathway) 11081 

17.8.1.1 Vitamin C (ascorbate) metabolism (Pathway) 11081 

17.8.1.2 Vitamin B1 (thiamin) metabolism (Pathway) 11084 

17.8.1.3 Vitamin B2 (riboflavin) metabolism (Pathway) 11086 

17.8.1.4 Vitamin B5 (pantothenate) metabolism (Pathway) 11088 

17.8.1.4.2 Coenzyme A biosynthesis (Pathway) 11088 

17.8.1.5 Vitamins B6 activation to pyridoxal phosphate (Pathway) 11093 

17.8.1.6 Cobalamin (Cbl, vitamin B12) transport and metabolism (Pathway) 11096 

17.8.1.7 Biotin transport and metabolism (Pathway) 11106 

17.8.1.8 Nicotinate metabolism (Pathway) 11111 

17.8.1.8.8 Nicotinamide salvaging (Pathway) 11115 

17.8.1.9 Metabolism of folate and pterines (Pathway) 11117 

17.8.1.10 Molybdenum cofactor biosynthesis (Pathway) 11126 

17.9 Metabolism of amino acids and derivatives (Pathway) 11128 

17.9.1 Amino acid synthesis and interconversion (transamination) (Pathway) 11129 

17.9.1.20 Serine biosynthesis (Pathway) 11149 

17.9.2 Branched-chain amino acid catabolism (Pathway) 11154 

17.9.3 Histidine catabolism (Pathway) 11176 

17.9.4 Lysine catabolism (Pathway) 11182 

17.9.5 Phenylalanine and tyrosine catabolism (Pathway) 11195 

17.9.6 Proline catabolism (Pathway) 11206 

17.9.7 Tryptophan catabolism (Pathway) 11210 

17.9.8 Urea cycle (Pathway) 11229 

17.9.9 Carnitine synthesis (Pathway) 11240 

17.9.10 Creatine metabolism (Pathway) 11244 

17.9.11 Metabolism of polyamines (Pathway) 11251 

17.9.11.1 Agmatine biosynthesis (Pathway) 11253 

17.9.11.6 Interconversion of polyamines (Pathway) 11261 

17.9.11.7 Methionine salvage pathway (Pathway) 11271 

17.9.12 Regulation of ornithine decarboxylase (ODC) (Pathway) 11282 

17.9.13 Amine-derived hormones (Pathway) 11290 

17.9.13.1 Catecholamine biosynthesis (Pathway) 11291 

17.9.13.2 Thyroxine biosynthesis (Pathway) 11300 

17.9.13.2.9 Regulation of thyroid hormone activity (Pathway) 11311 

17.9.13.3 Serotonin and melatonin biosynthesis (Pathway) 11315 

17.9.14 Glyoxylate metabolism (Pathway) 11321 

17.9.15 Sulfur amino acid metabolism (Pathway) 11333 

17.9.15.1 Methionine salvage pathway (Pathway) 11334 

17.9.15.6 Cysteine formation from homocysteine (Pathway) 11340 

17.9.15.9 Degradation of cysteine and homocysteine (Pathway) 11346 

17.9.15.9.8 Sulfide oxidation to sulfate (Pathway) 11357 

17.10 Metabolism of porphyrins (Pathway) 11367 

17.10.1 Heme biosynthesis (Pathway) 11368 

17.10.2 Heme degradation (Pathway) 11391 

17.11 Biological oxidations (Pathway) 11397 

17.11.1 Phase 1 - Functionalization of compounds (Pathway) 11399 

17.11.1.1 Cytochrome P450 - arranged by substrate type (Pathway) 11401 

17.11.1.1.1 Endogenous sterols (Pathway) 11404 

17.11.1.1.1.4 Sterols are 12-hydroxylated by CYP8B1 (Pathway) 11407 

17.11.1.1.2 Xenobiotics (Pathway) 11414 

17.11.1.1.2.2 Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 11416 (Pathway) 

17.11.1.1.2.10 CYP2E1 reactions (Pathway) 11428 

17.11.1.1.3 Fatty acids (Pathway) 11446 

17.11.1.1.4 Eicosanoids (Pathway) 11452 

17.11.1.1.5 Vitamins (Pathway) 11456 

17.11.1.1.6 Miscellaneous substrates (Pathway) 11462 

17.11.1.2 FMO oxidizes nucleophiles (Pathway) 11470 

17.11.1.3 COX reactions (Pathway) 11476 

17.11.1.4 Amine Oxidase reactions (Pathway) 11478 

11480 and H2O2 (Pathway) 

17.11.1.4.2 Polyamines are oxidized to amines, aldehydes and H2O2 by PAOs (Pathway)

17.11.1.5 Ethanol oxidation (Pathway) 11487 

17.11.2 Phase II conjugation (Pathway) 11498 

17.11.2.1 Glucuronidation (Pathway) 11499 

17.11.2.1.1 Formation of the active cofactor, UDP-glucuronate (Pathway) 11501 

17.11.2.2 Cytosolic sulfonation of small molecules (Pathway) 11507 

17.11.2.2.1 Transport and synthesis of PAPS (Pathway) 11509 

17.11.2.3 Acetylation (Pathway) 11531 

17.11.2.4 Methylation (Pathway) 11535 

17.11.2.5 Glutathione conjugation (Pathway) 11543 

17.11.2.5.1 Glutathione synthesis and recycling (Pathway) 11544 

17.11.2.6 Amino Acid conjugation (Pathway) 11559 

17.11.2.6.1 Conjugation of carboxylic acids (Pathway) 11560 

17.11.2.6.1.1 Conjugation of benzoate with glycine (Pathway) 11561 

17.11.2.6.1.2 Conjugation of phenylacetate with glutamine (Pathway) 11564 

17.11.2.6.1.3 Conjugation of salicylate with glycine (Pathway) 11568 

17.11.3 Aflatoxin activation and detoxification (Pathway) 11571 

17.12 Mitochondrial iron-sulfur cluster biogenesis (Pathway) 11596 

17.12.3 Electron transport from NADPH to Ferredoxin (Pathway) 11602 

17.13 O2/CO2 exchange in erythrocytes (Pathway) 11608 

17.13.1 Erythrocytes take up carbon dioxide and release oxygen (Pathway) 11610 

17.13.2 Erythrocytes take up oxygen and release carbon dioxide (Pathway) 11622 

17.14 Abacavir transport and metabolism (Pathway) 11633 

17.14.1 Abacavir transmembrane transport (Pathway) 11635 

17.14.2 Abacavir metabolism (Pathway) 11641 

17.15 Reversible hydration of carbon dioxide (Pathway) 11652 

17.16 Cytosolic iron-sulfur cluster assembly (Pathway) 11671 

17.16.3 CIA Targeting Complex transfers 4Fe-4S cluster to apoproteins (BlackBoxEvent)11678 18 Metabolism of proteins (Pathway) 11681 

18.1 Translation (Pathway) 11681 

18.1.1 Eukaryotic Translation Initiation (Pathway) 11681 

18.1.1.1 Cap-dependent Translation Initiation (Pathway) 11682 

18.1.1.1.1 Formation of a pool of free 40S subunits (Pathway) 11682 

18.1.1.1.2 Formation of the ternary complex, and subsequently, the 43S complex 11683 (Pathway) 

11684 subsequent binding to 43S (Pathway) 

18.1.1.1.3.5 Translation initiation complex formation (Pathway) 11686 

18.1.1.1.4 Ribosomal scanning and start codon recognition (Pathway) 11687 

18.1.1.1.5 GTP hydrolysis and joining of the 60S ribosomal subunit (Pathway) 11688 

18.1.1.1.6 Recycling of eIF2:GDP (Pathway) 11689 

18.1.1.2 L13a-mediated translational silencing of Ceruloplasmin expression (Pathway) 11690 

18.1.2 SRP-dependent cotranslational protein targeting to membrane (Pathway) 11692 

18.1.3 Eukaryotic Translation Elongation (Pathway) 11694 

18.1.3.3 Peptide chain elongation (Pathway) 11695 

18.1.4 Eukaryotic Translation Termination (Pathway) 11698 

18.2 Protein folding (Pathway) 11699 

18.2.1 Chaperonin-mediated protein folding (Pathway) 11700 

18.2.1.1 Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding (Pathway) 11702 

18.2.1.1.1 Prefoldin mediated transfer of substrate to CCT/TriC (Pathway) 11703 

18.2.1.1.2 Formation of tubulin folding intermediates by CCT/TriC (Pathway) 11708 

18.2.1.1.3 Folding of actin by CCT/TriC (Pathway) 11714 

18.2.1.2 Association of TriC/CCT with target proteins during biosynthesis (Pathway) 11719 

18.2.2 Post-chaperonin tubulin folding pathway (Pathway) 11724 

18.3 Post-translational protein modification (Pathway) 11752 

18.3.1 PTM: gamma carboxylation, hypusine formation and arylsulfatase activation 11753 (Pathway) 

18.3.1.1 Gamma-carboxylation, transport, and amino-terminal cleavage of proteins 11754 (Pathway) 

18.3.1.1.2 Gamma-carboxylation of protein precursors (Pathway) 11756 

18.3.1.1.3 Transport of gamma-carboxylated protein precursors from the endoplasmic11766 reticulum to the Golgi apparatus (Pathway) 

18.3.1.1.4 Removal of aminoterminal propeptides from gamma-carboxylated proteins11770 (Pathway) 

18.3.1.2 Hypusine synthesis from eIF5A-lysine (Pathway) 11776 

18.3.1.3 The activation of arylsulfatases (Pathway) 11781 

18.3.2 Post-translational modification: synthesis of GPI-anchored proteins (Pathway) 11785 

18.3.2.1 Synthesis of dolichyl-phosphate mannose (Pathway) 1176111785 18.3.2.1.1 dolichyl phosphate + GDP-alpha-D-mannose -> dolichyl phosphate 11787 D-mannose (Reaction) 

18.3.2.2 Synthesis of glycosylphosphatidylinositol (GPI) (Pathway) 11789 

18.3.2.3 Attachment of GPI anchor to uPAR (Pathway) 11805 

18.3.3 Asparagine N-linked glycosylation (Pathway) 11808 

11810 and transfer to a nascent protein (Pathway) 

18.3.3.1.1 Synthesis of substrates in N-glycan biosythesis (Pathway) 11812 

18.3.3.1.1.1 Synthesis of Dolichyl-phosphate (Pathway) 11814 

18.3.3.1.1.2 Synthesis of UDP-N-acetyl-glucosamine (Pathway) 11822 

18.3.3.1.1.3 Synthesis of GDP-mannose (Pathway) 11828 

18.3.3.1.1.4 Synthesis of dolichyl-phosphate mannose (Pathway) 11834 

18.3.3.1.1.5 Synthesis of dolichyl-phosphate-glucose (Pathway) 11835 

18.3.3.1.1.6 Sialic acid metabolism (Pathway) 11838 

18.3.3.3 N-glycan trimming in the ER and Calnexin/Calreticulin cycle (Pathway) 11895 

18.3.3.3.4 Calnexin/calreticulin cycle (Pathway) 11901 

18.3.3.3.4.5 ER Quality Control Compartment (ERQC) (Pathway) 11907 

18.3.3.4 Transport to the Golgi and subsequent modification (Pathway) 11919 

18.3.3.4.3 ER to Golgi Transport (Pathway) 

18.3.3.4.3.1 COPII (Coat Protein 2) Mediated Vesicle Transport (Pathway) 11923 

18.3.3.4.4 N-glycan trimming and elongation in the cis-Golgi (Pathway) 11925 

18.3.3.4.4.2 Progressive trimming of alpha-1,2-linked mannose residues from 11929 Man9/8/7GlcNAc2 to produce Man5GlcNAc2 (Pathway) 

18.3.3.4.5 N-glycan antennae elongation in the medial/trans-Golgi (Pathway) 11936 

18.3.3.4.5.1 Reactions specific to the hybrid N-glycan synthesis pathway (Pathway) 11937 

18.3.3.4.5.2 Reactions specific to the complex N-glycan synthesis pathway (Pathway)

18.3.3.4.5.3 N-Glycan antennae elongation (Pathway) 11945 

18.3.4 O-linked glycosylation (Pathway) 11958 

18.3.4.1 O-glycosylation of TSR domain-containing proteins (Pathway) 11959 

18.3.4.2 O-linked glycosylation of mucins (Pathway) 11963 

18.3.4.2.11 Termination of O-glycan biosynthesis (Pathway) 11977 

18.3.5 SUMOylation (Pathway) 11986 

18.3.5.1 Processing and activation of SUMO (Pathway) 11987 

18.3.5.1.1 SUMO is proteolytically processed (Pathway) 11989 

18.3.5.1.2 SUMO is conjugated to E1 (UBA2:SAE1) (Pathway) 11997 

18.3.5.1.3 SUMO is transferred from E1 to E2 (UBE2I, UBC9) (Pathway) 12003 

18.4 Mitochondrial protein import (Pathway) 12010 

18.5 Peptide hormone metabolism (Pathway) 12051 

18.5.1 Insulin processing (Pathway) 12052 

18.5.2 Synthesis, secretion, and deacylation of Ghrelin (Pathway) 12075 

18.5.3 Metabolism of Angiotensinogen to Angiotensins (Pathway) 12090 

18.5.4 Incretin synthesis, secretion, and inactivation (Pathway) 12119 

18.5.4.1 Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) 12121 (Pathway) 

18.5.4.2 Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic 12134 Polypeptide (GIP) (Pathway) 

18.5.5 Peptide hormone biosynthesis (Pathway) 12145 

18.5.5.2 Glycoprotein hormones (Pathway) 12147 

18.6 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like 12153 Growth Factor Binding Proteins (IGFBPs) (Pathway) 

18.7 Unfolded Protein Response (UPR) (Pathway) 12180 

18.7.1 ATF6-alpha activates chaperones (Pathway) 12182 

18.7.1.6 ATF6-alpha activates chaperone genes (Pathway) 12190 

18.7.2 IRE1alpha activates chaperones (Pathway) 12199 

18.7.2.7 XBP1(S) activates chaperone genes (Pathway) 12212 

18.7.3 PERK regulates gene expression (Pathway) 12281 

18.7.3.5 ATF4 activates genes (Pathway) 12289 

18.7.3.5.7 Expression of IL-8 (BlackBoxEvent) 12298 19 Muscle contraction (Pathway) 12300 

19.1 Striated Muscle Contraction (Pathway) 12300 

19.2 Smooth Muscle Contraction (Pathway) 12307 

19.2.7 ATP Hydrolysis By Myosin (Reaction) 12316 20 Mycobacterium tuberculosis biological processes (Pathway) 12318 

20.1 Mycothiol metabolism (Pathway) 12319 

20.1.1 Mycothiol biosynthesis (Pathway) 12320 

20.1.2 Mycothiol catabolism (Pathway) 12329 

20.1.3 Mycothiol-dependent detoxification (Pathway) 12332 

20.2 Trehalose biosynthesis (Pathway) 12341 

20.3 Sulfur compound metabolism (Pathway) 12349 

20.3.1 Sulfate assimilation (Pathway) 12350 

20.3.2 Sulfur amino acid metabolism (Pathway) 12358 

20.3.2.1 Cysteine synthesis from O-acetylserine (Pathway) 12359 

20.3.2.2 Cysteine synthesis from O-phosphoserine (Pathway) 12367 

20.4 Chorismate via Shikimate Pathway (Pathway) 12373 

20.4.7 Dephosphorylation of EPSP yields chorismate (Reaction) 12382 21 Neuronal System (Pathway) 12384 

21.1 Transmission across Electrical Synapses (Pathway) 12385 

21.1.1 Electric Transmission Across Gap Junctions (Pathway) 12386 

21.2 Transmission across Chemical Synapses (Pathway) 12392 

21.2.1 Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium 12393 Channels (Pathway) 

21.2.2 Neurotransmitter Release Cycle (Pathway) 12396 

21.2.2.1 Norepinephrine Neurotransmitter Release Cycle (Pathway) 12397 

21.2.2.2 Serotonin Neurotransmitter Release Cycle (Pathway) 12406 

21.2.2.3 Glutamate Neurotransmitter Release Cycle (Pathway) 12411 

21.2.2.4 Dopamine Neurotransmitter Release Cycle (Pathway) 12424 

21.2.2.5 Acetylcholine Neurotransmitter Release Cycle (Pathway) 12430 

21.2.2.6 GABA synthesis, release, reuptake and degradation (Pathway) 12437 

21.2.2.6.1 GABA synthesis (Pathway) 12439 

21.2.2.6.5 Reuptake of GABA (Pathway) 12446 

21.2.2.6.6 Degradation of GABA (Pathway) 12451 

21.2.3 Neurotransmitter Clearance In The Synaptic Cleft (Pathway) 12454 

21.2.3.3 Dopamine clearance from the synaptic cleft (Pathway) 12457 

21.2.3.3.2 Enzymatic degradation of dopamine by COMT (Pathway) 12459 

21.2.3.3.3 Enzymatic degradation of Dopamine by monoamine oxidase (Pathway) 12462 

21.2.3.4 Serotonin clearance from the synaptic cleft (Pathway) 12465 

21.2.3.4.2 Metabolism of serotonin (Pathway) 12467 

21.2.4 Neurotransmitter uptake and Metabolism In Glial Cells (Pathway) 12470 

21.2.4.1 Astrocytic Glutamate-Glutamine Uptake And Metabolism (Pathway) 12470 

21.2.5 Neurotransmitter Receptor Binding And Downstream Transmission In The 12475 Postsynaptic Cell (Pathway) 

21.2.5.1 Acetylcholine Binding And Downstream Events (Pathway) 12475 

21.2.5.1.1 Activation of Nicotinic Acetylcholine Receptors (Pathway) 12476 

21.2.5.1.1.1 Presynaptic nicotinic acetylcholine receptors (Pathway) 12477 

21.2.5.1.1.1.1 Highly calcium permeable nicotinic acetylcholine receptors (Pathway)12478 

21.2.5.1.1.1.2 Highly sodium permeable acetylcholine nicotinic receptors (Pathway)12482 

21.2.5.1.1.2 Postsynaptic nicotinic acetylcholine receptors (Pathway) 12486 

12487 (Pathway) 

21.2.5.1.1.2.2 Highly sodium permeable acetylcholine nicotinic receptors (Pathway)12490 

21.2.5.2 Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity 12491 (Pathway) 

21.2.5.2.1 Trafficking of AMPA receptors (Pathway) 12493 

21.2.5.2.1.2 Trafficking of GluR2-containing AMPA receptors (Pathway) 12496 

21.2.5.2.2 Activation of AMPA receptors (Pathway) 12502 

21.2.5.3 Activation of NMDA receptor upon glutamate binding and postsynaptic events12511 (Pathway) 

21.2.5.3.1 Unblocking of NMDA receptor, glutamate binding and activation (Pathway)12512 

21.2.5.3.2 Post NMDA receptor activation events (Pathway) 12519 

21.2.5.3.2.1 CREB phosphorylation through the activation of Ras (Pathway) 12520 

21.2.5.3.2.1.1 Ras activation uopn Ca2+ infux through NMDA receptor (Pathway) 12522 

21.2.5.3.2.1.4 RSK activation (Pathway) 12528 

21.2.5.3.2.2 CREB phosphorylation through the activation of Adenylate Cyclase 12533 (Pathway) 

21.2.5.3.2.3 CREB phosphorylation through the activation of CaMKII (Pathway) 12537 

21.2.5.3.2.4 CREB phosphorylation through the activation of CaMKK (Pathway) 12543 

21.2.5.3.2.4.1 Activation of CaMKK (Reaction) 12544 21.2.5.3.2.4.2 Activation of CaMK IV (Pathway) 12545 

21.2.5.4 Activation of Kainate Receptors upon glutamate binding (Pathway) 12548 

21.2.5.4.1 Ionotropic activity of Kainate Receptors (Pathway) 12550 

21.2.5.4.1.1 Activation of Na-permeable Kainate Receptors (Pathway) 12551 

21.2.5.4.1.2 Activation of Ca-permeable Kainate Receptor (Pathway) 12554 

21.2.5.4.2 Presynaptic function of Kainate receptors (Pathway) 12558 

21.2.5.5 GABA receptor activation (Pathway) 12561 

21.2.5.5.1 GABA A receptor activation (Pathway) 12563 

21.2.5.5.2 GABA B receptor activation (Pathway) 12566 

21.2.5.5.2.2 Activation of GABAB receptors (Pathway) 12569 

21.2.5.5.2.2.1 Inhibition of adenylate cyclase pathway (Pathway) 12570 

21.2.5.5.2.2.1.1 Adenylate cyclase inhibitory pathway (Pathway) 12571 

21.2.5.5.2.2.2 Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits12578 (Pathway) 

21.2.5.5.3 GABA A (rho) receptor activation (Pathway) 12581 

21.3 Potassium Channels (Pathway) 12584 

21.3.1 Ca2+ activated K+ channels (Pathway) 12585 

21.3.2 HCN channels (Pathway) 12591 

21.3.3 Inwardly rectifying K+ channels (Pathway) 12595 

21.3.3.1 G protein gated Potassium channels (Pathway) 12596 

21.3.3.1.1 Activation of G protein gated Potassium channels (Pathway) 12597 

21.3.3.2 Potassium transport channels (Pathway) 12598 

21.3.3.3 ATP sensitive Potassium channels (Pathway) 12600 

21.3.3.4 Classical Kir channels (Pathway) 12604 

21.3.4 Voltage gated Potassium channels (Pathway) 12606 

21.3.5 Tandem pore domain potassium channels (Pathway) 12609 

21.3.5.1 Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) 12610 (Pathway) 

21.3.5.2 TWIK related potassium channel (TREK) (Pathway) 12612 

21.3.5.3 TWIK-releated acid-sensitive K+ channel (TASK) (Pathway) 12615 

21.3.5.4 TWIK-related alkaline pH activated K+ channel (TALK) (Pathway) 12617 

21.3.5.5 TWIK-related spinal cord K+ channel (TRESK) (Pathway) 12619 

21.3.5.6 Tandem pore domain halothane-inhibited K+ channel (THIK) (Pathway) 12622 

21.3.5.6.1 Activation of THIK (Reaction) 12623 22 Organelle biogenesis and maintenance (Pathway) 12625 

22.1 Mitochondrial biogenesis (Pathway) 12626 

22.1.1 Activation of PPARGC1A (PGC-1alpha) by phosphorylation (Pathway) 12628 

22.1.2 Transcriptional activation of mitochondrial biogenesis (Pathway) 12634 

22.1.2.28 Expression of SIRT3 (BlackBoxEvent) 12672 23 Reproduction (Pathway) 12674 

23.1 Fertilization (Pathway) 12675 

23.1.1 Sperm Motility And Taxes (Pathway) 12676 

23.1.2 Interaction With Cumulus Cells (Pathway) 12683 

23.1.3 Interaction With The Zona Pellucida (Pathway) 12685 

23.1.4 Acrosome Reaction (Pathway) 12688 

23.1.5 Sperm:Oocyte Membrane Binding (Pathway) 12691 

23.1.5.1 CD9:Izumo Binding (Reaction) 12692 24 Signal Transduction (Pathway) 12694 

24.1 Signaling by EGFR (Pathway) 12697 

24.1.5 Phosphorylation of EGFR by SRC kinase (Reaction) 12706 24.1.6 EGFR interacts with phospholipase C-gamma (Pathway) 12707 

24.1.6.4 DAG and IP3 signaling (Pathway) 12711 

24.1.6.4.5 CaM pathway (Pathway) 12714 

24.1.6.4.5.2 Calmodulin induced events (Pathway) 12715 

24.1.6.4.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 12715 

24.1.6.4.5.2.1.1 PKA activation (Pathway) 12715 

24.1.6.4.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 12717 

24.1.6.4.5.2.3 Cam-PDE 1 activation (Pathway) 12719 

24.1.7 GRB2 events in EGFR signaling (Pathway) 12722 

24.1.7.4 RAF/MAP kinase cascade (Pathway) 12728 

24.1.7.4.1 RAF activation (Pathway) 12728 

24.1.7.4.2 MEK activation (Pathway) 12730 

24.1.7.4.2.2 RAF phosphorylates MEK (Pathway) 12731 

24.1.7.4.3 ERK activation (Pathway) 12732 

24.1.7.4.3.1 ERK1 activation (Pathway) 12732 

24.1.7.4.3.2 ERK2 activation (Pathway) 12734 

24.1.8 SHC1 events in EGFR signaling (Pathway) 12736 

24.1.8.5 RAF/MAP kinase cascade (Pathway) 12744 

24.1.8.5.1 RAF activation (Pathway) 12744 

24.1.8.5.2 MEK activation (Pathway) 12746 

24.1.8.5.2.2 RAF phosphorylates MEK (Pathway) 12746 

24.1.8.5.3 ERK activation (Pathway) 12747 

24.1.8.5.3.1 ERK1 activation (Pathway) 12747 

24.1.8.5.3.2 ERK2 activation (Pathway) 12749 24.1.8.5.3.2.1 MEK2 binds ERK-2 (Reaction) 12749 

24.1.9 GAB1 signalosome (Pathway) 12751 

24.1.9.6 PIP3 activates AKT signaling (Pathway) 12760 

24.1.9.6.7 AKT phosphorylates targets in the cytosol (Pathway) 12763 

24.1.9.6.9 AKT phosphorylates targets in the nucleus (Pathway) 12768 

24.1.9.6.10 Negative regulation of the PI3K/AKT network (Pathway) 12769 

24.1.10 EGFR downregulation (Pathway) 12782 

24.2 Signaling by FGFR (Pathway) 12807 

24.2.1 FGFR ligand binding and activation (Pathway) 12809 

24.2.1.1 FGFR1 ligand binding and activation (Pathway) 12811 

24.2.1.1.1 FGFR1b ligand binding and activation (Pathway) 12812 

24.2.1.1.2 FGFR1c ligand binding and activation (Pathway) 12816 

24.2.1.2 FGFR2 ligand binding and activation (Pathway) 12819 

24.2.1.2.1 FGFR2b ligand binding and activation (Pathway) 12820 

24.2.1.2.2 FGFR2c ligand binding and activation (Pathway) 12824 

24.2.1.3 FGFR3 ligand binding and activation (Pathway) 12827 

24.2.1.3.1 FGFR3b ligand binding and activation (Pathway) 12828 

24.2.1.3.2 FGFR3c ligand binding and activation (Pathway) 12832 

24.2.1.4 FGFR4 ligand binding and activation (Pathway) 12835 

24.2.1.5 Klotho-mediated ligand binding (Pathway) 12839 

24.2.1.5.1 betaKlotho-mediated ligand binding (Pathway) 12840 

24.2.1.5.2 FGFR1c and Klotho ligand binding and activation (Pathway) 12844 

24.2.2 Downstream signaling of activated FGFR (Pathway) 12848 

24.2.2.1 FRS2-mediated cascade (Pathway) 12849 

24.2.2.1.9 RAF/MAP kinase cascade (Pathway) 12861 

24.2.2.1.9.1 RAF activation (Pathway) 12862 

24.2.2.1.9.2 MEK activation (Pathway) 12863 

24.2.2.1.9.2.2 RAF phosphorylates MEK (Pathway) 12864 

24.2.2.1.9.3 ERK activation (Pathway) 12864 

24.2.2.1.9.3.1 ERK1 activation (Pathway) 12865 

24.2.2.1.9.3.2 ERK2 activation (Pathway) 12866 24.2.2.1.9.3.2.1 MEK2 binds ERK-2 (Reaction) 12867 

24.2.2.2 Phospholipase C-mediated cascade (Pathway) 12868 

24.2.2.2.4 DAG and IP3 signaling (Pathway) 12873 

24.2.2.2.4.5 CaM pathway (Pathway) 12874 

24.2.2.2.4.5.2 Calmodulin induced events (Pathway) 12875 

24.2.2.2.4.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 12875 

24.2.2.2.4.5.2.1.1 PKA activation (Pathway) 12875 

24.2.2.2.4.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 12877 

24.2.2.2.4.5.2.3 Cam-PDE 1 activation (Pathway) 12878 

24.2.2.3 SHC-mediated cascade (Pathway) 12879 

24.2.2.4 PI-3K cascade (Pathway) 12886 

24.2.2.4.8 PIP3 activates AKT signaling (Pathway) 12894 

24.2.2.4.8.7 AKT phosphorylates targets in the cytosol (Pathway) 12896 

24.2.2.4.8.9 AKT phosphorylates targets in the nucleus (Pathway) 12899 

24.2.2.4.8.10 Negative regulation of the PI3K/AKT network (Pathway) 12900 

24.2.3 Negative regulation of FGFR signaling (Pathway) 12902 

24.2.3.4 Spry regulation of FGF signaling (Pathway) 12907 

24.3 Signaling by Insulin receptor (Pathway) 12925 

24.3.3 Insulin receptor signalling cascade (Pathway) 12931 

24.3.3.1 SHC-related events (Pathway) 12932 

24.3.3.1.1 SHC activation (Pathway) 12932 

24.3.3.1.2 SHC-mediated signalling (Pathway) 12934 

24.3.3.1.2.3 RAF/MAP kinase cascade (Pathway) 12939 

24.3.3.1.2.3.1 RAF activation (Pathway) 12939 

24.3.3.1.2.3.2 MEK activation (Pathway) 12940 

24.3.3.1.2.3.2.2 RAF phosphorylates MEK (Pathway) 12941 

24.3.3.1.2.3.3 ERK activation (Pathway) 12942 

24.3.3.1.2.3.3.1 ERK1 activation (Pathway) 12942 

24.3.3.1.2.3.3.2 ERK2 activation (Pathway) 12944 

24.3.3.2 IRS-related events (Pathway) 12945 

24.3.3.2.1 IRS activation (Pathway) 12946 

24.3.3.2.2 IRS-mediated signalling (Pathway) 12948 

24.3.3.2.2.1 PI3K Cascade (Pathway) 12949 

24.3.3.2.2.1.3 PKB-mediated events (Pathway) 12951 

24.3.3.2.2.1.3.1 PDE3B signalling (Pathway) 12951 

24.3.3.2.2.1.3.2 mTOR signalling (Pathway) 12953 

24.3.3.2.2.1.3.2.1 Inhibition of TSC complex formation by PKB (Pathway) 12953 

24.3.3.2.2.1.3.2.4 mTORC1-mediated signalling (Pathway) 12956 

24.3.3.2.2.1.3.2.4.1 S6K1-mediated signalling (Pathway) 12957 

24.3.3.2.2.1.3.2.4.1.2 S6K1 signalling (Pathway) 12958 

24.3.3.2.2.1.3.2.4.2 Release of eIF4E (Pathway) 12961 

24.3.3.2.2.1.3.2.5 Energy dependent regulation of mTOR by LKB1-AMPK (Pathway)12963 

24.3.3.2.2.1.3.2.5.1 Regulation of AMPK activity via LKB1 (Pathway) 12964 

24.3.3.2.2.1.3.2.5.2 Regulation of Rheb GTPase activity by AMPK (Pathway) 12972 

24.3.3.2.2.1.4 Activation of PKB (Pathway) 12976 

24.3.3.2.2.2 SOS-mediated signalling (Pathway) 12979 

24.3.3.2.2.2.3 RAF/MAP kinase cascade (Pathway) 12983 

24.3.3.2.2.2.3.1 RAF activation (Pathway) 12984 

24.3.3.2.2.2.3.2 MEK activation (Pathway) 12985 

24.3.3.2.2.2.3.2.2 RAF phosphorylates MEK (Pathway) 12986 

24.3.3.2.2.2.3.3 ERK activation (Pathway) 12986 

24.3.3.2.2.2.3.3.1 ERK1 activation (Pathway) 12987 

24.3.3.2.2.2.3.3.2 ERK2 activation (Pathway) 12988 

24.3.3.3 Signal attenuation (Pathway) 12990 

24.3.5 Insulin receptor recycling (Pathway) 12997 

24.4 Signalling by NGF (Pathway) 13005 

24.4.1 NGF processing (Pathway) 13007 

24.4.2 p75 NTR receptor-mediated signalling (Pathway) 13016 

24.4.2.1 NFG and proNGF binds to p75NTR (Pathway) 13017 

24.4.2.2 Cell death signalling via NRAGE, NRIF and NADE (Pathway) 13022 

24.4.2.2.1 NRAGE signals death through JNK (Pathway) 13023 

24.4.2.2.2 NRIF signals cell death from the nucleus (Pathway) 13033 

24.4.2.2.3 NADE modulates death signalling (Pathway) 13044 

24.4.2.3 p75NTR negatively regulates cell cycle via SC1 (Pathway) 13049 24.4.2.3.1 PRDM4 (SC1) binds to p75NTR (Reaction) 13050 

24.4.2.4 p75NTR signals via NF-kB (Pathway) 13054 

24.4.2.4.1 p75NTR recruits signalling complexes (Pathway) 13055 

24.4.2.4.2 NF-kB is activated and signals survival (Pathway) 13067 

24.4.2.5 Ceramide signalling (Pathway) 13072 

24.4.2.6 p75NTR regulates axonogenesis (Pathway) 13077 

24.4.2.6.1 Axonal growth stimulation (Pathway) 13078 

24.4.2.6.2 Axonal growth inhibition (RHOA activation) (Pathway) 13081 

24.4.2.7 Regulated proteolysis of p75NTR (Pathway) 13088 

24.4.3 NGF signalling via TRKA from the plasma membrane (Pathway) 13096 

24.4.3.1 Activation of TRKA receptors (Pathway) 13097 

24.4.3.1.1 TRKA activation by NGF (Pathway) 13098 

24.4.3.1.2 NGF-independant TRKA activation (Pathway) 13104 

24.4.3.2 Signalling to ERKs (Pathway) 13108 

24.4.3.2.1 Signalling to RAS (Pathway) 13109 

24.4.3.2.1.6 RAF/MAP kinase cascade (Pathway) 13114 

24.4.3.2.1.6.1 RAF activation (Pathway) 13114 

24.4.3.2.1.6.2 MEK activation (Pathway) 13116 

24.4.3.2.1.6.2.2 RAF phosphorylates MEK (Pathway) 13116 

24.4.3.2.1.6.3 ERK activation (Pathway) 13117 

24.4.3.2.1.6.3.1 ERK1 activation (Pathway) 13117 

24.4.3.2.1.6.3.2 ERK2 activation (Pathway) 13119 

24.4.3.2.1.7 Feedback control in the MAPK signaling module (Pathway) 13121 

24.4.3.2.1.8 p38MAPK events (Pathway) 13121 

24.4.3.2.2 Signalling to p38 via RIT and RIN (Pathway) 13130 

24.4.3.2.2.4 RAF/MAP kinase cascade (Pathway) 13135 

24.4.3.2.2.4.1 RAF activation (Pathway) 13135 

24.4.3.2.2.4.2 MEK activation (Pathway) 13137 

24.4.3.2.2.4.2.2 RAF phosphorylates MEK (Pathway) 13137 

24.4.3.2.2.4.3 ERK activation (Pathway) 13138 

24.4.3.2.2.4.3.1 ERK1 activation (Pathway) 13138 

24.4.3.2.2.4.3.2 ERK2 activation (Pathway) 13140 

24.4.3.2.3 Prolonged ERK activation events (Pathway) 13141 

24.4.3.2.3.1 Frs2-mediated activation (Pathway) 13143 

24.4.3.2.3.1.7 RAF/MAP kinase cascade (Pathway) 13152 

24.4.3.2.3.1.7.1 RAF activation (Pathway) 13153 

24.4.3.2.3.1.7.2 MEK activation (Pathway) 13154 

24.4.3.2.3.1.7.2.2 RAF phosphorylates MEK (Pathway) 13155 

24.4.3.2.3.1.7.3 ERK activation (Pathway) 13155 

24.4.3.2.3.1.7.3.1 ERK1 activation (Pathway) 13156 

24.4.3.2.3.1.7.3.2 ERK2 activation (Pathway) 13157 

24.4.3.2.3.2 ARMS-mediated activation (Pathway) 13159 

24.4.3.2.3.2.6 RAF/MAP kinase cascade (Pathway) 13166 

24.4.3.2.3.2.6.1 RAF activation (Pathway) 13167 

24.4.3.2.3.2.6.2 MEK activation (Pathway) 13168 

24.4.3.2.3.2.6.2.2 RAF phosphorylates MEK (Pathway) 13169 

24.4.3.2.3.2.6.3 ERK activation (Pathway) 13169 

24.4.3.2.3.2.6.3.1 ERK1 activation (Pathway) 13170 

24.4.3.2.3.2.6.3.2 ERK2 activation (Pathway) 13171 

24.4.3.3 PLC-gamma1 signalling (Pathway) 13173 

24.4.3.3.3 DAG and IP3 signaling (Pathway) 13177 

24.4.3.3.3.5 CaM pathway (Pathway) 13178 

24.4.3.3.3.5.2 Calmodulin induced events (Pathway) 13178 

24.4.3.3.3.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 13179 

24.4.3.3.3.5.2.1.1 PKA activation (Pathway) 13179 

24.4.3.3.3.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 13180 

24.4.3.3.3.5.2.3 Cam-PDE 1 activation (Pathway) 13182 

24.4.3.4 PI3K/AKT activation (Pathway) 13183 

24.4.3.4.6 PIP3 activates AKT signaling (Pathway) 13189 

24.4.3.4.6.7 AKT phosphorylates targets in the cytosol (Pathway) 13191 

24.4.3.4.6.9 AKT phosphorylates targets in the nucleus (Pathway) 13193 

24.4.3.4.6.10 Negative regulation of the PI3K/AKT network (Pathway) 13195 

24.4.3.5 Signalling to STAT3 (Pathway) 13196 

24.4.3.6 Signalling to ERK5 (Pathway) 13199 

24.4.3.7 Retrograde neurotrophin signalling (Pathway) 13202 

24.4.3.8 Nuclear Events (kinase and transcription factor activation) (Pathway) 13208 

24.4.3.8.1 ERK/MAPK targets (Pathway) 13209 

24.4.3.8.1.7 ERKs are inactivated (Pathway) 13211 

24.4.3.8.2 CREB phosphorylation (Pathway) 13212 

24.5 Signaling by PDGF (Pathway) 13214 

24.5.10 Downstream signal transduction (Pathway) 13229 

24.5.10.3 PIP3 activates AKT signaling (Pathway) 13233 

24.5.10.3.7 AKT phosphorylates targets in the cytosol (Pathway) 13235 

24.5.10.3.9 AKT phosphorylates targets in the nucleus (Pathway) 13238 

24.5.10.3.10 Negative regulation of the PI3K/AKT network (Pathway) 13239 

24.5.10.7 DAG and IP3 signaling (Pathway) 13244 

24.5.10.7.5 CaM pathway (Pathway) 13246 

24.5.10.7.5.2 Calmodulin induced events (Pathway) 13246 

24.5.10.7.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 13246 

24.5.10.7.5.2.1.1 PKA activation (Pathway) 13246 

24.5.10.7.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 13248 

24.5.10.7.5.2.3 Cam-PDE 1 activation (Pathway) 13249 

24.5.10.14 RAF/MAP kinase cascade (Pathway) 13259 

24.5.10.14.1 RAF activation (Pathway) 13259 

24.5.10.14.2 MEK activation (Pathway) 13261 

24.5.10.14.2.2 RAF phosphorylates MEK (Pathway) 13261 

24.5.10.14.3 ERK activation (Pathway) 13262 

24.5.10.14.3.1 ERK1 activation (Pathway) 13262 

24.5.10.14.3.2 ERK2 activation (Pathway) 13264 

24.6 Signaling by VEGF (Pathway) 13272 

24.6.1 VEGF ligand-receptor interactions (Pathway) 13275 

24.6.1.2 VEGF binds to VEGFR leading to receptor dimerization (Pathway) 13279 

24.6.2 VEGFA-VEGFR2 Pathway (Pathway) 13287 

24.6.2.36 VEGFR2 mediated vascular permeability (Pathway) 13336 

24.6.2.51 VEGFR2 mediated cell proliferation (Pathway) 13365 

24.6.2.51.13 RAF/MAP kinase cascade (Pathway) 13379 

24.6.2.51.13.1 RAF activation (Pathway) 13379 

24.6.2.51.13.2 MEK activation (Pathway) 13380 

24.6.2.51.13.2.2 RAF phosphorylates MEK (Pathway) 13381 

24.6.2.51.13.3 ERK activation (Pathway) 13382 

24.6.2.51.13.3.1 ERK1 activation (Pathway) 13382 

24.6.2.51.13.3.2 ERK2 activation (Pathway) 13384 

24.6.3 Neurophilin interactions with VEGF and VEGFR (Pathway) 13385 

24.7 Signaling by SCF-KIT (Pathway) 13389 

24.7.8 PIP3 activates AKT signaling (Pathway) 13403 

24.7.8.7 AKT phosphorylates targets in the cytosol (Pathway) 13405 

24.7.8.9 AKT phosphorylates targets in the nucleus (Pathway) 13407 

24.7.8.10 Negative regulation of the PI3K/AKT network (Pathway) 13409 

24.7.20 RAF/MAP kinase cascade (Pathway) 13427 

24.7.20.1 RAF activation (Pathway) 13427 

24.7.20.2 MEK activation (Pathway) 13429 

24.7.20.2.2 RAF phosphorylates MEK (Pathway) 13429 

24.7.20.3 ERK activation (Pathway) 13430 

24.7.20.3.1 ERK1 activation (Pathway) 13430 

24.7.20.3.2 ERK2 activation (Pathway) 13432 

24.7.30 Regulation of KIT signaling (Pathway) 13446 

24.8 Signaling by ERBB2 (Pathway) 13460 

24.8.6 SHC1 events in ERBB2 signaling (Pathway) 13472 

24.8.6.5 RAF/MAP kinase cascade (Pathway) 13479 

24.8.6.5.1 RAF activation (Pathway) 13479 

24.8.6.5.2 MEK activation (Pathway) 13480 

24.8.6.5.2.2 RAF phosphorylates MEK (Pathway) 13481 

24.8.6.5.3 ERK activation (Pathway) 13482 

24.8.6.5.3.1 ERK1 activation (Pathway) 13482 

24.8.6.5.3.2 ERK2 activation (Pathway) 13484 

24.8.7 GRB2 events in ERBB2 signaling (Pathway) 13485 

24.8.7.5 RAF/MAP kinase cascade (Pathway) 13492 

24.8.7.5.1 RAF activation (Pathway) 13492 

24.8.7.5.2 MEK activation (Pathway) 13494 

24.8.7.5.2.2 RAF phosphorylates MEK (Pathway) 13494 

24.8.7.5.3 ERK activation (Pathway) 13495 

24.8.7.5.3.1 ERK1 activation (Pathway) 13495 

24.8.7.5.3.2 ERK2 activation (Pathway) 13497 

24.8.8 PI3K events in ERBB2 signaling (Pathway) 13498 

24.8.8.11 PIP3 activates AKT signaling (Pathway) 13511 

24.8.8.11.7 AKT phosphorylates targets in the cytosol (Pathway) 13513 

24.8.8.11.9 AKT phosphorylates targets in the nucleus (Pathway) 13516 

24.8.8.11.10 Negative regulation of the PI3K/AKT network (Pathway) 13517 

24.8.9 PLCG1 events in ERBB2 signaling (Pathway) 13519 

24.8.9.3 DAG and IP3 signaling (Pathway) 13523 

24.8.9.3.5 CaM pathway (Pathway) 13524 

24.8.9.3.5.2 Calmodulin induced events (Pathway) 13524 

24.8.9.3.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 13525 

24.8.9.3.5.2.1.1 PKA activation (Pathway) 13525 

24.8.9.3.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 13526 

24.8.9.3.5.2.3 Cam-PDE 1 activation (Pathway) 13528 24.8.9.3.5.2.3.1 Calmodulin activates Cam-PDE 1 (Reaction) 13528 

24.8.10 GRB7 events in ERBB2 signaling (Pathway) 13529 

24.8.11 Downregulation of ERBB2:ERBB3 signaling (Pathway) 13531 

24.9 Signaling by ERBB4 (Pathway) 13546 

24.9.6 SHC1 events in ERBB4 signaling (Pathway) 13559 

24.9.6.5 RAF/MAP kinase cascade (Pathway) 13565 

24.9.6.5.1 RAF activation (Pathway) 13565 

24.9.6.5.2 MEK activation (Pathway) 13567 

24.9.6.5.2.2 RAF phosphorylates MEK (Pathway) 13567 

24.9.6.5.3 ERK activation (Pathway) 13568 

24.9.6.5.3.1 ERK1 activation (Pathway) 13568 24.9.6.5.3.1.1 Inactivation of MEK1 by p34cdc2 (Reaction) 13568 

24.9.6.5.3.2 ERK2 activation (Pathway) 13570 

24.9.7 PI3K events in ERBB4 signaling (Pathway) 13571 

24.9.7.4 PIP3 activates AKT signaling (Pathway) 13576 

24.9.7.4.7 AKT phosphorylates targets in the cytosol (Pathway) 13578 

24.9.7.4.9 AKT phosphorylates targets in the nucleus (Pathway) 13580 

24.9.7.4.10 Negative regulation of the PI3K/AKT network (Pathway) 13582 

24.9.8 Nuclear signaling by ERBB4 (Pathway) 13583 

24.9.8.16 Prolactin receptor signaling (Pathway) 13606 

24.9.9 Downregulation of ERBB4 signaling (Pathway) 13611 

24.10 DAG and IP3 signaling (Pathway) 13617 

24.10.5 CaM pathway (Pathway) 13618 

24.10.5.2 Calmodulin induced events (Pathway) 13618 

24.10.5.2.1 PKA-mediated phosphorylation of CREB (Pathway) 13619 

24.10.5.2.1.1 PKA activation (Pathway) 13619 

24.10.5.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 13620 

24.10.5.2.3 Cam-PDE 1 activation (Pathway) 13622 

24.11 PIP3 activates AKT signaling (Pathway) 13623 

24.11.7 AKT phosphorylates targets in the cytosol (Pathway) 13625 

24.11.9 AKT phosphorylates targets in the nucleus (Pathway) 13627 

24.11.10 Negative regulation of the PI3K/AKT network (Pathway) 13629 

24.12 RAF/MAP kinase cascade (Pathway) 13631 

24.12.1 RAF activation (Pathway) 13631 

24.12.2 MEK activation (Pathway) 13632 

24.12.2.2 RAF phosphorylates MEK (Pathway) 13633 

24.12.3 ERK activation (Pathway) 13634 

24.12.3.1 ERK1 activation (Pathway) 13634 

24.12.3.2 ERK2 activation (Pathway) 13636 

24.13 Signaling by Rho GTPases (Pathway) 13637 

24.13.1 Rho GTPase cycle (Pathway) 13640 

24.14 Signaling by BMP (Pathway) 13651 

24.15 Signaling by TGF-beta Receptor Complex (Pathway) 13673 

24.15.1 TGF-beta receptor signaling activates SMADs (Pathway) 13673 

24.15.1.10 Downregulation of TGF-beta receptor signaling (Pathway) 13677 

24.15.2 TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 13688 (Pathway) 

24.15.3 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer (Pathway) 13690 

24.15.3.1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription (Pathway) 13690 

24.15.3.2 Downregulation of SMAD2/3:SMAD4 transcriptional activity (Pathway) 13697 

24.16 Signaling by NOTCH (Pathway) 13704 

24.16.1 Pre-NOTCH Expression and Processing (Pathway) 13707 

24.16.1.1 Pre-NOTCH Transcription and Translation (Pathway) 13712 

24.16.1.2 Pre-NOTCH Processing in the Endoplasmic Reticulum (Pathway) 13747 

24.16.1.3 Pre-NOTCH Processing in Golgi (Pathway) 13754 

24.16.2 Signaling by NOTCH1 (Pathway) 13773 

24.16.2.1 Activated NOTCH1 Transmits Signal to the Nucleus (Pathway) 13780 

24.16.2.2 NOTCH1 Intracellular Domain Regulates Transcription (Pathway) 13825 

24.16.3 Signaling by NOTCH2 (Pathway) 13856 

24.16.3.1 NOTCH2 Activation and Transmission of Signal to the Nucleus (Pathway) 13861 

24.16.3.2 NOTCH2 intracellular domain regulates transcription (Pathway) 13885 

24.16.4 Signaling by NOTCH3 (Pathway) 13903 

24.16.5 Signaling by NOTCH4 (Pathway) 13909 

24.17 Signaling by GPCR (Pathway) 13915 

24.17.1 GPCR ligand binding (Pathway) 13917 

24.17.1.1 Class A/1 (Rhodopsin-like receptors) (Pathway) 13918 

24.17.1.1.1 Peptide ligand-binding receptors (Pathway) 13919 

24.17.1.1.1.13 Chemokine receptors bind chemokines (Pathway) 13939 

24.17.1.1.1.15 Tachykinin receptors bind tachykinins (Pathway) 13965 

24.17.1.1.1.16 Vasopressin-like receptors (Pathway) 13971 

24.17.1.1.1.27 Orexin and neuropeptides FF and QRFP bind to their respective 13991 receptors (Pathway) 

24.17.1.1.1.29 Formyl peptide receptors bind formyl peptides and many other ligands14000 (Pathway) 

24.17.1.1.1.33 Relaxin receptors (Pathway) 14009 

24.17.1.1.2 Amine ligand-binding receptors (Pathway) 14026 

24.17.1.1.2.1 Muscarinic acetylcholine receptors (Pathway) 14028 

24.17.1.1.2.2 Adrenoceptors (Pathway) 14032 24.17.1.1.2.2.1 Alpha-1 adrenoceptors bind catecholamines (Reaction) 14033 

24.17.1.1.2.3 Dopamine receptors (Pathway) 14036 

24.17.1.1.2.4 Histamine receptors (Pathway) 14040 

24.17.1.1.2.5 Serotonin receptors (Pathway) 14045 

24.17.1.1.3 Hormone ligand-binding receptors (Pathway) 14053 

24.17.1.1.4 Eicosanoid ligand-binding receptors (Pathway) 14059 

24.17.1.1.4.1 Prostanoid ligand receptors (Pathway) 14061 

24.17.1.1.4.2 Leukotriene receptors (Pathway) 14072 

24.17.1.1.5 Nucleotide-like (purinergic) receptors (Pathway) 14078 

24.17.1.1.5.1 P2Y receptors (Pathway) 14080 

24.17.1.1.5.2 Adenosine P1 receptors (Pathway) 14096 

24.17.1.1.6 Hydroxycarboxylic acid-binding receptors (Pathway) 14100 

24.17.1.1.10 Lysosphingolipid and LPA receptors (Pathway) 14109 

24.17.1.1.11 Opsins (Pathway) 14115 

24.17.1.1.12 Free fatty acid receptors (Pathway) 14120 

24.17.1.2 Class B/2 (Secretin family receptors) (Pathway) 14136 

24.17.1.2.1 Calcitonin-like ligand receptors (Pathway) 14137 

24.17.1.2.3 Glucagon-type ligand receptors (Pathway) 14146 

24.17.1.3 Class C/3 (Metabotropic glutamate/pheromone receptors) (Pathway) 14167 

24.17.2 GPCR downstream signaling (Pathway) 14177 

24.17.2.1 G alpha (s) signalling events (Pathway) 14178 

24.17.2.2 G alpha (i) signalling events (Pathway) 14191 

24.17.2.3 G alpha (z) signalling events (Pathway) 14203 

24.17.2.4 G alpha (q) signalling events (Pathway) 14216 

24.17.2.4.10 Effects of PIP2 hydrolysis (Pathway) 14233 

24.17.2.4.10.6 Arachidonate production from DAG (Pathway) 14235 

24.17.2.5 G alpha (12/13) signalling events (Pathway) 14240 

24.17.2.6 G-protein beta:gamma signalling (Pathway) 14256 

24.17.2.6.1 G beta:gamma signalling through PI3Kgamma (Pathway) 14257 

24.17.2.6.2 G beta:gamma signalling through PLC beta (Pathway) 14262 

24.17.2.7 Olfactory Signaling Pathway (Pathway) 14267 

24.17.3 Opioid Signalling (Pathway) 14272 

24.17.3.2 G-protein activation (Pathway) 14275 

24.17.3.4 G-protein mediated events (Pathway) 14285 

24.17.3.4.1 PLC beta mediated events (Pathway) 14286 

24.17.3.4.1.6 Ca-dependent events (Pathway) 14293 

24.17.3.4.1.6.1 phospho-PLA2 pathway (Pathway) 14294 

24.17.3.4.1.6.2 CaM pathway (Pathway) 14299 

24.17.3.4.1.6.2.2 Calmodulin induced events (Pathway) 14299 

24.17.3.4.1.6.2.2.1 PKA-mediated phosphorylation of CREB (Pathway) 14299 

24.17.3.4.1.6.2.2.1.1 PKA activation (Pathway) 14299 24.17.3.4.1.6.2.2.1.1.1 Adenylate cyclase produces cAMP (Reaction) 14300 

24.17.3.4.1.6.2.2.2 CaMK IV-mediated phosphorylation of CREB (Pathway) 14301 

24.17.3.4.1.6.2.2.3 Cam-PDE 1 activation (Pathway) 14303 

24.17.3.4.2 Adenylate cyclase activating pathway (Pathway) 14304 

24.17.3.4.3 Adenylate cyclase inhibitory pathway (Pathway) 14310 

24.17.3.5 DARPP-32 events (Pathway) 14312 

24.17.4 Gastrin-CREB signalling pathway via PKC and MAPK (Pathway) 14326 

24.17.4.2 G alpha (q) signalling events (Pathway) 14329 24.17.4.2.1 Liganded Gq-activating GPCRs bind inactive heterotrimeric Gq (Reaction)14329 

24.17.4.2.10 Effects of PIP2 hydrolysis (Pathway) 14331 

24.17.4.2.10.6 Arachidonate production from DAG (Pathway) 14333 

24.17.4.3 EGFR Transactivation by Gastrin (Pathway) 14334 

24.17.4.4 RAF/MAP kinase cascade (Pathway) 14343 

24.17.4.4.1 RAF activation (Pathway) 14343 

24.17.4.4.2 MEK activation (Pathway) 14344 

24.17.4.4.2.2 RAF phosphorylates MEK (Pathway) 14345 

24.17.4.4.3 ERK activation (Pathway) 14346 

24.17.4.4.3.1 ERK1 activation (Pathway) 14346 

24.17.4.4.3.2 ERK2 activation (Pathway) 14348 

24.18 Signaling by Wnt (Pathway) 14350 

24.18.1 WNT ligand biogenesis and trafficking (Pathway) 14352 

24.18.2 Degradation of beta-catenin by the destruction complex (Pathway) 14356 

24.18.2.7 Beta-catenin phosphorylation cascade (Pathway) 14358 

24.18.2.13 repression of WNT target genes (Pathway) 14362 

24.18.3 TCF dependent signaling in response to WNT (Pathway) 14364 

24.18.3.2 WNT mediated activation of DVL (Pathway) 14365 

24.18.3.4 disassembly of the destruction complex and recruitment of AXIN to the 14367 membrane (Pathway) 

24.18.3.6 formation of the beta-catenin:TCF transactivating complex (Pathway) 14370 

24.18.3.6.1 binding of TCF/LEF:CTNNB1 to target gene promoters (Pathway) 14371 

24.18.3.7 deactivation of the beta-catenin transactivating complex (Pathway) 14376 

24.18.3.8 degradation of DVL (Pathway) 14380 

24.18.3.9 degradation of AXIN (Pathway) 14384 

24.18.3.11 regulation of FZD by ubiquitination (Pathway) 14388 

24.18.3.12 negative regulation of TCF-dependent signaling by WNT ligand antagonists (Pathway) 

24.18.3.13 negative regulation of TCF-dependent signaling by DVL-interacting proteins14393 (Pathway) 

24.18.4 beta-catenin independent WNT signaling (Pathway) 14394 

24.18.4.1 PCP/CE pathway (Pathway) 14396 

24.18.4.1.11 Asymmetric localization of PCP proteins (Pathway) 14416 

24.18.4.1.12 WNT5A-dependent internalization of FZD4 (Pathway) 14429 

24.18.4.1.13 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 (Pathway) 14435 

24.18.4.2 Ca2+ pathway (Pathway) 

24.19 Signaling by Hippo (Pathway) 14476 

24.20 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) (Pathway) 14521 

24.20.3 IGF1R signaling cascade (Pathway) 14526 

24.20.3.1 SHC-related events triggered by IGF1R (Pathway) 14527 

24.20.3.1.3 SHC-mediated signalling (Pathway) 14531 

24.20.3.1.3.3 RAF/MAP kinase cascade (Pathway) 14531 

24.20.3.1.3.3.1 RAF activation (Pathway) 14532 

24.20.3.1.3.3.2 MEK activation (Pathway) 14533 

24.20.3.1.3.3.2.2 RAF phosphorylates MEK (Pathway) 14534 

24.20.3.1.3.3.3 ERK activation (Pathway) 14534 

24.20.3.1.3.3.3.1 ERK1 activation (Pathway) 14535 

24.20.3.1.3.3.3.2 ERK2 activation (Pathway) 14536 

24.20.3.2 IRS-related events triggered by IGF1R (Pathway) 14538 

24.20.3.2.4 IRS-mediated signalling (Pathway) 14544 

24.20.3.2.4.1 PI3K Cascade (Pathway) 14544 

24.20.3.2.4.1.3 PKB-mediated events (Pathway) 14545 

24.20.3.2.4.1.3.1 PDE3B signalling (Pathway) 14545 

24.20.3.2.4.1.3.2 mTOR signalling (Pathway) 14546 

24.20.3.2.4.1.3.2.1 Inhibition of TSC complex formation by PKB (Pathway) 14546 

24.20.3.2.4.1.3.2.4 mTORC1-mediated signalling (Pathway) 14547 

24.20.3.2.4.1.3.2.4.1 S6K1-mediated signalling (Pathway) 14548 

24.20.3.2.4.1.3.2.4.1.2 S6K1 signalling (Pathway) 14548 

24.20.3.2.4.1.3.2.4.2 Release of eIF4E (Pathway) 14550 

24.20.3.2.4.1.3.2.5 Energy dependent regulation of mTOR by LKB1-AMPK 14550 (Pathway) 

24.20.3.2.4.1.3.2.5.1 Regulation of AMPK activity via LKB1 (Pathway) 14551 

24.20.3.2.4.1.3.2.5.2 Regulation of Rheb GTPase activity by AMPK (Pathway) 14552 

24.20.3.2.4.1.4 Activation of PKB (Pathway) 14553 

24.20.3.2.4.2 SOS-mediated signalling (Pathway) 14554 

24.20.3.2.4.2.3 RAF/MAP kinase cascade (Pathway) 14555 

24.20.3.2.4.2.3.1 RAF activation (Pathway) 14555 

24.20.3.2.4.2.3.2 MEK activation (Pathway) 14556 

24.20.3.2.4.2.3.2.2 RAF phosphorylates MEK (Pathway) 14557 

24.20.3.2.4.2.3.3 ERK activation (Pathway) 14558 

24.20.3.2.4.2.3.3.1 ERK1 activation (Pathway) 14558 

24.20.3.2.4.2.3.3.2 ERK2 activation (Pathway) 14560 

24.21 Signaling by Activin (Pathway) 14561 

24.21.9 Antagonism of Activin by Follistatin (Pathway) 14571 

24.22 Visual phototransduction (Pathway) 14576 

24.22.1 Retinoid metabolism and transport (Pathway) 14578 

24.22.2 The canonical retinoid cycle in rods (twilight vision) (Pathway) 14615 

24.22.2.14 Biosynthesis of A2E, implicated in retinal degradation (Pathway) 14636 

24.22.3 The retinoid cycle in cones (daylight vision) (Pathway) 14644 

24.22.4 The phototransduction cascade (Pathway) 14663 

24.22.4.1 Activation of the phototransduction cascade (Pathway) 14665 

24.22.4.2 Inactivation, recovery and regulation of the phototransduction cascade 14681 (Pathway) 

24.23 Signaling by Leptin (Pathway) 14713 

24.23.20 RAF/MAP kinase cascade (Pathway) 14746 

24.23.20.1 RAF activation (Pathway) 14747 

24.23.20.2 MEK activation (Pathway) 14748 

24.23.20.2.2 RAF phosphorylates MEK (Pathway) 14749 

24.23.20.3 ERK activation (Pathway) 14749 

24.23.20.3.1 ERK1 activation (Pathway) 14750 

24.23.20.3.2 ERK2 activation (Pathway) 14751 

24.24 Integrin alphaIIb beta3 signaling (Pathway) 14753 

24.24.14 GRB2:SOS provides linkage to MAPK signaling for Integrins (Pathway) 14758 

24.24.15 p130Cas linkage to MAPK signaling for integrins (Pathway) 14759 

24.25 Signaling by Hedgehog (Pathway) 14763 

24.25.1 Hedgehog ligand biogenesis (Pathway) 14765 

24.25.1.6 Release of Hh-Np from the secreting cell (Pathway) 14776 

24.25.1.11 Hh C-terminal fragments are degraded by the proteasome (BlackBoxEvent)14793 25 Transmembrane transport of small molecules (Pathway) 14795 

25.1 ABC-family proteins mediated transport (Pathway) 14795 

25.1.2 ABCA transporters in lipid homeostasis (Pathway) 14798 

25.1.3 Mitochondrial ABC transporters (Pathway) 14810 

25.2 SLC-mediated transmembrane transport (Pathway) 14818 

25.2.1 Transport of inorganic cations/anions and amino acids/oligopeptides (Pathway) 14819 

25.2.1.1 Bicarbonate transporters (Pathway) 14821 

25.2.1.2 Sodium/Calcium exchangers (Pathway) 14828 

25.2.1.3 Sodium/Proton exchangers (Pathway) 14833 

25.2.1.4 Cation-coupled Chloride cotransporters (Pathway) 14839 

25.2.1.5 Multifunctional anion exchangers (Pathway) 14845 

25.2.1.6 Sodium-coupled phosphate cotransporters (Pathway) 14851 

25.2.1.6.1 Type II Na+/Pi cotransporters (Pathway) 14852 

25.2.1.7 Amino acid transport across the plasma membrane (Pathway) 14857 

25.2.1.9 Organic anion transporters (Pathway) 14907 

25.2.1.10 Proton-coupled neutral amino acid transporters (Pathway) 14917 

25.2.1.11 Proton/oligonucleotide cotransporters (Pathway) 14918 

25.2.2 Hexose transport (Pathway) 14923 

25.2.2.4 Glucose transport (Pathway) 14925 

25.2.2.4.6 Regulation of Glucokinase by Glucokinase Regulatory Protein (Pathway) 14928 

14933 amine compounds (Pathway) 

25.2.3.1 Facilitative Na+-independent glucose transporters (Pathway) 14934 

25.2.3.1.3 Class II GLUTs (Pathway) 14938 

25.2.3.2 Na+-dependent glucose transporters (Pathway) 14945 

25.2.3.3 Inositol transporters (Pathway) 14949 

25.2.3.5 Sodium-coupled sulphate, di- and tri-carboxylate transporters (Pathway) 14955 

25.2.3.7 Proton-coupled monocarboxylate transport (Pathway) 14964 

25.2.3.8 Metal ion SLC transporters (Pathway) 14968 

25.2.3.8.5 Zinc transporters (Pathway) 14975 

25.2.3.8.5.1 Zinc efflux and compartmentalization by the SLC30 family (Pathway) 14976 

25.2.3.8.5.2 Zinc influx into cells by the SLC39 gene family (Pathway) 14983 

25.2.3.9 Na+/Cl- dependent neurotransmitter transporters (Pathway) 14997 

25.2.3.12 Rhesus glycoproteins mediate ammonium transport. (Pathway) 15010 

25.2.3.14 Organic cation/anion/zwitterion transport (Pathway) 15019 

25.2.3.14.1 Organic cation transport (Pathway) 15021 

25.2.3.14.2 Organic anion transport (Pathway)  15035  

25.2.4 Transport of vitamins, nucleosides, and related molecules (Pathway) 15042 

15044 membrane (Pathway) 

25.2.4.4 Transport of nucleotide sugars (Pathway) 15064 

25.2.4.5 Transport of fatty acids (Pathway) 15076 

25.2.4.6 Transport of organic anions (Pathway) 15079 

25.3 Aquaporin-mediated transport (Pathway) 15088 

25.3.1 Passive transport by Aquaporins (Pathway) 15091 

25.3.2 Vasopressin regulates renal water homeostasis via Aquaporins (Pathway) 15115 

25.3.3 Transport of glycerol from adipocytes to the liver by Aquaporins (Pathway) 15134 

25.4 Iron uptake and transport (Pathway) 15139 

25.4.12 Transferrin endocytosis and recycling (Pathway) 15151 

25.5 Ion channel transport (Pathway) 15163 

25.5.1 Ion transport by P-type ATPases (Pathway) 15164 

25.5.2 Ligand-gated ion channel transport (Pathway) 15179 

25.5.3 Stimuli-sensing channels (Pathway) 15184 

25.5.3.21 TRP channels (Pathway) 15223 

25.5.3.21.2 TRPM4,5 transport extracellular Na+ to cytosol (Reaction) 15226 26 DNA replication and repair (Pathway) 15228 

26.1 DNA repair (Pathway) 15228 

26.1.1 Base Excision Repair (Pathway) 15229 

26.1.1.1 Base Excision Repair, AP site formation (Pathway) 15230 

26.1.1.1.1 Depyrimidination (Pathway) 15231 

26.1.1.2 Resolution of Abasic Sites (AP sites) (Pathway) 15240 

26.1.2 DNA damage bypass (Pathway) 15243 

15244 (Pathway) 

26.1.2.2 Translesion synthesis by DNA polymerases bypassing lesion on DNA template15248 (Pathway) 

26.1.2.2.1 Translesion synthesis by Pol zeta (Pathway) 15249 

26.1.2.2.2 Translesion synthesis by Pol eta (Pathway) 15254 

26.1.2.2.3 Translesion synthesis by Pol kappa (Pathway) 15258 

26.1.3 DNA Damage Reversal (Pathway) 15265 

26.1.4 Nucleotide Excision Repair (Pathway) 15268 

26.1.4.1 DNA damage recognition in global genomic repair (Pathway) 15269 

26.1.5 Chk1-controlled and DNA-damage induced centrosome duplication (Pathway) 15279 

26.1.6 Double strand break repair (Pathway) 15288 

26.1.6.1 Homologous recombination repair (Pathway) 15289 

26.1.6.1.1 Homologous recombination repair of replication-dependent double-strand 15290 breaks (Pathway) 

26.1.6.1.2 Homologous recombination repair (HRR) of replication-independent 15298 double-strand breaks (Pathway) 

26.1.6.1.2.1 ATM mediated response to DNA double-strand break (Pathway) 15299 

26.1.6.1.2.1.3 ATM mediated phosphorylation of repair proteins (Pathway) 15300 

26.1.6.1.2.2 Recruitment of repair and signaling proteins to double-strand breaks 15312 (Pathway) 

26.1.6.1.2.3 Processing of DNA double-strand break ends (Pathway) 15318 

26.1.6.1.2.4 Homologous DNA pairing and strand exchange (Pathway) 15321 

26.1.6.2 Non-homologous end joining (NHEJ) (Pathway) 15328 

26.1.7 Fanconi Anemia Pathway in DNA repair (Pathway) 15339 

26.2 Telomere maintenance (Pathway) 15346 

26.2.1 Assembly of telomerase and telomere extension (Pathway) 15352 

26.2.2 Packaging of telomere ends (Reaction) 15366 27 Innate Immune System (Pathway) 15368 

27.1 Complement Cascade (Pathway) 15369 

27.1.1 Creation of classical C3 convertase (Pathway) 15371 

27.1.1.1 Lectin-mediated initiation of complement cascade (Pathway) 15373 

27.1.1.2 Classical antibody-mediated complement activation (Pathway) 15379 

27.1.2 Creation of alternative pathway C3 convertase (Pathway) 15393 

27.1.2.1 Formation of fluid-phase convertase C3 (Pathway) 15395 

27.1.2.2 Formation of membrane-bound convertase C3 (Pathway) 15402 

27.1.8 Formation of membrane attack complex (MAC) (Pathway) 15419 

27.1.10 Anaphylatoxins initiate inflammatory responses (Pathway) 15433 

27.1.11 Regulation of complement cascades (Pathway) 15440 

27.2 Toll-like receptors (TLR) cascades (Pathway) 15467 

27.2.1 TLR2 subfamily cascade (Pathway) 15470 

27.2.1.3 MyD88:TIRAP-dependent cascade initiated on plasma membrane (Pathway) 15474 

27.2.1.3.6 NFkB and MAPK activation mediated by TRAF6 (Pathway) 15488 

27.2.1.3.6.8 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15505 (Pathway) 

27.2.1.3.6.9 MAPK activation in TLR cascade (Pathway) 15515 

27.2.1.3.6.9.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15518 activation (Pathway) 

27.2.1.3.6.9.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.1.3.6.9.3 ERK activation (Pathway) 15544 

27.2.1.3.6.9.3.1 ERK2 activation (Pathway) 15546 

27.2.2 TLR3 cascade (Pathway) 15555 

27.2.2.3 IKK related kinases bound to dsRNA:TLR3:TICAM1 activate IRF3 (Pathway) 15560 

27.2.2.3.1 Viral dsRNA:TLR3:TICAM1 Complex Activates TBK1 (Pathway) 15563 

27.2.2.3.2 Viral dsRNA:TLR3:TICAM1 Complex Activates IKBKE_CHICK (Pathway) 15576 

27.2.2.4 NFkB activation mediated by RIP1 complexed with activated TLR3 (Pathway) 15585 

27.2.2.5 TRAF6 mediated induction of the anti inflammatory cytokines (Pathway) 15594 

27.2.2.5.7 TAK1 activates NFkB by phosphorylation and activation of IKKs complex 15610 (Pathway) 

27.2.2.5.8 MAPK activation in TLR cascade (Pathway) 15611 

15611 (Pathway) 

27.2.2.5.8.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway) 15612 

27.2.2.5.8.3 ERK activation (Pathway) 15614 

27.2.2.5.8.3.1 ERK2 activation (Pathway) 15614 

27.2.3 TLR4 cascade (Pathway) 15616 

27.2.3.4 MyD88:TIRAP-dependent cascade initiated on plasma membrane (Pathway) 15622 

27.2.3.4.6 NFkB and MAPK activation mediated by TRAF6 (Pathway) 15623 

27.2.3.4.6.8 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15626 (Pathway) 

27.2.3.4.6.9 MAPK activation in TLR cascade (Pathway) 15627 

27.2.3.4.6.9.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15627 activation (Pathway) 

27.2.3.4.6.9.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.3.4.6.9.3 ERK activation (Pathway) 15630 

27.2.3.4.6.9.3.1 ERK2 activation (Pathway) 15630 

27.2.4 TLR5 cascade (Pathway) 15632 

27.2.4.2 MyD88 cascade initiated on plasma membrane (Pathway) 15635 

27.2.4.2.6 NFkB and MAPK activation mediated by TRAF6 (Pathway) 15647 

27.2.4.2.6.8 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15650 (Pathway) 

27.2.4.2.6.9 MAPK activation in TLR cascade (Pathway) 15651 

27.2.4.2.6.9.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15651 activation (Pathway) 

27.2.4.2.6.9.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.4.2.6.9.3 ERK activation (Pathway) 15654 

27.2.4.2.6.9.3.1 ERK2 activation (Pathway) 15654 

27.2.5 TLR7 cascade (Pathway) 15656 

27.2.5.2 MyD88-dependent cascade initiated on endosome membrane (Pathway) 15659 

27.2.5.2.6 NFkB and MAPK activation mediated by TRAF6 upon TLR7 or TLR21 15671 stimulation (Pathway) 

27.2.5.2.6.9 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15689 (Pathway) 

27.2.5.2.6.10 MAPK activation in TLR cascade (Pathway) 15690 

27.2.5.2.6.10.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15690 activation (Pathway) 

27.2.5.2.6.10.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.5.2.6.10.3 ERK activation (Pathway) 15693 

27.2.5.2.6.10.3.1 ERK2 activation (Pathway) 15693 

27.2.5.2.6.10.3.1.5 Nuclear translocation of phospho ERK2 dimer (Reaction) 1566915695 27.2.6 TLR15 cascade (Pathway) 15695 

27.2.6.2 MyD88 cascade initiated on plasma membrane (Pathway) 15698 

27.2.6.2.6 NFkB and MAPK activation mediated by TRAF6 (Pathway) 15700 

27.2.6.2.6.8 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15703 (Pathway) 

27.2.6.2.6.9 MAPK activation in TLR cascade (Pathway) 15704 

27.2.6.2.6.9.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15704 activation (Pathway) 

27.2.6.2.6.9.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.6.2.6.9.3 ERK activation (Pathway) 15707 

27.2.6.2.6.9.3.1 ERK2 activation (Pathway) 15707 

27.2.7 TLR21 cascade (Pathway) 15709 

27.2.7.2 MyD88-dependent cascade initiated on endosome membrane (Pathway) 15711 

27.2.7.2.6 NFkB and MAPK activation mediated by TRAF6 upon TLR7 or TLR21 15713 stimulation (Pathway) 

27.2.7.2.6.9 TAK1 activates NFkB by phosphorylation and activation of IKKs complex15716 (Pathway) 

27.2.7.2.6.10 MAPK activation in TLR cascade (Pathway) 15717 

27.2.7.2.6.10.1 Activated TAK1 mediates Jun kinases (JNK) phosphorylation and 15717 activation (Pathway) 

27.2.7.2.6.10.2 Activated TAK1 mediates p38 MAP kinase phosphorylation (Pathway)

27.2.7.2.6.10.3 ERK activation (Pathway) 15720 

27.2.7.2.6.10.3.1 ERK2 activation (Pathway) 15720 

27.3 RLR (RIG-like receptor) mediated induction of IFN alpha/beta (Pathway) 15722 

27.3.3 TRAF mediated activation of IRF (Pathway) 15729 

27.3.4 Caspase-8 and -10 mediated induction of NF-kB (Pathway) 15746 

27.3.5 TRAF6 mediated NF-kB activation (Pathway) 15756 

27.3.6 Negative Regulation of MDA5 signaling (Pathway) 15768 

27.3.6.4 NLRX1 inhibits IPS1 signaling (Reaction) 15775 28 Metabolism (Pathway) 15777 

28.1 Carbohydrate metabolism (Pathway) 15778 

28.1.1 Glucose transport (Pathway) 15778 

28.1.2 Glycolysis (Pathway) 15788 

28.1.3 Gluconeogenesis (Pathway) 15803 

28.2 Pyruvate metabolism (Pathway) 15835 

28.3 Lipid metabolism (Pathway) 15845 

28.3.1 Sphingolipid metabolism (Pathway) 15845 

28.4 The tricarboxylic acid cycle (Pathway) 15856 

28.5 Amino acid metabolism (Pathway) 15874 

28.5.1 Arginine metabolism (Pathway) 15874 

28.6 Nucleotide metabolism (Pathway) 15889 

28.6.1 Pyrimidine metabolism (Pathway) 15890 

28.6.1.1 De novo synthesis of UMP (Pathway) 15890 

28.6.2 Purine metabolism (Pathway) 15902 

28.6.2.1 De novo synthesis of IMP (Pathway) 15903 

28.6.2.2 De novo synthesis of AMP (Pathway) 15920 

28.6.2.3 De novo synthesis of GMP (Pathway) 15925 

28.6.2.4 Urate synthesis (Pathway) 15928 

28.7 Heme metabolism (Pathway) 15935 

28.7.1 Heme synthesis (Pathway) 15936 

28.7.1.17 protoporphyrin IX + Fe++ => heme + 2 H+ (Reaction) 15957 29 Mus musculus biological processes (Pathway) 15959 

29.1 Circadian Clock (Pathway) 15960 

29.1.4 Bmal1:Clock,Npas2 activates circadian gene expression (Pathway) 15968 

29.1.20 Rora activates circadian gene expression (Pathway) 16010 

29.2 Meiotic Recombination (Pathway) 16016 

29.3 Meiotic Synapsis (Pathway) 16034 

29.4 NoRC negatively regulates rRNA expression (Pathway) 16047 

29.5 Signaling by Leptin (Pathway) 16058 

29.6 Transcriptional Regulation of Adipocyte Differentiation in 3T3-L1 Pre-adipocytes 16085 (Pathway) 

